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Summary 
Familial hypercholesterolaemia (FH) and familial defective apolipoprotein B-IOO (FDB) 
are relatively common disorders of lipid and lipoprotein metabolism caused by mutations 
in the low density lipoprotein receptor (LDLR) and apolipoprotein B (apo B) genes, 
respectively. DNA analyses at these loci were performed in 132 molecularly-
uncharacterised South African, 11 Costa Rican and 13 New Zealand subjects with 
clinical features of heterozygous FH. Mutation R3500Q causing FDB was identified in a 
relatively large proportion (~30%) of the New Zealand patients. LDLR gene defects 
were identified in 4 Costa Rican and 6 New Zealand FH patients. Sixty-five different 
LDLR gene mutations were identified in South African hypercholesterolaemics, 
revealing ten founder-type mutations. 
Haplotype analysis at the LDLR and apo B loci excluded the likelihood that 
mutations in these two genes underlie the FH phenotype in one of the New Zealand 
families. The apparently autosomal dominant hypercholesterolaemia (ADH) in this 
family could also not be linked to a newly identified gene locus, designated FH3. 
Analysis of the New Zealand study cohort, although small, demonstrated both mutational 
-- --- ---_.- ~-
and locus heterogeneity in ADH. 
Analysis was also extended to include subjects from the various ethnic groups 
within South Africa. The high prevalence of FH in Afrikaners of European descent is in 
striking contrast to the reported virtual absence of this lipid disorder in the Black South 
African population. In addition to three previously-described Afrikaner founder 
mutations (D154N, D206E and V408M), four minor founder mutations, D200G, S285L, 
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C356Y and G361V, were identified in 12 Afrikaner families. Surprisingly, a 6-bp 
deletion in exon 2 ofthe LDLR gene was detected at a relatively high frequency (28%) in 
Black FH patients. This fmding, as well as clinical correlations performed in the patients, 
suggests that the expression of FH mutations in the Black population may be altered due 
to interaction with other genetic and/or environmental factors, therefore leading to 
underdiagnosis of the disease. Common LDLR gene mutations have also been described 
in South African Indians (P664L) and Jews (del 197), most likely as a consequence of 
multiple introductions of defective genes into these relatively isolated communities. 
Caucasoid admixture was recognised as a major factor contributing to the FH phenotype 
in the indigenous South African population of mixed ancestry from the Western Cape, 
where six founder-type mutations account for the disease in 22% of cases. The high 
prevalence of specific LDLR gene mutations in different population groups facilitates an 
improved diagnostic service for FH in South Africa. 
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Opsomming 
Familiele hipercholesterolemie (FH) en familiele defektiewe apolipoprotelen B-I00 
(FDB) is relatief algemene afwykings in lipied en lipoprotelen metabolisme wat 
onderskeidelik veroorsaak word deur mutasies in die lae digtheids lipoprotelen reseptor 
(LDLR) en apolipoproteleri B-I00 (apo B) gene. Molekulere DNS analise van hierdie 
lokusse is uitgevoer in 132 Suid Afrikaanse, 11 Costa Rikaanse en 13 New Zealandse 
pasiente waar die geen mutasies onderliggend, aan die kliniese beeld van heterosigotiese 
FH onbekend was. Mutasie R3500Q wat FDB veroorsaak was in 'n relatief groot aantal 
van die New Zealandse pasiente (~30%) teenwoordig. LDLR geen defekte is in 4 Costa 
Rikaanse en 6 New Zealandse FH pasiente geldentifiseer. Vyf en sestig verskillende 
LDLR geen mutasies is aangetoon in die Suid Afrikaanse populasie waarvan tien stigter-
geen mutasies is. 
Haplotipe analise van die LDLR en apo B lokusse het die moontlikheid uitgesluit 
dat mutasies in hierdie twee gene verantwoordelik is vir die FH fenotipe in een van die 
New Zealandse families. Die waarskynlik outosomaal dominante hipercholesterolemie 
(ODH) in hierdie familiekon ooknie toegeskryfwQrdaan ~n nuwe_geldentifiseerde geen 
lokus genaamd FH3 nie. Analise van die New Zealandse studie paneel het dus beide 
mutasie en lokus heterogeniteit in ODH gedemonstreer. 
Analise was uitgebrei deur die toevoeging van individue van verskeie etniese 
groepe van Suid-Afrika. Die hoe voorkoms van FH in Afrikaners van Europese afkoms is 
, in opvallende kontras met die voorheen vermeende feitlike afwesigheid van hierdie lipied 
afwyking in die Swart Suid-Afrikaanse populasie. Afgesien van drie bekende Afrikaner 
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stigter mutasies (D154N, D206E en V408M), is nog vier relatief algemene mutasies, 
D200G, S285L, C356Y en G361V, ge'identifiseer in 12 Afrikaner families. 'n 
Onverwagse bevinding was die opsporing van 'n 6-bp delesie in ekson 2 van die LDLR 
geen teen 'n relatief hoe frekwensie (28%) in Swart FH pasiente. Hierdie bevinding, 
sowel as kliniese korrelasies wat in hierdie groep pasiente uitgevoer is, impliseer dat FH 
moontlik ondergediagnoseer word in die Swart populasie weens interaksie van 
defektiewe LDLR gene met ander genetiese en/of omgewingsfaktore. Algemene LDLR 
geen mutasies is ook beskryf in Suid Afrikaanse Indiers (P664 L) en J ode (del 197), heel 
waarskynlik as 'n gevolg van veelvuldige oordrag van defektiewe gene in hierdie relatief 
ge'isoleerde gemeenskappe. Kaukasier vermenging is herken as 'n belangrike faktor 
onderliggend aan die FH fenotipe in die inheemse W es-Kaapse kleurling populasie van 
Suid-Afrika, waar ses stigter-tipe mutasies verantwoordelik is vir die siekte in 22% van' 
gevalle. Die hoe voorkoms van spesifieke LDLR geen mutasies in verskillende populasie 
groepe maak populasie-gerigte DNA dililgnose van FH moontlik in Suid Afrika. 
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Chapter 1 
Introduction 
1 
Coronary Heart Disease (CHD) is one of the leading causes of death in Westemised 
countries, where it accounts for approximately 25% of all mortality. Elevated plasma 
cholesterol concentrations leading to atherosclerosis affect approximately 4.8 million South 
Africans and place them high at risk of developing eHD. Although eHD remains 
uncommon in urban blacks (Walker 1999), it has been noted that the prevalence of this 
condition is increasing in this population in South Africa. 
Dyslipidaemia is caused by a combination of heritable and environmental factors. 
Primary hyperlipidaemias include (i) familial hypercholesterolaemia (FH), (ii) familial 
defective apolipoprotein BI00 (FDB), (iii) familial combined hyperlipidaemia (FeRL), (iv) 
polygenic hyPerlipidaemia, (v) familial hypertriglyceridaemia (FHT) and (vi) familial 
dysbetalipoproteinaemia (FD). These genetic causes of dyslipidaemia are classified in 
categories of Fredrickson (Fredrickson et al. 1967) type ITa (i, ii, iv), types ITa, llb and IV 
(iii), types IV and V (v) and type III hyperlipoproteinaemias (vi). 
Lipoprotein abnormalities are a result of disorders of cholesterol metabolism, 
including low den~ity liEoErot~ins_ (LPL), very-low density-lipoproteins (VLDL), -remnants 
and chylomicrons. Secondary dyslipidaemia is associated with other conditions, such as 
diabetes mellitus, hypothyroidism, obesity and alcohol abuse. 
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2 
1.1 Cholesterol metabolism 
Cholesterol plays an important role in the production of bile, steroid hormones ( cortisone) 
and sex hormones (androgen/oestrogen), and is vital for the intactness of cell membranes. 
The synthesis of cholesterol is mediated by hydroxymethylglutaryl coenzyme A (HMG 
CoA) reductase from acetyl coenzyme A (Acetyl-CoA), via mevalonic acid, squalene, and 
other intermediates. 
Cholesterol is transported in lipoproteins (protein/lipid macromolecules) that 
circulate in the bloodstream. Four types of lipoprotein abnormalities are frequently found in 
the population and are present in 50-80% of myocardial infarction (MI) survivors (Breslow 
1992). These lipoprotein defects are: (i) increased chylomicron remnant- and intermediate-
density lipoprotein (IDL) concentrations; (ii) increased very-low-density lipoprotein (VLDL) 
levels and decreased high-density lipoprotein (HDL)-cholesterolleve1s; (iii) increased low-
density lipoprotein (LDL)-cholesterollevels and (iv) increased Lp(a) levels. 
Chylomicrons (secreted by the intestine) and VLDL (secreted by the liver) are the 
- -_. 
two triglyceride (TG)-rich lipoproteins. The chylomicrons carry the exogenous TG. The 
exogenous (or dietary) component of cholesterol comes from saturated fats which are 
converted by the body into LDL cholesterol or LDL. The precursor of LDL, VLDL, carries 
endogenous TG. The endogenous (metabolic) component of cholesterol comes from the 
synthesis of cholesterol in the cells of the body, particularly the liver cell or hepatocyte. The 
LDL-deposits cholesterol from the blood in the arteries (via a protein carrier, apoprotein B) 
and the HDL transports excess cholesterol (via a protein carrier, apoprotein A) from the 
arteries and returns it to the liver where it is broken down for removal from the body. Lp(a) 
is a modified form of LDL and is a risk factor for the development of CHO (Utermann 
1989). 
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3 
The LDLR is a transmembrane glycoprotein that binds LDL and mediates its uptake 
into the liver cell or hepatocyte. In the absence of functional receptors, LDL's remain in the 
blood plasma which cause deposits to form inside blood vessels. The deposits are formed 
through an oxidation interaction between the LDL and free radicals on the inside wall of the 
artery. These deposits causing atherosclerosis are called plaques. The accumulation of 
cholesterol inside the hepatocyte down-regulates the expression of the LDLR gene. 
In hyperlipidaemics, the risk of developing CHD can greatly be reduced by the use of 
appropriate drugs (e.g. cholestyramine, HMG-CoA reductase inhibitors) and by eliminating 
or modifying additional risk factors. Preventive measures include a cholesterol-free diet, 
avoiding stress, weight control, physical exercise, regular evaluation of hypertension, and 
cessation of smoking. If the liver enzyme HMG CoA reductase is blocked (by statins), 
cholesterol synthesis ceases and the LDLR is stimulated to siphon more cholesterol into the 
cell, thus lowering the serum LDL. Costly procedures such as LDL apheresis and liver 
transplantation may prolong life of homozygous FH patients. 
1.2 Autosomal dominant hypercholesterolaemia (ADH) 
Several genetic conditions have been identified that affect lipid. levels. The clinical 
manifestations of severely elevated LDL cholesterol concentration are defmed as two 
relatively common genetic disorders, namely familial hypercholesterolaemia (FH) 
(Goldstein et al. 1995) and familial defective apolipoprotein B-IOO (FDB) (Innerarity et al. 
1990). FH is caused by mutations in the LDLR gene (Hobbs et al. 1992) and FDB by 
mutations in the apoB gene (Soria et al. 1989). Recently, a third major locus for ADH, 
designated FH3, was mapped to chromosome Ip34.1-32 (Varret et al. 1999/Appendix 3, 
Hunt et al. 1999). This genome-wide gene search 'performed by Varret et al. (1999) 
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4 
(Appendix 3) also provided evidence of a fourth locus underlying the FH phenotype. The 
genetic heterogeneity of FH was confirmed by Haddad et al. (1999), who excluded the 
involvement of mutations in the LDLR- and apoB genes in a clinically diagnosed FH family. 
Familial combined hyperlipidaemia (FCHL) is a common genetic disorder of 
unknown cause that accounts for (up to 10% of patients with myocardial infarction (M!) 
(Brown and Goldstein 1991). FCHL affected patients may have elevated LDL cholesterol 
levels, elevated VLDL triglyceride levels or both within the same family. Pajukanta et al. 
(1998) localised a locus associated with FCHL on human chromosome 1q21-q23 in families 
from a Finnish isolate. The hyperlipidaemia gene (Hyp/ipJ) for combined hyperlipidaemia 
was furthermore mapped to chromosome 3 in a mutant mouse strain, which is syntenic to 
human chromosome 1q21-q23 (Castellani et al. 1998). Additional putative FCHL loci have 
recently been reported in Finnish families with the TG, TC or apoB traits, after a genome-
wide screen (Pajukanta et al. 1999). 
There is now also evidence of a new lipid disorder, an autosomal recessive form of 
FH (Zuliani et al. 1999). It was suggested that the disease phenotype in two Sardinain 
families may be due to marked reduction of in vivo LDL catabolism, caused by a selective 
reduction in hepatic LDL uptake. 
1.2.1 Familial hypercholesterolaemia (FH) 
_. -- ---_. - ._. "-
FH is a co-dominantly inherited lipid disorder with a heterozygote frequency of 
approximately 1 in 500 individuals in most populations. The homozygous form is rare, 
occurring in approximately 1 in a million individuals (Goldstein et al. 1995). 
FH heterozygotes express half the normal LDLR activity, which may result in a 
twofold increase in the plasma concentrations of LDL cholesterol levels (above the 95 th 
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percentile for age and gender), the presence of visible LDL-derived cholesterol deposits in 
the tendons of the hands and feet (tendon xanthomas) and premature CHD (Goldstein et al. 
1995). Homozygotes express little or no LDLR activity and therefore the plasma cholesterol 
levels are higher (15.0 mmoVI or above) and the generalised atherosclerosis and 
cardiovascular disease (CVD) more severe. In FH homozygotes, this phenotype is 
associated with death in childhood. In heterozygous FH patients, the disease may appear in 
the early 20's and, without treatment, it is quite likely that the patient will die early from a 
heart attack. In men this occurs between the ages 35 to 55 years and in women by ages 55 to 
75 years, since women are probably protected by oestrogen (Pyorala et al. 1994). 
Mutations in the LDLR gene have been extensively studied as a cause of the clinical 
manifestations of ADH. This gene, located on the short arm of chromosome 19pI3.1-p13.3, 
is composed of 18 exons coding for a membrane-bound glycoprotein of 839 amino acids 
(Yamamoto et al. 1984, Sudhof et al. 1985). The mature LDLR consists of five distinct 
functional domains: ligand binding, exons 2-6; epidermal growth factor (EGF) precursor 
homology, exons 7-14; carbohydrate side chains (O-linked sugars), exon 15; membrane 
spanning, exons 16-17 and cytoplasmic, exons 17-18; with its N-terminal signal sequence 
(21 hydrophobic amino acids) on the outside of the plasma membrane and the C-terminal 
sequence inside the cell cytoplasm (Russell et al. 1984). The promoter (5'-flanking) region, 
located within the first 200 bp upstream of the initiation codon of exon 1, consists of cis-
acting DNA sequence (mRNA initiation sites, two TATA boxes; three closely spaced 16 bp 
direct repeats; two sterol regulatory elements) that control LDLR gene transcription (Sudhof 
et al. 1987). The 16 bp repeats are responsible for binding of several transcription factors. 
Repeats 1 and 3 contain Spl-binding sites, a trans-acting transcription factor, which are 
responsible for basal transcription of the LDLR g~ne in the presence and absence of sterols 
(Dawson et al. 1988). Repeat 2, designated the sterol regulatory element (SRE 1), interacts 
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with essential transcription binding proteins (SREBP-l) to induce high-level expression of 
the LDLR gene (Yokoyama et al. 1993, Dliner et al. 1996, Streicher et al. 1996). SRE 1 is 
responsible for sterol-mediated repression of the gene when cellular cholesterol levels are 
high (Smith et al. 1990, Briggs et al. 1993). Footprinting 1 (FPl) and footprinting 2 (FP2), 
two cis-acting regulatory elements, are essential for maximal induction of transcription 
(Mehta et al. 1996). Sterols, cytokines, growth factors and hormones are additional 
substances that may influence regulation of transcription of the LDLR gene (Dawson et al. 
1988, Mazzone et al. 1989, Rudling et al. 1992, Stopeck et al. 1993). 
Several DNA polymorphisms have been identified in the LDLR gene that can be 
used to follow the inheritance of the defective gene in FH families (Hobbs et al. 1992). 
Genetic markers provide the necessary tools for the identification of different or recurrent 
, 
FH mutations, to study the origin of a common mutation (a particular mutation is likely to be 
associated with a specific haplotype) and for co-segregation analysis as a basis for (prenatal) 
DNA diagnosis of FH where the disease-causing mutation has not been identified. Four 
intragenic markers defined by the restriction enzymes SmaI (ex on 7), StuI (exon 8), Avail 
(exon 13) and NcoI (exon 18) and two highly informative micro satellite markers, D19S221 
and D19S394 (Haddad et al. 1997), located 1.3 Mb centromeric and 250 kb telomeric to the 
LDLR gene respectively, are frequently used for this purpose in population studies. 
To date, more than 600 different mutations have been described in the LDLR gene 
world wide (http://www.ucl.ac.uklfh and http://www.umd.necker.fr.). Point mutations, small 
deletions and insertions are responsible for the majority of FH cases. About 15 % of all 
point mutations are situated at splice junctions (Krawczak et al. 1992), and similar fmdings 
have recently been described in FH patients (Peeters et al. 1999). Large gene alterations 
have been detected in the minority of cases, mostly by Southern blot analysis prior to the 
availability of polymerase chain reaction (PCR)-based assays. The mutations have been 
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grouped into five classes based on their phenotypic effects on LDLR function. Class 1 
mutants fail to produce receptors (null alleles). Class 2 mutants produce receptors, but do 
not transport them from the endoplasmic reticulum (ER) to the Golgi apparatus (transport 
defective alleles). Class 3 mutant receptors reach the cell surface, but fail to bind LDL 
(binding defective alleles). Class 4 mutant receptors reach the cell surface and bind LDL, 
but fail to cluster in coated pits and cannot internalise LDL (internalisation defective alleles). 
Class 5 mutant receptors fail to discharge the ligand in the endosome and cannot recycle to 
the cell surface (recycling defective alleles). 
Most individuals with heterozygous FH are not diagnosed with the disease and are 
therefore not treated adequately to prevent or delay the development of CHD. This situation 
led to the initiation of an international project aimed at Making Early Diagnosis to Prevent 
Early Deaths in MEDical PEDigrees (MEDPED). MEDPED is based on a family screening 
approach to identify and treat affected FH individuals (Williams et a1. 1993). FDB patients 
are also included in the MEDPED project, since FH and FDB share similar clinical and 
biochemical characteristics. The MEDPED initiative may in future elect to include other 
familial lipid disorders such as type III hyperlipidaemia, familial combined hyperlipidaemia 
(FCHL) or polygenic hypercholesterolaemia, and can also be applied to other common 
genetic diseases (Kotze and Callis 1999). 
1.2.2 Familial defective apolipoprotein B-I00 (FDB) 
FDB occurs as a consequence of LDL particles which bind poorly to the LDLR, because of 
mutations in the binding area of the apo B gene. This gene is the main constituent peptide of 
LDL and serves as the ligand for receptor-mediated uptake of LDL (Brown and Goldstein 
1986). The apo B gene spans 43 kb on chromosome 2p23-24 (Knott et a1. 1985) and has 29 
exons and 28 introns (Blackhart et a1. 1986). The most frequent mutation is a glutamine to 
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arginine substitution at codon 3500 (R3500Q) in exon 26 of the gene (Soria et a1. 1989). 
Several studies have indicated that FDB is associated with a relatively mild disease, 
comparable to polygenic hypercholesterolaemia (Tybjerg-Hansen and Humphries 1992, 
Miserez and Keller 1995) or receptor-defective FH (Kotze et a1. 1994). The clinical 
phenotype of FDB homozygotes is less severe than those of FH homo zygotes (Schaefer et a1. 
1997). 
This dominantly inherited genetic disorder occurs in approximately 1 in 500 
individuals in most European countries. Higher frequencies have been reported in 
Switzerland (Miserez et a1. 1994) and Belgium (Kotze et a1. 1994), and lower frequencies 
south ofthe Alpes, in Russia, in Scandinavia, and in Denmark (Hansen 1998). FDB is rare in 
the South African popUlation, most likely as a result of under representation of mutation 
R3500Q in South African settler populations (Rubinsztein et a1. 1995). Previous studies 
have indicated that the common FDB 3500 mutation originated in Europe, prior to racial 
diversity (Ludwig and McCarthy 1990). 
1.3 Common LDLR gene mutations in different populations 
FH tends to occur more frequently in certain populations of the world, such as the Afrikaners 
- - ----
in South Africa, the French Canadians, the Finnish, the Lebanese Christian Arabs, and 
Lithuanian Jews (Table 1). This phenomenon is probably a consequence of the establishment 
of thesepopulatioris by a few original founders who carried only a small fraction of the total 
genetic variation of the parental population (Mayr 1963, Davignon and Roy 1993). 
• 1I. S. • 
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Table 1. Populations where FH is prevalent due to founder LDLR gene mutations. 
[~QJ;J,t~jl';:j/'i;:,ti(ll~~~tigm1~;I;{ 'Y~i},!ft ~~Iel~y~t~~~~;~~ ;1N!g!1!g~iJJ~;';;.i'ij!l~ ~~Jtl~rd'~·$r· 
South Africa Afrikaners 1 in 70 D206E FH Afrikaner-l 
Canada 
(Quebec-
Province) 
Finland 
(North 
Karelia) 
Israel 
Jews 
Indians 
French- Canadians 
Finnish 
Christian Lebanese 
Ashkenazi Jews 
Druze 
Sephardic Jews 
1 in 100 
1 in 100 
} in 270 
1 in 441 
1 in 100 
1 in 80 
V 408M FH Afrikaner-2 
D154N FHAfrikaner-3 
197delGGT FH Lithuanian 
P664L FH Gujerat 
> 15-kb del FH French Canadian-l 
5-kb del FH French Canadian-5 
W66G FH French Canadian-4 
E207K FH French Canadian-3 
C646Y FH French Canadian-2 
Y468X 
9-kb del 
7-bp del at 925 
G823D 
L380H 
C660X 
197delGGT 
Y167X 
D147H 
FHHeisinki 
FH North Karelia 
FHTurku 
FHPori 
FHLebanese 
FH Lithuanian 
9 
1,2 
1,2 
2 
3 
4 
5 
6 
7 
7 
7 
8 
9 
10 
11 
11 
12 
3 
13 
14 
*References: (1) Leitersdorf et aL 1989, (2) Kotze et aL 1989, 1991, (3) Meiner et aL 1991, (4) 
Kotze et aL 1997, (5) Hobbs et aL 1987, (6) Ma et al. 1989, (7) Leitersdorf et al. 1990, (8) Simard et 
al. 1994, (9) Koivisto et al. 1992 (10) Aalto-Setala et al. 1989, (11) Koivisto et al. 1995, (12) 
Lehrman et al. 1987, (13) Landsberger et al. 1992, (14) Leitersdorf et al. 1993 
The relatively high frequency of a disease in some populations because of a founder effect 
and/or genetic drift, following the introduction of a deleterious mutation in the gene pool, 
may be explained mainly through migration and geographical or cultural isolation (Zlotogora 
1994). 
A set of alleles at polymorphic sites within a given gene, that are ill linkage 
disequilibrium with a mutation, may represent the founder haplotype (Labuda et al. 1997). 
This information on the chromosomal background of a given mutation can be used to trace 
back a genetic alteration to one common ancestor whilst the spread of specific FH alleles can 
also be followed in different parts of the world. Haplotype analysis can also provide 
information on the possible independent occurrence of a specific mutation in patients from 
different populations. The identification of founder mutations in the LDLR gene has been a 
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helpful tool in the implementation of genetic screenmg programs m specific population 
groups (Leitersdorf et al. 1989, 1990, Koivisto et al. 1992, Kotze et al. 1995). 
South Africa 
Founder-related LDLR gene defects underlie the high prevalence of FH in several South 
African ethnic groups, including in the Afrikaners (Caucasians), Jews (Ashkenazi) and 
Indians. This is largely due to the early and/or recurrent introduction of specific mutations 
into relatively isolated communities and subsequent population expansion (Kotze et al. 1991, 
Meiner et al. 1991, Rubinsztein et al. 1994). An apparently low FH frequency has been 
reported in the South African Black population, originating from central Africa. 
In the South African Afrikaner population three LDLR gene mutations, D 154N, 
D206E and V 408M, account for -90% of FH in affected individuals (Leitersdorf et al. 1989, 
Kotze et al. 1989, 1991). Mutation V408M that is responsible for -15% ofFH in Afrikaners 
was also detected by nefesche et al. (1993) in the Netherlands and by Schuster et al. (1993) 
in Germany. These [mdings reflect the fact that Afrikaners. originated from about 2 000 
settlers who immigrated from Holland, Germany and France in the 1 i h and 18th centuries. 
Approximately 1 million of the roughly 2.5 million Afrikaners who were founded by one 
shipload m 1652 still have the surnames of 20 origip.al settlers 
(http://helix.biology.mcmaster.ca/3j3/3j3.founder). The first British immigrants arrived in 
South Africa around 1820, forcing the Dutch settlers to the north (Transvaal) (Botha and 
Beighton 1983). These groups were isolated for a long time from other populations, due to 
cultural and religious differences. Mutations D154N and D206E occur in approximately 10% 
and 65% of FH patients in the Afrikaner population, respectively (Kotze et al. 1991, Graadt 
van Roggen et al. 1991). These common Afrikaner mutations identified in exon 4 were 
found in the Netherlands in FH patients of British origin, but were not identified in the Dutch 
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population (Defesche et al. 1993). Mutation D206E was also identified in FH patients from 
London (Gudnason et al. 1993). It is therefore highly likely that these mutations were 
introduced into South Africa by British immigrants. 
The three Afrikaner founder mutations represent 15% of disease-related mutations in 
the Coloured population of South Africa, a people of mixed ancestry (San, Khoi, African 
Negro, Madagascar, Javanese and European origin) (Loubser et al. 1999). Caucasoid 
admixture therefore contributes significantly to the FH phenotype in this indigenous South 
African population. A 2.5 kb deletion of exons 7 and 8 is also relatively common (~1 0%) in 
South Africans of mixed ancestry (Henderson et al. 1988). A study performed by Peeters et 
al. (1997) excluded the likelihood that this deletion is the same one described by Top et al. 
(1990) in the Dutch population. 
The increased prevalence of FH in South African Jews and Indians appears to be a 
consequence of recurrent introduction of specific LDLR gene mutations into these relatively 
isolated communities. The predominant FH Lithuania mutation in the Ashkenazi Jews 
entails a 3-bp deletion of codon 197 and was also identified in the majority of South African 
FH-Jews (Meiner et al. 1991). This mutation may be responsible for FH in up to 80% of 
South African Jews. Lithuania immigrants who came to South Africa between 1880 and 
1910 gave rise to most of the inhabitants ~fth~ Sout~ Afri~an Ashkel!azi population. 
Mutation P664L that is prevalent in the West of India, the Gujerat Province, is the 
most common mutation (~50%) among South African Indians (Kotze et al. 1997). Their 
ancestors came -to South Africa as traders under British auspices between 1860 and 1911. 
Most were from areas in the Gujerat province and the other major group came from 
Kathiowar on the Arabian Sea. South African Indians are of diverse cultural and religious 
origin; 65% Hindus, 21 % Muslims and 7.5% Christians (Rubinsztein et al. 1994). 
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The majority of mutations identified to date in Africans are those detected in the 
South African Black population (Hobbs et al. 1992, Varret et al. 1998/ Appendix 2). In this 
study it is shown that a 6-bp deletion in ex on 2 of the LDLR gene (Leitersdorf et al. 1988) 
predominates in the South African Black population. 
Canada 
The Canadians, with the exception of French-Canadians and the indigenous Indians, 
constitute a heterogeneous population of mainly British, Irish and Dutch descent. The French 
Canadian population descended from approximately 7 000 original settlers who emigrated 
from northeastern and western France to eastern Canada in the 1 i h and 18th centuries 
(Laberge 1966). This population remained genetically isolated from English influences due 
to social and geographic factors. The FH prevalence varies between different regions among 
French Canadians: Bas St-LaurentiGaspesie (1 in 167), Cote-Nord in Northeastern Quebec 
(1 in 81) and SLSJ (1 in 122) (Moorjani et al. 1989). Eleven LDLR gene mutations account 
for more than 90% of FH cases in the French-Canadian population (Minnich et al. 1995, 
Vohl et al. 1997, Couture et al. 1999). Two deletions represent the most common mutations. 
A > 15-kb deletion of the promoter and exon 1 resulting in a null allele (Hobbs et al. 1987), 
shows the highest frequency (71.2%) in the Bas St-LaurentiGaspesie region, while a 5-kb 
-- ----
deletion of exons 2 and 3 (Ma et al. 1989) represent 2% of FH cases. Missense mutation 
W66G had the highest frequency (59.2%) in the Saguenay-Lac-St-Jean/Cote-Nord region. 
Mutations-- E207K (3%), C646Y (6%) (Leitersdorf et al. 1990) and Y468X also occur 
frequently in this population (Simard et al. 1994). The large deletion was also identified in 
France (Fumeron et al. 1992), and ancestors of individuals with this so-called French 
Canadian deletion were traced back from the same region in northeast of Montreal, Canada, 
called Kamouraska (Jompe et al. 1988). 
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Finland 
Finns emigrated in the 16th and 1 i h century to Varmlandin, the central part of Sweden and 
then further west to the Eastern part of Norway (Opsahl and Winge 1990). The highest 
density ofFH patients in the Polvijarvi region of North Karelia represent a FH prevalence of 
1 in 143 (Vuorio et al. 1997). A 9.5-kb deletion from intron 15 to exon 18 and a 7-bp 
deletion (CCCATCA) at 925 in exon 6, are very common mutations in the Southeast and 
Midwest of Finland, respectively. Together these mutations account for approximately 90% 
of FH cases in Finland (Aalto-Setala et al. 1989, Koivisto et al. 1993). The FH-Helsinki 
mutation was also identified in Norway probably as a consequence of an independent 
mutational event (Rodningen et al. 1992). Two missence mutations, G823D and L380H, are 
responsible for FH in approximately 8% of the remaining cases (Koivistoet al. 1995). 
Founder effects in villages with relative homogeneity within specific rural communities are 
thought to underline the high frequency of FH in certain areas in Finland (Levanlinna 1972, 
Norio et al. 1973). 
Several founder LDLR mutations were identifIed in_Israel, each ill a defined group: 
Christian-Arabs, Ashkenazi, Sephardic Jews and Druze. 
The FH Lithuania mutation, a 3-bp deletion in exon 4 (Gly 197) of the LDLR gene, 
- -
is predominantly present in Ashkenazi Jews in Israel. Lithuanian Jews have immigrated to 
countries all over the world, which explains the world wide distribution of the Lithuanian 
mutation. The high incidence of this mutation among South African Jews (Meiner et al. 
1991) is probably due to significant immigration of the Lithuanian Jews to South Africa. 
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FH among Christian Lebanese is mainly caused by a mutation in exon 14 that creates 
a Hinf I restriction site (Lehrman et al. 1987). This mutation produces a premature 
termination codon found to be responsible for FH in several Lebanese homozygous cases. 
The adult Christian-Arab population, living in the Galilee region of northern Israel, consists 
mainly of Lebanese who have immigrated over the last two centuries. Genetic isolation in a 
predominantly Muslim environment and a high degree of consanguinity contributed to the 
high frequency of this mutation in Christian Lebanese (Lehrman et al. 1987). The Lebanese 
mutation was also identified among Brazilian FH patients (Figueredo et al. 1992), most 
likely as a consequence of an independent mutational event. 
Mutation Y167X in exon 4 is responsible for the majority of FH cases in a small 
Middle Eastern Islamic sect, in two distinct Druze villages, Majdal Shams and Ein Kuniye, 
from the Golan Height in Northern Israel (Landsberger et al. 1992). The Druze community 
remained isolated because of religious restrictions and have the highest prevalence of 
consanguineous marriages in Israel (Freundlich and Hino 1984). 
Another mutation in exon 4 of the LDLR gene (DI47H) causes FH in ~10% of the 
Jewish Sephardic popUlation originating from Safed in Northern Israel (Leitersdorf et al. 
1993, Reshef et al. 1996) .. 
The geographical distribution of founder mutations, together with other relatively common 
LDLR gene mutations identified in different populations in the world, is illustrated in fig. 1. 
It is unlikely that a founder effect would occur. and be maintained in heterogeneous 
populations, such as in North America and Europe. These populations have a plethora of 
LDLR gene mutations, which are mostly restricted to single families. Interestingly, in some 
European populations increased frequencies of specific LDLR gene mutations have been 
reported. 
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Fig. I. Geographical distribution offounder/common LDLR gene mutations: I. Iceland, 2. Scotland, 3. United Kingdom, 4. ltaly, 5. Spain, 6. French Canadian (Quebec), 7. South Africa, 8. Norway, 9. Finland, 10. Denmark, II. Netherlands, 12. Belgium, 
13. Greece, 14. Israel, IS. India, 16. Japan, 17. China (Hong Kong). 
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United Kingdom 
The United Kingdom harbours a genetically heterogeneous population with regard to racial 
and ethnic origin, and therefore the presence of a founder mutation was considered unlikely 
(Day et al. 1997a). However, mutation E80K (Gudnason et al. 1993) detected in Manchester, 
932del A and D461N in Northern Ireland (Ward et al. 1995) and R392X (Day et al. 1997b) 
in Southampton, occur at frequencies of 12%, 8-9% and 10%, respectively. Haplotype 
studies revealed that mutation E80K arose from a single ancestor less than 1000 years ago 
(Wenham et al. 1998). This regional variation in the frequency of mutations might be due to 
population expansion over the last 100-200 years, with the effect being diluted by migration 
(Humphries et al. 1997). 
Spain 
Although the Spanish population is a heterogenous population with a broad spectrum of 
mutations in the LDLR gene (Cenarro et al. 1998), mutations E10X (exon 2) and 518deiG 
(exon 4) were found to be responsible for 20% and 13.3% of FH cases, respectively 
(Cenarro et al. 1996). Most of these FH subjects of Spanish origin were from the Aragon 
region. Haplotype analysis revealed that both mutations probably originated from a common 
ancestor. 
Belgium 
Mutation C122X accounts for 16% ofFH-cases in southern Belgium, but is less frequent in 
Northern Belgium (Descamps et al. 1997). Haplotype analysis revealed the same 
chromosomal background in all the families with mutation C122X, but extensive 
genealogical studies failed to reveal a common ancestor. 
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Italian 
A spectrum of mutations identified in FH homozygous Italian patients confirmed the allelic 
heterogeneity of FH in this population. Mutations D200G, C358R, V502M, G528D and 
P664L were identified in 3 or more unrelated FH cases. Each mutation has been associated 
with the same haplotype (Bertolini et a1. 1999). 
Greece 
Six LDLR gene mutations were identified in 60% of Greek FH heterozygotes. These 
mutations, G528D (22.7%), V408M (14.7%), S265R (11.3%), C152R (5.3%), D280G 
-~ 
(3.3%) and C292X (2.7%), represent a common ancestor for each mutation, which is 
consistent with the geographical distribution of FH families with these mutations throughout 
the country. Estimation of the number of generations from a common ancestor, indicates 
that these mutations arose in Greece within the last 1000 years (Traeger-Synodinos et a1. 
1998). Mutation V 408M was detected on a different haplotype than that reported for 
Afrikaners implying a recurrent mutational event at the CpG hotspot (Schuster et a1. 1993). 
Denmark 
Mutations W23X (15%), W66G (15%) and W556S (12%) account for a relatively large 
proportion of FH cases in Denmark '(Jensen et a1. 1997). Haplotypes identical in families 
with the W23X and W66X mutations, respectively, suggesting that the patients probably had 
common ancestors. The high prevalence of these mutations might be due to their 
introduction in Denmark in small isolated tribes before the whole country was populated 
(Jensen et a1. 1996). 
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Netherlands 
The Afrikaner founder mutation V408M also occurs at an increased frequency (1.5%) in the 
Dutch FH population. This mutation probably originated in the Netherlands and was 
introduced into South Africa by a Dutch settler in the 17th century (Defesche et al. 1993). 
Four LDLR gene mutations were associated with strong geographical preferences in the 
Netherlands: W23X (exon 2) is predominantly found in the Northeast, the combined defect 
N543H (exon 11)/2393 del 9-bp (exon 17) in the Northwest, the 191-2 (A~G) (intron 2) in 
the southwest and 1359-1 (G~A) (intron9) in the midsouth (Defesche and Kastelein 1998). 
Scotland 
A geographical preference of LDLR gene mutation C163Y (8.8%) has been reported in the 
Glasgow area, west of Scotland. The same D19S394 allelic size co-segregated with the FH 
phenotype in five of the seven probands with this mutation. This fmding is compatible with 
the mutation having occurred relatively recently on a chromosome of that allelic size, with 
the allelic association being maintained because of the small genetic distance (Lee et al. 
1998). 
Norway 
Three founder-type mutations underlying FH, S78X (8%), G~A at 193+1 (25%) and 
. C210G (8%) (Leren et al. 1994, Tonst~d et al. 1995, Sundvold et al. 1996), predominate in 
Norway~-Mlitati6if S78X -o"ccUrred on tliesame chromosomal background in all five families 
studied by Lerenet al. (1994). The splice mutation was associated with an identical 
haplotype in 16 of 20 families analysed. 
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Iceland 
In Iceland the presence of a founder mutation has been reported in the western part of the 
country. Mutation 694+2T ~C in intron 4 is present in approximately 60% of index cases 
and in half of these cases a common ancestor could be traced (Gudnason et al. 1997). The 
frequency of FH in Iceland has not been established, but is presumed to be similar to other 
countries. 
India 
The P664L mutation was first identified in a FH homozygote of Asian Indian origin in the 
Gujerat province of India (Soutar et al. 1989). This mutation occurs at a CpG dinucleotide 
and creates a Pst I site in exon 14 of the LDLR gene. Two different haplotypes were found 
in association with P664 L in FH patients in the UK, suggesting that the mutation arose 
independently in these cases (King-Underwood et al. 1991). This mutation, also identified in 
South African Indians by Rubinsztein et al. (1992), was probably spread across all over the 
world wherever the Muslim Gujeratis settled. 
China 
There are more than 50 different ethnic groups in China, of which the Hans forms the 
majod.iY. The Hans Chinese originated in the Yangtze and the Hwang Ho valleys. Although 
China is a relative isolated population over many generations, no evidence for a founder 
gene effect has been -found in the Jiang-su province where the majority of inhabitants are 
from the Yangtze valley group (Sim et al. 1994). An interesting observation is the apparently 
low plasma cholesterol levels and lack of xanthomata or premature CHD in Chinese FH 
heterozygotes studied by Sun et al. (1994). Mak et al. (1998a), however, observed the same 
clinical features in Chinese patients in Hong Kong as reported in Western countries or Japan, 
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and have also described three possible common mutations, C308Y, L393R and V408M, in 
this patient group. The L393R mutation accounts for 7.1 % of FH cases in the Hong Kong 
group and occurred on the same haplotype as described in German patients. Due to the 
geographical distance and historic ethnic differences, it is reasonable to assume that mutation 
L393R arose independently at the CpG hotspot (Mak et al. 1998b). 
Five LDLR gene mutations were found to underlie the disease in 30% of Japanese FH 
patients: 1845+2T~C (13.3%), C317S (6.7%), K790X (6.7%), P664L (3.3%) and E119K 
(1.7%). Mutation 1845+2 T~C has so far been found only in the Japanese population. 
Mutation C317S appears to be localised to the Kansai district, although the other mutations 
were widely distributed all over Japan. Since Japanese people are almost uniracial, and Japan 
is geographically isolated (Maruyama et al. 1995), these mutations may be considered 
founder-type sequence changes. 
1.4 Diagnosis of FH 
FH may be suspected in individuals with high cholesterol concentrations, normal triglyceride 
levels, tendon xanthomas and a family history of CHD. Early diagnosis ofFH permits timely 
treatment which may prevent of delay the development of CHD. Although the FH phenotype 
lends itself to clinical diagnosis, not all cases can be diagnosed with certainty due to clinicaJ 
variability of the disease, particularly in FH heterozygotes (Thompson et al. 1989, Kotze et 
al. 1993a, Gudnason et al. 1994, Pimstone et al. 1998). Sometimes the clinical expression 
of a given mutation varies within a family (Hobbs et al. 1989, Kotze et al. 1993b). Genetic 
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and environmental factors which may confer additional atherosclerotic risk to FH 
heterozygotes, such as elevated Lp(a) levels, hypertension, high blood homocysteine levels, 
diabetes, elevated iron levels, diet, old age and smoking may influence the disease 
expression and make prediction of CHD risk generally difficult. A defmite diagnosis of FH 
can be established by the application of genetic testing to defme the disease-causing 
mutation. DNA-based tests involve the screening of gross gene rearrangements by Southern 
blot analysis and/or long-range PCR, while point mutations, small deletions and insertions 
are usually detected by single strand conformation polymorphism (SSCP) analysis (Orita et 
al. 1989), denaturing gradient gel electrophoresis (DGGE) (Sheffield et al. 1989), RNase A 
cleavage (Myers et al. 1985) and/or chemical cleavage analysis (Cotton et al. 1988). Known 
mutations that predominate in specific population groups can be identified by restriction 
enzyme digestion of PCR products (Saiki et al. 1985) where appropriate, or allele-specific 
PCR (Newton et al. 1989). Kotze et al. (1995) have developed a multiplex PCR to identify 
mUltiple LDLR gene mutations in a single test. 
In this study, a combined heteroduplex-single strand conformation polymorphism 
(HEX-SSCP) method (Kotze et al. 1995) was applied to screen for unknown mutations in the 
promoter and coding region of the LDLR gene. Denaturing gradient gel electrophoresis 
(DGGE), performed according to Nissen et al. (1996), was applied in cases where no 
mutations could be identified using the HEX-SSCP method. Direct sequencing was 
subsequently performed to identify mutations in PCR products demonstrating mobility shifts 
·on polyacrylamide gels. . The detailed experimental procedures used in this study are 
described in the form of flow charts in Appendix 1. 
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Aims of Study 
Evaluation of the types and frequencies of mutations in different ethnic groups may broaden 
knowledge on the disease patterns in different population groups. The present study focussed 
on extensive DNA analysis of patients diagnosed with FH, in order to: 
investigate the molecular basis and mechanisms underlying inherited familial 
hyperlipidaemias in different population groups 
identify disease-causing mutations in hypercholesterolaemic index patients and 
subsequently in their relatives as part of the MED-PED initiative 
compare the spectrum of LDLR gene mutations in different South African 
populations 
develop a cost effective population-directed molecular screening strategy for FH in 
the South African population 
contribute to the establishment of a comprehensive predictive diagnostic service for 
FH in South Africa 
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Abstract 
Combined heteroduplex single-strand conformation polymorphism (HEX-SSCP) analysis 
of the promoter and coding region of the low density lipoprotein receptor (LDLR) gene 
revealed a novel C to T mutation at nucleotide position 2056 in a Costa Rican patient 
with heterozygous familial hypercholesterolemia (FR). This nonsense mutation, Q665X, 
results in a termination codon in the epidermal growth factor (EGF) precursor homology 
domain of the mature LDLR. 
Introduction 
Familial hypercholesterolemia (FH) IS an autosomal pominant disease caused by 
I 
mutations in the low density lipoprotein receptor (LDLR) gene. FH is characterised by 
raised plasma LDL cholesterol levels, tendon xanthomas and premature coronary heart 
• 2 dIsease (CE-ID). The prevalence of FH is about 1 in 500 in most populations. 
Characterisation of FH mutations is important for definite diagnosis, genetic counselling 
and optimal treatment of the disease in affected families. 
Materials and Methods 
Blood samples were obtained with informed consent from two members of a Costa Rican 
family. Both were diagnosed with heterozygous FH based on clinical features and 
. .. _ _ . 2 
elevated LDL cholesterol levels (>5 mmolll). Levels of total plas~a cholesterol (TC), 
high density lipoprotein cholesterol (HDLC) and triglycerides (TG) were determined by 
standard techniques as previously described.3 
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Genomic DNA was amplified by the polymerase chain reaction (PCR), using 20 sets of 
4 
oligonucleotide primers according to Jensen et al. (1996). PCR amplified fragments 
were screened by combined heteroduplex single-strand conformation polymorphism 
5 (HEX-SSCP) analysis according to Kotze et al. (1995). Direct DNA sequencing ofPCR 
products was performed using Sequenase Version 2.0 T7 DNA polymerase (United States 
Biochemical) according to the manufacturer's instructions. Restriction enzyme analysis 
of exon 14 PCR products was performed by AciI digestion, electrophor~sis in a 10% 
polyacrylamide gel and ethidium bromide staining. The ex on 14 PCR was performed 
usmg primers 14.3 (5'-CCTGACTCCGCTTCTTCTGCC-3') and 14.4 (5'-
. ACGCAGAAACAAGGCGTGTGC-3,).1 
Results and Discussion 
Mutation analysis showed a SSCP in exon 14 of the LDLR gene. Direct DNA sequence 
analysis revealed a novel C to T mutation, designated Q665X. This nonsense mutation at 
nucleotide position 2056 was predicted to destroy an AciI restriction enzyme cutting site, 
and this was confirmed in the DNA of the index case and her affected brother. After AciI 
digestion of the PCR product, the normal allele was cut into fragments of 113 bp, 83 bp 
and 8 bp, while an additional fragment of 196 bp was observed in the FH patient 
hetero~gous tor mutation Q665X (Fig. 1 ).- This nonsense mutation, which occurred in 
the second functional domain of the LDLR, is predicted to affect protein production or 
function. A truncated protein that would be rapidly degraded in the extracellular space is 
. I 6 
likelyto·be synthesised.' The mutation may also lead to skipping of the exon in which 
.. 1 d 7 It IS ocate . 
We have recently described an 8 bp insertion in a Costa Rican FH family, revealing an 
3 
insertional hotspot in exon 4 of the LDLR gene. Although knowledge on the molecular 
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basis of FH in Costa Rica is limited, the identification of yet another novel LDLR gene 
mutation in the family analysed suggests that this population has its own spectrum ofFH-
related mutations. The Q665X mutation was absent in 10 unrelated Costa Rican FH 
patients after AciI digestion ofPCR-amplified DNA. 
Fig. 1. Identification ofa novel mutation, Q665X, in exon 14 of the LDLR gene. AciI 
digested PCR products of a normal control (lane I) and the patient (lane 2). 
Stellenbosch University  https://scholar.sun.ac.za
45 
Acknowledgments 
Drs. J.G. Jimenez and M.A. Vargas are thanked for provision of blood samples, and lipid· 
and clinical data of the patients. J. Brusnicky is thanked for critical reading of the 
manuscript. This work was supported by the South African Medical Research Council 
and the Universities of Stellenbosch and Costa Rica. This work is part of a thesis to be 
submitted in fulfillment of the requirements for the degree of Doctor of Philosophy, 
University of Stellenbosch. 
Stellenbosch University  https://scholar.sun.ac.za
46 
References 
1. Hobbs, H. H., Brown, M. S. & Goldstein J. L. (1992). Molecular genetics of the 
LDL receptor gene in familial hypercholesterolemia. Human Mutation 1,445-66. 
2. Goldstein, J. L., Hobbs, H. H. & Brown, M. S. (1995). Familial 
hypercholesterolemia. In The Metabolic Basis of Inherited Disease. 7th edn, 
(Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D., eds.) Pp. 1981-2030. New 
York: McGraw-Hill. 
3. Kotze, M. J., Thiart, R., Loubser, 0., et al. (1996). Mutation analysis reveals an 
insertional hotspot in exon 4 of the LDL receptor gene. Human Genetics 98, 476-
78. 
4. Jensen, H. K., Jensen, L. G., Hansen, P. S., Faergeman, O. & Gregersen, N. 
(1996). High sensitivity of the single-strand conformation polymorphism method 
for detecting sequence variations in the low-density lipoprotein receptor gene 
validated by DNA sequencing. Clinical Chemistry 42, 1140-46. 
5. --Kotze, M. J., Theart, L., Callis, M.;-Peeters, A. V., Thiart, R. & Langenhoven, E. 
(1995). Nonradioactive mUltiplex PCR screening strategy for the simultaneous 
detection of multiple low-density lipoprotein receptor gene mutations. PCR 
Methods & Aplications 4, 352-56. 
6. Lehrrnan,M. A., Schneider, W. J., Brown, M. S., et al. (1987). The Lebanese 
allele at the low density lipoprotein receptor locus. The Journal of Biological 
Chemistry 262,401-10. 
Stellenbosch University  https://scholar.sun.ac.za
47 
7. Dietz, H. C., Valle, D., Francomano, C. A., Kendzior, R. J. Jr., Pyeritz, R. E. & 
Cutting, G. (1993). The skipping of constitutive exons in vivo 'induced by 
nonsense mutations. Science 259,680-83. 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3 
Mutation analysis in a small cohort of New Zealand patients 
originating from the United Kingdom demonstrates genetic 
heterogeneity in familial hypercholesterolaemia 
48 
Rochelle Thiartl*, Mathilde Varret2, Caroline J Lintote, Russell S Scote, Odell Loubser1#, L. du 
Plessis, J Nico P de Villiers 1 *, Catherine Boileau2, Maritha J Kotze1 * 
*MRC Cape Heart Group, IDivision of Human Genetics, Faculty of Medicine, University of 
Stellenbosch, Tygerberg 7505, South Africa 
2INSERM U383, H6pital Necker-Enfants Malades, Universite Rene Descartes, Paris V, 149-161 
rue de Sevres, 75743 Paris Cedex 15, France 
3Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand 
Submitted for pUblication 
Stellenbosch University  https://scholar.sun.ac.za
49 
Abstract 
Familial hypercholesterolaemia (FH) and familial defective apolipoprotein B-I00 (FDB) are 
relatively common lipid disorders caused by mutations in the low density lipoprotein receptor 
(LDLR) and apolipoprotein BI00 (apo B) genes, respectively. Molecular analysis at these loci 
were performed in eight Caucasoid New Zealand subjects with clinical features of heterozygous 
FR. Utilisation of an in vitro lymphocyte receptor assay demonstrated normal receptor function 
in four patients, of whom three screened positive for the founder-type apo B mutation, R3500Q, 
causing FDB. Four patients with reduced LDLR function, consistent with heterozygous FR, 
revealed 3 previously documented mutations in exons 3 (W66X), 6 (C292Y), and 7 (G322S) of 
the LDLR gene and a novel 2-bp deletion (TC or CT) after nucleotide 1204 (or 1205) in exon 9. 
The remaining patient was found to be FHlFDB negative after extensive mutation screening using 
both denaturing gradient gel electrophoresis (DGGE) and heteroduplex-single strand 
conformation polymorphism (HEX-SSCP) analysis. Haplotype analysis at the LDLR and apo B 
loci [mally excluded the likelihood that mutations in these two genes underlie the FR phenotype 
in the molecularly uncharacterised family. This study demonstrated both mutational and locus 
heterogeneity in a small cohort of New Zealand hypercholesterolaemics originating from the 
United Kingdom. 
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Introduction 
Apolipoprotein (apo) B is the major protein component of low-density lipoprotein (LDL) and 
mediates binding and uptake of LDL by its receptor on the cell surface. 1 Defects in the apo B-I00 
gene may prevent binding of the LDL to the receptor2,3 and result in a phenotype designated 
familial defective apolipoprotein B 100 (FDB), that is clinically indistinguishable from familial 
hypercholesterolaemia (FH).4 Both FH and FDB are characterised by raised LDL cholesterol 
levels, the presence of tendon xanthomata and premature coronary atherosclerosis2, and occur at 
an estimated prevalence of 1 in 500 individuals. 
Accurate diagnosis of FH and FDB can be performed by screening genomic DNA for 
mutations in the LDLR- and apo B genes. Although FDB is usually caused by mutation R3500Q5 
or a less common mutation: R3531C,6 undetermined mutations ill. the apo B gene may explain 
some presentations of autosomal dominant hypercholesterolaemia (ADH). ApoB - LDLR 
interactions may also be affected by processes such as antibody binding7 to e~ther the LDLR or 
apo B moiety. The potential heterogeneity of abnormalities of receptor-ligand binding suggests 
that the clinical syndrome characterised by very high LDL cholesterol levels could be diverse for 
molecular aetiology. A more precise determination of the molecular basis of phenotypic familial 
hyperlipidaemia can be addressed through specific assays measuring LDLR activity and by LDL 
binding assays. -The finding of normal receptor activity in a patient with very high cholesterol 
levels indicates a non-receptor defect, and further molecular studies are then warranted to exclude 
FDB or other LDL binding abnormalities. In this study 8 New Zealand patients from Anglo-
Saxon origin-were screened for mutations in the LDLR and apo B genes, in order to defme the 
spectrum of mutations underlying the clinical phenotype of heterozygous FH in these SUbjects. 
Materials and Methods 
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Patients 
A total of 8 unrelated hypercholesterolemic individuals, attending the Lipid Disorders Clinic at 
the Christchurch Hospital in New Zealand, were the subjects of the study. These Caucasoid New 
Zealanders of Anglo-Saxon origin were diagnosed with heterozygous FH, based on the presence 
of tendon xanthomata and a parental history of hypercholesterolaemia. All patients had normal 
renal, hepatic and thyroid function. 
Biochemical Analysis 
- - - -~ 
Blood samples were collected for measurement of lipids after a 12 hour fasting period, following 
6 weeks of an extensive diet. Hypolipidemic drug therapy was withdrawn 6 weeks prior to blood 
sampling. Plasma was used for lipid and apolipoprotein determinations, whereas blood cells 
were utilised for DNA preparation8 in the Hunter-Nye lipid Laboratory in Dunedin (NZ). -:rotal 
plasma cholesterol (TC) and total triglycrides (TO) were measured using enzymatic kits 
(Boehringer Mannheim) and controls from the Australian Lipid Standardisation programme. 
High density lipoprotein cholesterol (HDLC) was measured in the supernatant obtained after 
precipitation of lipoproteins containing apolipoprotein B from plasma. LDL cholesterol levels 
were calculated using the Friedwald equation.9 
LDLR-activity-
Specific assays measuring LDLR activity and LDL binding assays were assessed using the 
method of Cuthbert et al.9 A complete description has been given elsewhere.10 
Mutation detection 
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Four patients who exhibited normal LDLR function were screened for FDB as previously 
described. I I Patients without mutatio~s in the apo B gene were subjected to extensive mutation 
screening of the LDLR gene. Polymerase Chain Reaction (PCR)12 amplification of the promoter 
and coding regions were performed, using 20 sets of exon-specific primers according to Jensen et 
al.13 The study population has previously been screened for mutations in exon 4 of the LDLR 
genelO and therefore this part of the gene was excluded from the analysis. PCR-amplified 
fragments were screened by combined heteroduplex single-strand conformation polymorphism 
(HEX-SSCP) analysis according to Kotze et al. 14 which was performed on three different 
polyacrylamide gel systems in order to increase mutation detection efficiency. Direct sequencing 
of PCR products that revealed aberrant electrophoresis patterns were performed by the dideoxy-
chain termination DNA sequencing method using a commercial kit (Sequenase version 2.0 DNA 
sequencing kit) and/or fluorescence cycle sequencing followed by detection on a Perkin Elmer 
ABI PRISM 310 sequencer. Detection of mutations W66X, C292Y and 0322S were confirmed 
by XbaI, RsaI and BgIT restriction enzyme analysis, respectively. Restriction-enzyme digested 
PCR products were resolved on a 10% polyacrylamide gel (3%C) and visualised by staining with 
ethidium bromide. 
Haplotype analysis 
Haplotype analysis using polymorphic markers at the apo B [variable number of tandem repeats 
(VNTR),_dinucleotide TG-(TO)n, signal peptid€ ESP) markers]lS.I7 -and LDLR [DI9S394, 
D19S583, dinucleotide TA (TA) n]18-20 loci was performed in the family of patient KD. No 
mutations could be identified in this patient after extensive DNA screening using both HEX-
SSCP- arialysis- and DOGE performed according to Nissen et al?1 Blood samples were obtained 
with informed consent from seven family members for the haplotype analysis. 
Results and Discussion 
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The demographic and clinical characteristics of 8 hypercholesterolaemic subjects are summarised 
in Table 1, together with disease-related mutations identified in the apo Band LDLR genes. 
LDLR studies demonstrated reduced receptor mediated uptake of LDL consistent with 
heterozygous FH in subjects IB, ST, JS and JB, in whom LDLR gene mutations were identified, 
while the remaining patients had completely normal receptor function on repeated assay (data not 
shown). Detection ofthe common apo B mutation R3500Q causing FDB in subjects A W, RA and 
PR was compatible with these results. TC levels ranged from 9.4 to 10.3 mmoVI in these three 
patients, and from 7.8 mmoVI to 9.9 mmoVI in the four FH patients. It is noteworthy that the TC 
levels are generally higher in the FDB patients than in the FH patients, since previous studies 
suggested that FDB may be associated with a milder disease phenotype?2, 23 
The four different mutations identified in the LDLR gene are illustrated in Figure 1. The 
three previously-described point mutations in exons 3 (W66X),24 6 (C292y)24 and 7 (G322S)3 
alter known restriction enzyme recognition sites and could be confirmed in genomic DNA using 
XbaI, RsaI and BglI, respectively. The novel2-bp deletion (TC or CT) identified after nucleotide 
1204 (or 1205) creates a stop codon at residue 418. This deletion most likely causes the FH 
phenotype in patient IB, since the translational frameshift would result in a truncated protein 
lacking essential domains of the receptor. Family members were not available to confirm 
-- ---
Mendelian inheritance of the LDLR gene mutations identified in this study, but these mutations 
were absent in 100 normal chromosomes screened by HEX-SSCP analysis. 
The remaining patient with normal LDLR activity, but without a known FDB mutation, 
presented with a total cholesterol level of 7.8 mmoVI after following a cholesterol-lowering diet 
for 6 weeks. Haplotype analysis in the family of this patient (KD), using highly polymorphic 
markers at the LDLR and apo B genes, fmally reduced the likelihood that mutations in these 
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genes are responsible for the disease phenotype. Although limited data are available in this 
relatively small family, it is clear that the two normocholesterolaemic children of the index 
patient inherited different chromosomes from their father (Figure 2). 
Exclusion of FH and FDB in family KD after extensive mutation screening and haplotype 
analysis, is in accordance with earlier observations that there remains a proportion of clinical FH 
patients in whom no detectable defects can be identified in the LDLR or apo B genes,25-27 
suggesting that there might be a third gene underlying the FH phenotype. The combined use of 
HEX-SSCP and DGGEmutation screening is expected to detect up to 100% of small mutations. 
This family was therefore included in the linkage analysis performed by Varret et ai. (1999),28 
using micro satellite markers DlS2892 and DlS2722, shown to map near a third locus implicated 
in ADH. The likelihood that the putative gene on chromosome 1 causes the FH phenotype in 
family KD was, however, also excluded.28 Studies are underway to determine whether the 
hypercholesterolaemia in this family is caused by yet another locus recently implicated in ADH 
(M. Varret et aI., unpublished results). 
The demonstration of both mutational and locus heterogeneity in ADH in the small cohort 
of New Zealand hypercholesterolaemics studied complicates DNA diagnosis of FH in this 
population. However, the fact that the founder-type apo B gene mutation, R3500Q, was detected 
in three of the molecularly characterised hypercholesterolaemics studied, implies that a 
significant proportion of affected Caucasians living in New Zealand may have FDB. Although 
screening of a larger population sample needs to be undertaken to confirm this, future molecular 
diagnostic approaches in this population should first focus on detection or exclusion of mutation 
R3500Q. The apparently high prevalence of FDB in New Zealand hypercholesterolaemics 
originating from the United Kingdom may be due to a founder effect,similar to the situation 
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described for FH in South Africa, where three LDLR gene mutations (D154N, D206E and 
V408M) are responsible for the disease in 90% of Afrikaners of European descent.29 FDB was 
found to be rare in South Africa, most likely as a consequence of a "negative" founder effect 
which diluted the frequency of mutation R3500Q in the settlers relative to their parent European 
populations.3o Notably, the most common mutation D206E detected in South Africa, causing FH 
in approximately 60% of Afrikaners, has been identified in only one of the New Zealand FH 
patients screened for mutations in exon 4 of the LDLR gene. lO 
This study highlighted the value of pNA-based diagnostic methods in the complete 
elucidation of the genetics of ADH. The identification of new genes causing the FH phenotype 
may lead to the development of novel therapeutic approaches to prevent cardiovascular disease, 
which remains the leading cause of death in many countries. 
Table 1 Demographic and clinical data ofthe probands screened for mutations in the apo Band 
LDLRgenes 
Subjects Sex Age XMTA CHO TC TG HOLC LOLC Mutation Referenc 
e 
(yrs} (mmol/Q 
Normal LOLR function: Apo B gene 
AW F 42 + + 9.4 0.6 1.4 7.7 R3500Q 5 
RA M 48 + + 10.3 2.7 1.2 7.9 R3500Q 5 
PR F 49 + 10.2 1.1 0.9 8.8 R3500Q 5 
KO M 59 + .+ 7.8 2.5 1.3 5.3 None 
Reduced LOLR function: LOLR gene 
IB M 31 + 8.9 1.4 1.3 6.9 1204del2 New 
ST M 41 + 9.9 1.8 1.2 7.9 C292Y 24 
JS M 43 + 9.8 1.1 1.2 8.1 W66X 24 
JB F 69 + + 9.8 1.0 1.8 7.4 G322S 3 
XMTA, tendon xanthomas; CHD, coronary heart disease 
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Figure 1 Identification of mutations in the LDLR gene. A, Automated fluorescent sequence 
analysis demonstrates a 2-bp TC or CT deletion in FH affected individual ffi. B, Restriction 
enzyme analysis of PCR products of exons 3 (XbaI) , 6 (RsaI) and 7 (BgII). FH affected 
individuals are indicated in lanes 1, 3 and 5 for the respective exons. PCR products of normal 
controls was loaded in lane 2 (ex on 3), lane 4 (exon 6) and lane 6 (exon 7). 
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Figure 2 Segregation analysis of the LDLR and Apo B loci in family KD (II:3). Pretreatment 
total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density 
lipoprotein (LDL) levels in mmolll together with the respective ages (in years) of family members 
are indicated below the pedigree symbols. The disease status of ill:3 was uncertain. MI, 
myocardial infarction; nd, not determined. 
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Abstract 
In South Africa the high prevalence of familial hypercholesterolaemia (FH) among 
Afrikaners, Jews and Indians due to founder genes is in striking contrast to its reported virtual 
absence in the Black popUlation in general. In this study the molecular basis of primary 
hypercholesterolaemia was studied in 16 Africans diagnosed with FH. DNA analysis using 
three screening methods resulted in the identification of seven different mutations in the 
coding region of the low-density lipoprotein (LDLR) gene in lO of the patients analysed. 
These included a 6-bp deletion (GCGATG) accounting for 28% of defective alleles, and six 
point mutations (D151H, R232W, R385Q, E387K, P678L, R793Q) detected in single 
families. The Sotho patient with missense mutation R232W was also heterozygous for a de 
novo splicing defect 313+1G~A. Several silent mutations/polymorphisms were detected in 
I 
the LDLR and apolipoprotein B genes, including a base change (g~t) at nucleotide position-
175 in the FP2 LDLR regulatory element. This promoter variant was detected at a 
significantly higher frequency (P<0.05) in FH patients compared to controls, and occurred in 
cis with mutation E387K in one family. Analysis of four intragenic LDLR gene 
polymorphisms demonstrated that the same chromosomal background was identified at this 
-locus in the-four FH patients-with the-6~bpdeletion. Detection of-the 6-bpdeletion in Xhosa, 
Pedi and Tswana FH patients suggests that it is an ancient mutation predating tribal separation 
approximately 3000 years ago. 
- - - --
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Introduction 
Autosomal dominant hypercholesterolaemia (ADH) is most commonly caused by mutations in 
the low-density lipoprotein receptor (LDLR) gene causing familial hypercholesterolaemia 
(FH), or in the apolipoprotein B (apo B) gene causing familial defective apo B (FDB).I, 2 
These biochemical defects result in the precipitation of excess cholesterol, and clinical 
characteristics include tendon xanthomata and premature coronary heart disease (CHD). The 
estimated incidence of both FH and FDB is approximately 1 in 500 in most Caucasian 
populations. 
In the Afrikaner population of South Africa, the prevalence of FH has been increased 
to approximately 1 in 70, as a consequence of a founder effect following the introduction of at 
least three defective LDLR gene alleles by European settlers.3-5 This is in striking contrast to 
the apparently low prevalence of FH in the Black population, reported to have migrated from 
Central Africa to the South in three main groups, the Nguni's (Xhosa, Tembu, Swazi and 
Zulu) along the east coast, the Sotho's (South Sotho, North SotholPedi, West Sotho/Tswana) 
who settled further west on the Transvaal highveld, and the Venda's living in the Northern 
Transvaal area.6, 7 We suspect that FH is not frequently recognised in Africans due to altered 
clinical expression, an_~_llot ~e_cause _of a_l~werJnutati()n pr~valenQe compared to most other 
populations. Previous studies have indicated that the mutational mechanisms giving rise to 
germ-line mutations is largely a function of the local DNA sequence environment.8-10 
Since the situation in South Africa is ideal for studies of underlying lipid-related 
genetic differences among population groups,11 we attempted to identify Black 
hypercholesterolaemics to determine the spectrum of mutations in the promoter and coding 
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region of the LDLR gene and in exon 26 of the apoB gene. FDB has not previously been 
studied in the South African Black population, but was found to be rare in other South African 
populations, most likely due to a "negative" founder effect that diluted the frequency of the 
common apo B3500 mutation in the immigrants relative to their parent populations.12 
Subjects and Methods 
Subjects 
Blood samples were collected from 56 Black patients attending lipid clinics in South Africa, 
after obtaining informed consent and ethical approval by the regional Review Committees. 
Details on clinical features and ethnicity were provided by the referring clinicians. Sixteen 
patients with a diagnosis of "classical" or "probable" FH, including two FH homozygotes, 
were selected for extensive mutation analysis for the coding and promoter region ofthe LDLR 
gene and exon 26 of the apo B gene. Blood samples were also obtained from 38 of their 
family members (table 1). Classical FH (12 probands) was defmed as the occurrence of 
pretreatment total cholesterol (TC) >7 mmolll, with the presence of tendon xanthomata and/or 
premature CHD in the index case or a fIrst-degree relative. Probable FH (4 probands) was 
defIned by the same pretreatment cholesterol level anQ prim~ hyperchol~sterolaemia and/or 
. --- - --- --- - -- .~- .. - -
premature CHD in the family (table 1). DNA samples of the 40 lipid clinic patients without 
the FH phenotype, but who had hyperlipidaemia or normal lipid profIles in the presence of 
vascular disease, were included for analysis of specifIc regions of the LDLR gene. Ninety-six 
individuals drawn from the same population (19 Pedi's, 21 Sotho'S, 27 Xhosa's, 29 Zulu's) 
were sampled as controls. TC, high-density lipoprotein cholesterol (HDLe) and triglyceride 
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(TG) determinations and extraction- of genomIc DNA were performed usmg standard 
methods!3 Plasma LDL-cholesterol (LDLC) concentrations were calculated with the 
Friedewald formula [LDLC=TC-(HDL+TG/2.18)].!4 
Mutation detection 
Heteroduplex single-strand conformation polymorphism (HEX-SSCP) analysis was 
performed in South Africa,!5 and denaturing gradient gel electrophoresis (DGGE) in 
Denmark!6 and Scotland,17 to screen polymerase chain reaction (PCR)-amplified genomic 
DNA for mutations in the LDLR and apo B genes. For HEX-SSCP analysis, the exon-specific 
primers described by Jensen et al.!8 were used, while the promoter region of the LDLR gene 
was amplified usmg primers 5'-GAGGCAGAGAGGACAATGGC-3' and 5'-
CCACGTCATTTACAGCATTTCAATG -3'. Base changes in the promoter region were 
numbered according to Hobbs et al.!9 after adding an additional A within the AAAA stretch 
preceding repeat 1, which is missing from the published sequence.20 PCR products showing 
aberrant electrophoresis patterns were sequenced on both strands with a PCR Product 
Sequencing kit (Amersham) andlor an automated sequencer ABI 373A. 
HaploJ)'fJe anal)lsl~ 
Haplotype analysis using four LDLR gene polymorphisms was performed according to Theart 
et al.2! Microsatellite markers VWA31, FIAI and THOI (Profiler kit, Applied Biosystems) 
were used to test for biological consistency in two families. 
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Statistical analysis 
Allele frequencies were detennined by allele counting. Testing for significance of 
heterogeneity in mutation frequencies among patient and control groups was based on the Chi-
square and Fisher's exact tests. 
Results 
Extensive DNA screening of the LDLR gene in 16 Black FH patients, using both the DGGE 
and HEX-SSCP screening methods, revealed 6 missense mutations in individual families and 
a 6-bp deletion in four probands (table 1).22 The deletion (FH Cape Town-I), previously 
described in a Xhosa FH homozygote,23 and missense mutations D151H and R385Q have not 
(yet) been reported in other populations. Haplotype SmaI+/StuI+IAvaII- was associated with 
the deletion in all three FH heterozygotes and a homoallelic FH homozygote. Screening of the 
coding region in DNA of the four FH patients heterozygous for a base change (g~t) at 
nucleotide position -175 of the LDLR gene promoter, resulted in the detection of a recycling-
deficient mutation E387K19 in the DNA of subject EF. Interestingly, this Pedi proband was 
found to be extremely heterogeneous at the DNA level, since a silent C to T base change was 
furthe~ore det~cted atJ:lllcleotid~_positioI!J 104 in ~xon 8, in addition to two silent mutations 
in the apo B gene. The G to C change in the third base of codon 3540 (T3540T) and the T to 
C change in the third base of codon 3552 (T3552T) in the apo B gene have previously been 
reported in Nigerian and African Arp.erican subjects, respectively.17 One of the daughters of 
proband EF (ll-3 in fig. 1) carried two copies of the silent apo B mutation at codon 3540. 
RFLP analysis indicated that haplotype SmaI+/StuI+1 A vall-INcol+ co-segregated with the -
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175t allele in the family (fig. 1). This chromosomal background was also identified in two of 
the other probands with the sequence substitution at -175 in the LDLR promoter region, while 
haplotype Sma1-/StuI+/AvaIT+lNcol+ was associated with the t allele in the Tswana proband 
(LM), who also carried the T3552T variant in the apo B gene. 
In order to determine whether the two mutations identified in each of probands EF 
and SH occur in cis or in trans on their respective chromosomes, blood samples were obtained 
from additional family members for segregation analysis. Pedigree analysis in the family of 
EF demonstrated that mutation E387K and the -175g~t variant occur on the same 
chromosome (fig.l). All the family members who inherited the 387K1-175t haplotype (I-I, 1-2, 
IT-2, IT-4, ill-2 and ill-5) had abnormally high TC and LDLC levels. Individual IT-2, with a 
clinical diagnosis of heterozygous FH, was homozygous for the t allele at nucleotide position -
175. This implies that her deceased father (husband of the index case) also carried the -
175g~t promoter variant, but in the absence of mutation E387K. Her normocholesterolaemic 
son (ill-I), as well as her brother inherited this paternal chromosome, the latter presenting 
with a moderately raised TC value. The proband's son (IT-I) and one of her daughters (IT-3) 
(confirmed by marker studies using highly informative micro satellites ) had moderately raised 
plasma cholesterol concentrations in the absence of either the promoter variant or the exonic 
mutation, indicating that another unknoWll-factor-contributes to the abnormal lipid profile 
observed in this family. TC concentrations were found to be very low in the general Black 
population (approximately 3 mmol/l) compared with other South African groupS?4, 25 
DNA screening of the 53-year old father of proband CK, diagnosed with 
homozygous FH, revealed homozygosity for the t allele at nucleotide position -175. His TC 
and LDLC levels were 6.11 mmoVI and 4.29 mmol/l, respectively, which is comparable to 
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that of a FH heterozygote. Plasma TG and HOLC concentrations were 1.49 mmoVI and 1.14 
mmoVl, respectively, and the only clinical feature indicative of hyperlipidaemia in this 
obligate FH heterozygote was corneal arcus. 
HEX-SSCP analysis indicated that the splicing defect identified in exon 3 represents 
a de novo event in the family of SH, since it was not present in any of his close relatives 
analysed. Familial relationship was illustrated by transmission of the exon 5 mutation 
(R232W) from the father (72 years, TC 4.1 mmoVl), and was further substantiated by marker 
studies using three highly informative microsatellites (data not shown). Mutation R232W was 
absent in the normocholesterolaemic brother (30 years, TC 3.5 mmoVI) and sister (42 years, 
TC 3.3 mmoVl) of the proband. Their mother aged 62 years presented with a TC level of 2.9 
mmoVl. It was therefore not possible to determine whether the splice mutation occurred in cis 
in the proband on the paternal chromosome bearing mutation R232W, or in trans on the 
normal maternal chromosome. 
Subsequent DNA screening of 96 control individuals from the general Black 
population comprising 56 Nguni's (27 Xhosa'S, 29 Zulu's) and 40 Sotho's (19 Pedi's, 21 
Sotho's) resulted in the identification of 6 individuals [4 Nguni's (1 Xhosa, 3 Zulu's) and 2 
Sotho's (1 Pedi, 1 Sotho)] heterozygous (6%) for the -175t allele. Although the number of 
. patients analysed is small, the ftequency of this allele appeared to be higher within each 
- --- - ~---
tribal group (2/6 Nguni's and 2110 Sotho's with FH) compared to the controls (4/56 Nguni's 
and 2/40 Sotho's). An overall statistically significant difference (P<0.05) was observed 
between the presence of the rare t allele in the general Black population (0.03) compared to 
its frequency of 0.13 in the patieiIts diagnosed with classical or probable FH (X2=5.916, Idf, 
P=0.0149). We furthermore identified 5 carriers of the -175g~t polymorphism among 40 
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lipid clinic patients without the FH phenotype (13 %), demonstrating an intermediate allele 
frequency of 0.06. This was not significantly different from the frequencies observed in the 
FH (X2=1.326, Idf, P=0.249) or control (X2=1.474, Idf, P=0.224) groups. Variant -175g~t 
was also detected in 1147 DNA samples of control individuals from the Venda tribe studied by 
Ehrenborg et a1.25 while absent in more than 300 Caucasians screened.26 
Discussion 
Numerous LDLR gene mutations (>600) have been identified in FH patients world-wide, but 
. d BI k Afr· I . 19 22 23 27 A ·k· fi d· . th 6 b genetIc ata on ac lcan popu atlOns are rare. ' " stn mg ill mg IS at a - p 
deletion predominates in a small number (5/18) ofFH patients 19,23,28, this study identified in the 
South African Black population, where this lipid disorder is thought to be rare. This deletion 
in exon 2 removes an aspartic acid and a glycine from the first cysteine-rich ligand binding 
repeat of the LDLR, and impairs its transport but not lipoprotein binding in fibroblasts. 23 
Frequent detection of a deleterious mutation can be due to consanguinity, recurrent mutational 
events, genetic drift, founder gene effect, multiple introduction of the mutation into a 
population or heterozygote advantage. 
The_6-bp ~eletion ide~tified ()riginaUy in ahomoallelic Xhosa FH homozygote,23 and 
now also in a homozygous Pedi and three FH heterozygotes (Pedi and two Tswana's) on the 
same haplotype, have not (yet) been ·reported in other populations. These fmdings largely 
exclude the likelihood of a recurrent mutational event due to slipped mispairing or multiple 
entries of the deletion-mutation into the Black population. Detection of the deletion in 
different tribes suggests that it originated in Africa approximately 3000 years ago prior to 
Stellenbosch University  https://scholar.sun.ac.za
72 
tribal separation.29 Although FH patients with the deletion may therefore be distantly related, 
family ties cannot at present explain its relatively high prevalence among Black FH patients. 
The apparently low prevalence of FH in South African Blacks and the large population size 
furthermore argue against a founder effect. It is, however, possible that the deletion-mutation 
was propagated and inherited within a small group of people who later evolved separately into 
different African tribes. Another plausible explanation is that this deleterious deletion-
mutation may be associated with a selective advantage in Africa. Already in 1990 Hobbs and 
colleagues3o noted that the presence of several founder mutations in different South African 
population groups 4, 31 may be indicative of a Darwinian selection that favours the 
heterozygous state in this region of the world. Since the most likely selective agent in Africa 
would be infectious diseases, the fmding that LDLR-deficient mice are protected against lethal 
endotoxemia and severe gram-negative infections32 supports the likelihood of such an 
evolutionary selection mechanism conferring a survival advantage. In addition to binding and 
inactivating endotoxin, lipoproteins also bind certain viruses and inhibit their infectivi~3 
Although the family data presented in this study demonstrate that the -17Sg-H 
polymorphism residing in a cis-acting element in the LDLR promoter34 does not cause the FH 
phenotype in affected individuals, further studies are warranted to investigate the likelihood 
that t!?:is varia1!t mayinfluel!~e disease expression._The likelihood that .the significantl)[ higher 
frequency of the -17Sg~t promoter polymorphism in South African Black FH patients 
compared with controls (P<O.OS) is caused by linkage disequilibrium with another 
downstream mutation causing the FH phenotype, was excluded by haplotype studies which 
demonstrated that the rare t allele was associated with different LDLR haplotypes. This allele 
furthermore co-segregated with missense mutation E387K in one family. These different 
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chromosomal backgrounds may be the result of recombination events, reflecting the age of the 
-175g~t variant. Compared to Caucasians, Blacks are considered older in evolutionary 
terms35 and can therefore be expected to have accumulated variation over a longer time 
period. It is possible that the -175g~t polymorphism did not spread to other parts of the 
Id h · b· C· 1· 18 36 this study Th Afr· .. f wor , ence Its apparent a sence m aucaslan popu atlOns. ' , e Ican ongm 0 
the -175g~t variant was confirmed by detection of the rare t allele at a low frequency in 
control DNA samples obtained from Nigerians and African-Americans.26 African Americans 
originated mostly from the western African coast and arrived in North America between the 
16th and 19th centuries. 
One Sotho proband was heterozygous for a known splicing defect in intron 3 
(313+1G~A) and for the R232W mutation in exon 5. In all the patients with mutation 
313+ 1 G~A studied to date, the splicing defect is associated with a clinical picture of severe 
hypercholesterolaemia and early CHD.37, 38 Patient SH had a TC concentration of 13 mmo1l1, 
but it is uncertain whether this high level is solely due to the 313+ 1 G~ A mutation or whether 
there is an additional effect of the downstream R232W mutation. Family studies could not 
rule out the possibility of a double mutation, but demonstrated that the splicing defect is the 
consequence of a de novo mutation. None of the family members of SH were 
-hypercholesterolaemi-c,- including his 72':"year old father (LDLC 1.9 mmo1l1), who was 
heterozygous for mutation R232W. This fmding indicates that R232W does not affect LDLR 
fun~t!onor,alternatively, that clinical expression of this missense mutation is altered by other 
genetic and/or environmental factors. 
Although the identified missense mutations have not yet been characterised further, 
they are likely contributors to the FH phenotype in our patient sample, since all the codon 
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changes involve conserved ammo acids and were not detected in the normal population. 
Screening for mutations causing FDB16, 17, 39 resulted in the identification of two silent 
mutations T3540T and T3552T (data not shown) previously described in a Nigerian and 
African American subject, respectively.17 Failure to identify disease-related mutations in all 
the patients studied may be due to limitations imposed by the screening techniques used, 
clinical misdiagnosis ofFH, or mutations in other genes causing the ADH phenotype.4o, 41 
Both the Zulu and Pedi patients clinically diagnosed with homozygous FH presented 
with relatively low pretreatment TC levels «15 mmolll) for this severe condition1 and neither 
have yet suffered from CHD. The relatively mild expression of homozygous FH in these 
subjects largely precludes an estimation of the prevalence of heterozygous FH in the South 
African Black population based on the prevalence of homozygous FH. Elevated plasma 
cholesterol levels causing FH in a family frequently remain undetected until the occurrence of 
coronary events or clinical signs indicative of FH is observed in one or more family members. 
This may particularly be the case in the South African Black population, as 
hypercholesterolaemics with lipid profiles compatible with the diagnosis of heterozygous FH 
frequently lack xanthomata characteristic of this condition.42, this study None of the FH 
heterozygotes with the relatively severe 6-bp deletion in exon 223 presented with CHD. These 
fmdings provide evidence that FH is probably underdiagnosed -in the South African Black 
population, most likely as a consequence of altered expression of FH-related mutations. This 
may be due to interaction with other genetic and environmental factors, including a prudent 
.. ~-
dietY Data provided by us and others43-45 therefore suggest that clinicallbiochemical criteria 
for the diagnosis ofFH need to be different by country/population and that DNA methods may 
assist in making a defmitive disease diagnosis. 
" 
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Table 1 
Characteristics of African pro bands analysed for LDLR and apo B gene mutations 
Index Ancestry Sex Age TC TG HDL LDL Clinical LDLRgene 
(mmoVI)C sequence changes 
CM Xhosa F 52 8.5 2.7 1.5 5.8 CHD R793Q 
MX Xhosa M 50 :10.8 2.0 0.9 9.0 Arc,Xan -175~-H 
AN Swazi F 58 .10.1 0.9 1.3 8.4 Are, Xan, CHD D151H 
AS Swazi M 49 8.0 1.0 2.1 5.4 Are, CHD P678L 
AM3 Swazi/Zulu F 56 8.3 1.5 1.9 5.7 Arc 
CKb Zulu M 26 13.8 0.8 1.3 12.1 Arc,Xan -175g~t 
SH Sotho M 33 12.7 2.2 1.2 10.5 Arc,Xan 313+1G~A; R232W 
RK Sotho M 58 10.7 2.3 1.0 8.6 CHD R385Q 
KN° Pedi F 32 14.9 0.8 1.4 13.1 Arc,Xan 6-bp del, 6-bp del 
EF Pedi F 56 13.1 1.1 1.2 11.4 Are, PVD, CHD E387K; -175g~t; C347C 
LP Pedi F 61 9.4 0.8 0.9 8.1 Arc,Xan 6-bp del 
CN3 Pedi F 57 7.4 2.6 0.9 5.3 Arc,PVD 
RM3 PediiTswana F 54 :10.8 0.4 1.3 9.3 Are, ?Xan 
LM3 Tswana F 56 6.1 1.8 1.8 3.5 Arc,CHD -175g~t 
RL Tswana F 30 9.3 0.8 1.7 7.2 Arc,Xan 6-bp del 
CS Tswana F 47 7.9 0.7 1.7 5.9 Arc 6-bp del 
The majority of mutations summarised in this table were included in a recent mutation update. 
Reference plasma cholesterol concentrations in the general Black population are given in ref. 24 
Apo B gene 
sequence changes 
T3552T; T3540T 
T3552T 
TC, total cholesterol; TG, triglycerides, HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CHD, coronary 
heart disease, PVD, peripheral vascular disease, Are, arcus comealis; Xan, xanthomata. 
3Probable FH; bClinical FH homozygotes; cPretreatment concentrations, except for proband LM for whom pretreatment levels was not available 
J 
Relatives 
Tested 
0 
0 
0 
0 
11 
1 
4 
0 
0 
10 
3 
6 
3 
0 
0 
0 
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Figure 1 Pedigree of proband EF (arrow) clinically diagnosed with heterozygous FR. 
Clinical, biochemical and genetic data are provided for individuals of whom DNA samples 
were available. Those with elevated plasma cholesterol levels are indicated by dark-
(mutation-positive for E387K) and shaded symbols. The presence (+) or absence (-) ofLDLR 
gene mutations and recognition sites for SmaI, Stu!, AvaIl and NcoI are indicated. 
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Abstract 
Familial hypercholesterolaemhl (FH) has been a focus of research in South Africa since 1980, 
when this lipid disorder was recognised as a common cause of premature coronary heart 
disease (CHD) in Afrikaners of European. descent. Extension of clinical and biochemical 
studies to also include molecular analysis of the low-density lipoprotein receptor (LDLR) 
gene, revealed 65 different mutations in South African hypercholesterolaemics. In addition to 
mutations D154N, D206E and V408M which account for FH in 90% of affected Afrikaners, 
four missense mutations D200G, S285L, C356Y and G361V representing possible minor 
founder events, were identified in this relatively homogeneous population group; Common 
mutations have also been described in South African .Indians (P664L) and Jews (del 197), 
most likely as a consequence of multiple introductions of defective genes into these isolated 
communities, following earlier expansion· in the parent countries. Subsequent mutation 
analysis of the indigenous South African population of mixed ancestry revealed that the 
aforementioned LDLR gene mutations contribute significantly (~20%) to their FH phenotype. 
Predominance of a 6-bp deletion identified in exon 2 of the LDLR gene in the Black 
population, where FH appears to be extremely rare, raises the possibility that heterozygous 
FH may be associated with a selective advantage in Africa. Delineation of the mutational 
spectrum in South African FH patients has revealed that variation in the LDLR promoter 
region may significantly influence the expression of FH-related gene defects in indigenous 
African populations where these mutations prevail. 
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Introduction 
Familial hypercholesterolaemia (FH) contributes significantly to the high mortality rate from 
coronary heart disease (CHD) worldwide (Goldstein et al. 1995). To date, more than 600 
mutations (http://www.ucl.ac.uklfh and http://www.umd.necker.fr.) underlying this common 
lipid disorder have been identified (~1I500) in the low-density lipoprotein receptor (LDLR) 
gene. Despite the general diversity of mutations responsible for FH, some mutant alleles are 
common in specific South African ethnic groups (Kotze et al. 1991a, 1998, Meiner et al. 
1991), which serve as a helpful tool in the implementation of population-directed genetic 
screening programs. Founder effects with or without genetic drift probably resulted in an 
increased prevalence of FH in Afrikaners (Seftel et al. 1980) and several other homogeneous 
populations groups (Lehrman et al. 1987, Moorjani et al. 1989), but are unlikely to occur in 
countries with great ethnic and genetic diversity. FH is not associated with infertility, and 
therefore the gene frequency would not be influenced by negative selection (heterozygote 
disadvantage) in the heterozygous state. 
This review will focus on new perspectives derived from delineation of the mutational 
spectrum of the LDLR gene in the South African population, known to be enriched with 
specific founder LDLR gene mutations. Although these common mutations impose a major 
risk for the development of CHD, several advantages could be derived for diagnostic and 
research purposes. The unique South African Afrikaner community is a valuable candidate 
population for mapping of genetic traits, analysis of geographic distribution and origins of 
mutations, investigation of new causes of the FH phenotype in patients without founder-
related mutations, delineation of gene-gene interactions, evaluation of factors modulating 
phenotypic expression of the disease, and studies of genetic determinants of therapeutic 
response (Davigon and Roy, 1993). 
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Exploiting the "founder effect" in the Afrikaner population 
The Afrikaner population of South Africa provides an excellent example of founder events in 
human evolution. The high prevalence of several genetic diseases in this population 
(http://helix.biology.mcmaster.cal3j3/3j3.founder) resulted from a restriction in genetic 
variability due to geographic isolation and strict religious/cultural bonds, coupled to rapid 
population expansion over 10-12 generations. Molecular-genetic research of FH in South 
Africa was initiated in 1986, in an attempt to investigate the founder hypothesis (Sefiel et al. 
1980) implying that a limited number ofLDLR gene mutations would underlie the disease in 
the Afrikaner population. Initially, intragenic restriction fragment length polymorphisms 
(RFLPs) were used to defme haplotype associations, demonstrating a predominance of three 
distinct chromosomes in the FH population compared with a control group (Kotze et al. 1987, 
1989a, Leitersdorf et al. 1989). Subsequent cloning and/or DNA sequence analysis of the 
disease-associated chromosomes led to the identification of three founder-related point 
mutations, D154N, D206E and V408M, collectively accounting for the disease in ~90% of 
affected Afrikaners (Kotze et al. 1989b, 1990, 1991a, Leitersdorf et al. 1989). Based on this 
knowledge, a cost-effective polymerase chain reaction (PCR)-based method was developed 
for the simultaneous analysis of all three founder mutations in a single multiplex assay (Kotze 
et al. 1995). Direct mutation screening demonstrated that DNA diagnosis of FH is more 
accurate than a clinical diagnosis (Kotze et al. 1992, Koivisto et al. 1992). Genotype-
phenotype correlation studies performed in the Afrikaner population furthermore 
demonstrated for the first time that mutational heterogeneity in the LDLR gene may influence 
the phenotypic expression of heterozygous FH (Kotze et al. 1993a, Graadt van Roggen et al. 
1995). However, other genetic and environmental factors were found to contribute to 
Stellenbosch University  https://scholar.sun.ac.za
89 
expression of disease-causing mutations (Kotze et al. 1993b, Pimstone et al. 1998), which 
complicates accurate diagnosis of FR. 
To assure continuing awareness of this treatable disorder in South Africa and to 
highlight the importance of family studies, particularly in cases where the gene defect has 
been identified in an index patient, two Genetic Information Meetings were held during 1998. 
These events were an extension (Kotze et al. 1996a) of the international MED-PED project 
(Williams et al. 1993). This initiative also served as a paradigm of other common genetic 
diseases in South Africa (Kotze and Callis 1999). 
Population screening to define the mutational spectrum in South Africa 
Since 1994, the focus of FH research in South Africa has been aimed at the development of a 
comprehensive population-directed molecular test for accurate diagnosis of this disease. 
Knowledge of the mutational spectrum underlying FH in different South African ethnic 
groups is a prerequisite for such a screening approach. Therefore, DNA samples of FH 
patients without any of the previously-described founder-type mutations (Kotze et al. 1991 a, 
1998, Meiner et al. 1991, Kotze et al. 1997, Loubser et al. 1999), were subjected to extensive 
mutation analysis ofthe promoter and coding region ofthe LDLR gene. A total of 65 different 
LDLR gene mutations, including ten founder-type mutations highlighted in Table 1, have 
been identified in the diverse South African population. Predominance of a limited number of 
LDLR gene mutations in specific groups facilitated the development of a cost-effective 
population-directed screening strategy for accurate diagnosis of FH in South Africa. 
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Afrikaner population: Identification of four additional' "minor founder" LDLR gene 
mutations 
Previous mutation and haplotype studies demonstrated that the three common Afrikaner 
mutations, identified in exons 4 (D154N, D206E) and 9 (V408M) of the LDLR gene, were 
probably introduced into South Africa from the United Kingdom and the Netherlands, 
respectively (Gudnason et al. 1993, Defesche et al. 1993). Extended mutation analysis of 
Afrikaner FH patients without these three common mutations revealed 10 additional sequence 
changes in this population (Table 1). Four missense mutations, D200G, S285L, C356Y and 
G361 V, occurred in 12 apparently unrelated Afrikaner families. Notably, in a study performed 
approximately ten years ago four unique FH-associated haplotypes were identified (Kotze et 
al. 1989a), which defmed the chromosomal backgrounds for each of these "minor founder 
mutations". In order to further assess the likelihood of a common origin or recurrent 
mutational events in all the above cases, haplotype studies were extended using two highly 
informative micro satellite markers, D19S221 and D19S394, located 1.3 Mb centromeric and 
250 kb telomeric to the LDLR gene, respectively (Traeger-Synodinos et al. 1998). In general, 
the genotype results were consistent with a common ancestry for each mutation. Minor 
differences in allelic sizes detected in a small proportion of the samples, can probably be 
- _. - ---" - - - - - - - - -- - - -
attributed to replication slippage within the repeats. Unequal crossing-over events are highly 
unlikely in this context, because the differences in allele sizes involved only single repeats. 
Similar results were obtained for 13 patients with mutation D154N, 25 with D206E and 6 
with V 408M, and therefore it was not possible to make any predictions on the historical ages 
of these sequence changes. However, mutation S285L in exon 6 was probably 
introduced/arose most recently in the Afrikaner population, since association with identical 
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alleles for both D19S221 and D19S394 was demonstrated in Afrikaner families with this 
mutation. 
Previous detection of mutations D200G and S285L in the United Kingdom and the 
Netherlands respectively, ,indicate that their mutational origins can probably be traced back to 
these countries (Hobbs et al. 1992, Gudnason et al. 1993), although both the mutations have 
also been observed in other populations (http://www.ucl.ac.uk/fu). In contrast, novel 
mutations C356Y and G361 V have not previously been described in other populations. None 
of the mutations were identified in the normal population, and both involve evolutionary 
conserved residues (Mehta et al. 1991) in the epidermal growth factor (EGF) precursor 
homology domain of the LDLR gene. This domain mediates acid-dependent dissociation of 
the receptor and ligand in the e.ndosome and therefore mutations in this LDLR region are 
likely to affect receptor recycling (Hobbs et al. 1992). Mutations D200G, S285L, C356Y and 
G361V co-segregated with hypercholesterolaemia in the respective families. All the 'other 
mutations detected in single Afrikaner families have been described previously, and were 
confirmed by restriction enzyme analysis where appropriate. Identification of at least seven 
founder-related LDLR gene mutations among Afrikaners may imply that the reported FH 
prevalence of 1170 in Afrikaners, based on screening for three mutations causing FH in 90% 
of cases and a background prevalence of 11500 (Steyn et al. 1997), may be an underestimate. 
Mixed ancestry: Caucasoid admixture contributes significantly to the FH phenotype 
The prevalence of FH has not yet been determined in South Africans of mixed ancestry, but 
the clinical impression is that it is relatively high. Loubser et al. (1999) have demonstrated 
that three Afrikaner founder mutations contribute significantly (15%) to the FH phenotype in 
this indigenous South African ethnic group (Coloured population). Mutations D154N and 
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D206E were associated with the same haplotype in the Coloured and Afrikaner populations, 
indicating a common origin. Detection of mutation V 408M on different chromosomal 
backgrounds can probably be ascribed to a recombination or gene conversion event (Loubser 
et al. 1999). The 3-bp deletion of codon 197 found to be common in Aszkenazi Jews and 
mutation P664L that is frequently detected in Indians (Table 1), were probably introduced 
, 
into the Coloured popUlation by recent admixture. These mutations, together with the 
Afrikaner founder mutations and a 2.5-kb deletion involving exons 7-8 (4%), account for FH 
in at least 20% of affected Coloureds living in the Western Cape Peninsula (Loubser et al. 
1999). In one of the probands of mixed ancestry, a promoter mutation (-59c~t) was identified 
within the 10-bp core sequence of repeat 2, which resulted in reduced LDLR transcriptional 
activity (Scholtz et al. 1999). This mutation was detected in her normocholesterolaemic son, 
together with a single base change at nucleotide position -124 (c~t) which increases LDLR 
promoter activity (~160%). The intra-familial phenotypic variability observed amongst 
individuals with the -59c~t mutation has therefore been ascribed to allelic interaction, 
suggesting that variation in the LDLR promoter region may significantly influence the 
expression of FH-related mutations in populations where these mutations prevail. Notably, 
polymorphic sequence variants are frequently detected in the LDLR promoter region in 
populations with an African genetic element, but appear to be absent in_ Caucasians (Top et al. 
1992, Hoogendijk 1999). The Coloured population appears to be an excellent example of the 
consequence of admixture in populations with different disease risks due to genetic factors, 
and is a potential candidate for admixture linkage disequilibrium (ALD) approaches to map 
genes involved in CHD and other complex traits. 
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Black population: Predominance of a 6-bp deletion 
Hypercholesterolaemia in the South African Black population (Nguni's, Sotho's and Venda's) 
appears to be an unusual fmding (Seedat et al. 1993). However, it has been reported that the 
prevalence of ischaemic heart disease is increasing among urban Blacks in South Africa, 
which can probably be ascribed to adoption of a western lifestyle. Interestingly, a 6-bp 
deletion (GCGATG) has been detected in exon 2 of the LDLR gene (Leitersdorf et al. 1988) 
in four apparently unrelated Tswana and Pedi patients. Two of these patients from different 
tribal groups were homo allelic FH homozygotes (Leitersdorf et al. 1988, Thiart et al. in 
press). The observation that this deletion is associated with the same haplotype in different 
tribes, indicates that this may be an ancient mutation predating tribal separation approximately 
3000 years ago (Thiart et al. submitted). A promoter polymorphism at nucleotide position -
175 (g~t) was detected at a significantly higher frequency in FH patients compared to 
controls drawn from the same population (P<0.05), suggesting that this variant might 
exacerbate the expression of other FH-related mutations in South African Black patients 
(Thiart et al. submitted). Future studies should indicate whether this -175 g~t variant 
detected exclusively in populations with an African genetic element (Hoogendijk 1999) might 
impose a health threat withwesternisatio_nand/Ol"J.llay beAlle to other selective forces _ 
involved in human evolution. Although plasma cholesterol levels were similar in subjects 
from the general population with and without this sequence variant, preliminary data has 
revealed a significant association between the -175t allele and diastolic blood pressure 
(P=0.019) (MJ Kotze and C Lombard, unpublished data). 
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South African Indian population: CpG hotspot mutations are a frequent cause of FH 
The increased prevalence of FH in the South African Indian community (~1I1 00) has been 
attributed to a combination of recurrent mutational events, multiple entries of disease genes 
and/or a reflection of a founder gene mutation in India. Mutation P664L, originating from the 
Gujerat Province in the West of India, was found to be the most common mutation (47%) in 
South African Indians (Rubinsztein et al. 1992, Kotze et al. 1997). Further mutation analysis 
indicated that CpG hotspot mutations, such as P664 L, are a frequent cause of FH in the South 
African Indian population. All the Indian FH patients with mutation P664 L shared the same 
haplotype. Haplotype analysis of mutation E207K, detected in two apparently unrelated 
Indian families, suggested a common origin in India (Kotze et al. 1997). This mutation has 
previously been identified on different chromosomal haplotypes in genetically distinct 
populations (Leitersdorf et al. 1990, Hobbs et al. 1992). 
South African Jewish population: High prevalence of FH due to the Lithuanian mutation 
The South African Jewish population appears to have a particularly high incidence of FH, 
most likely as a consequence of multiple entries of defective genes into this relatively isolated 
community over recent years. An in-frame 3-bp deletion (GlyI97), designated the FH 
Lithuania mutation, was reported to occur in the majority (80%) of South African Jews with 
. . 
FH (Meiner et al. 1991). However, in an extended. analysis of Jewish FH patients living in 
South Africa, the Lithuanian mutation was identified in less than 50% of patients diagnosed 
with heterozygous FH (M Callis et al. unpublished data). This mutation has also been 
identified in many Ashkenazi Jewish families throughout the world (Meiner et al. 1991). 
Additionally, three novel mutations were identified in South African Jews, which include a 
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nonsense mutation QI04X, a missense mutation N407K and a splice-site mutation 
1358+1G---+A. Mutation Q104X results in a truncated protein causing the disease phenotype. 
Mutation N407K was identified in a patient who was also heterozygous for the common 
Afrikaner mutation D206E. The two daughters of this patient who inherited mutation N407K, 
presented with normal cholesterol levels (M Callis and FJ Raal, unpublished data). Mutation 
1358+ 1 G---+A affects the invariant GT dinucleotide at the splice donor site and can therefore 
be expected to cause FH in the patient with this mutation. 
European ancestry: identification of various private mutations 
Eighteen private mutations were identified in individuals from different ancestries living in 
South Africa. These mutations may have been introduced into South Africa by recent 
immigrants or occurred as random events. These patients originated mostly from European 
countries, where admixture is not uncommon. Mutation 2140+5G---+A (Heath et al. 1999) was 
identified in a patient of Irish descent, as well as a South African Jewish patient. Although 
this splice mutation does not involve a conserved base, it is associated with a consensus value 
of 0.84 (Krawczak et al. 1992). A novel complex mutation involving both a deletion and an 
insertion in the~same gen~_:tegion was_qetected in~~xon 10 iIla Welsh patient. This mutation 
deletes sixteen bases from nucleotide 1379 to 1394 (ACGGCGTCTCTTCCTA), which is 
replaced by five bases (CAGCT). Six amino acids, His439_Gly440_VaI441_Ser442_Ser443_Tyr444, 
were replaced by two amino acids, Pro439_Ala44o. Interestingly, analysis of the sequence close 
to the mutation revealed that the CAGCT motif, inserted in the mutant LDLR gene, is found 
11 nucleotides upstream of this mutation. The insertion results in a stop codon at amino acid 
position 441 and is therefore highly likely to affect LDLR function and cause FH. 
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Although founder events are highly unlikely in heterogeneous populations, some 
mutations may occur at an increased prevalence in certain geographical regions. These 
include the combined defect N543H12393 del 9-bp identified in one of our probands 
originating from Northwest Netherlands, where this mutation is predominantly found 
(Defesche and Kastelein 1998), and those described in the United Kingdom (Day et al. 
1997a) and Belgium (Descamps et al. 1997). The high frequency of these mutations not 
associated with an increased disease prevalence in the respective countries, may be 
attributible to geographical isolation. 
Comparative analysis in different populations: Ratio of missense to stop mutations 
The 65 mutations identified in the South African population occurred throughout the promoter 
and coding region of the LDLR gene (Fig. 1). These included 42 (65%) missense mutations, 6 
(9%) nonsense mutations, 9 (14%) deletions, 2 (3%) insertions, 1 (2%) deletion/insertion, 3 
(5%) donor splice-site mutations and 2 (3%) acceptor splice-site mutations. Most of the 
mutations occur in exons 4, 8 and 9. Exon 4 is known to be a "hotspot" area for LDLR gene 
mutations (Gudnason et al. 1994, Kotze et al. 1996b, Day et al. 1997b). Although deletions 
and insertions are frequently identified, combined deletional and insertional (ID) events are 
very rare. Such complex mutations have previously been reported in the LDLR gene 
(Y amakawa-Kobayashi et al. 1994, Koivisto and Kontula 1996). Mutations that occur in 
introns may affect splicing and make them an important target for molecular analysis (Peeters 
et al. 1999). Variation in the LDLR promoter region that may affect transcription, has so far 
only been detected in South Africans with an African genetic element. 
The majority of sequence changes detected in the South African population are point 
mutations involving amino acid substitutions. Notably, Day et al. (1997b) have recently 
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reported a four-fold higher than expected ratio (1/5 vs 1/20) of stop mutations than missense 
mutations in FH patients. In the South African population the ratio of single base substitutions 
resulting in stop codons compared to those causing amino acids substitutions was 1110. This 
may suggest that the local environment may readily "unmask" phenotypically less severe 
(compared to stop mutations leading to truncated proteins) LDLR mutations. This fmding 
may be related to dietary habits of the local popUlation (e.g. fatty diet in Afrikaners') andlor 
interaction with other sequence changes at the LDLR gene locus (e.g. promoter variants in FH 
patients with an African genetic element), or may be an indication that FH patients had an 
advantage during earlier times when infectious diseases were rampant in Africa. Support for 
the latter hypothesis came from the fmding that LDLR-deficient mice are protected against 
certain infections (Netea et a1. 1996), and reports that LDL may bind certain viruses and 
inhibit their infectivity (Feingold and Grunfeld 1997). Notably, Hobbs et a1. (1990) were the 
first to speculate on the likelihood of a Darwinian selection that may favour the heterozygous 
FH state in Africa. 
Familial defective apolipoprotein B-IOO (FDB) in South Africa 
Another common lipid disorder that is phenotypically indistinguishable from FH, familial 
defective apolipoprotein- B 1 00 (FDB), was found to be rare in-South Africa (Kotze et a1. 
1991b, Rubinsztein et a1. 1995). FDB is caused by mutation R3500Q, or less common 
mutations such as R3531C and R3500W in the apolipoprotein BIOO (apoB) gene (Soria et a1. 
1989, Pullinger et a1. 1995, Gaffney et a1. 1995). Rubinsztein et a1. (1993b) reported 
compound heterozygosity for FH mutation D206E and the FDB mutation R3500Q in a large 
Afrikaner pedigree. One family member had a combination of mutations D206E, V 408M and 
R3500Q. Individuals with both FH and FDB presented with lipid levels and clinical features 
that are intermediate in severity between the heterozygous and homozygous FH state. 
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The R3500Q mutation was recently identified in a single FH patient of mixed ancestry 
(Loubser et al. 1999) and in an Afrikaner hypercholesterolaemic referred for molecular 
diagnosis of FH (E. Langenhoven, personal communication). Two silent mutations, T3540T 
and T3552T, previously described in the apo B gene in Nigerian and African American 
subjects (Pullinger et al. 1999) were identified in two South African Black individuals (Thiart 
et al. submitted). 
Autosomal Dominant Hypercholesterolaemia (ADH) 
Failure to identify FH- or FDB-related mutations in approximately half of the South African 
patients with a clinical diagnosis of heterozygous FH, despite the use of three sensitive 
mutation detection methods (Kotze et al. 1995, Nissen et al. 1996), can pe considered a 
reflection oflocus heterogeneity in ADH, as recently demonstrated by Varret et al. (1999) and 
Hunt et al. (1999). A new locus designated FH3 was localised to human chromosome Ip34.1-
p32 in a number of families. Lack of linkage to the known ADH loci provided evidence that a 
fourth locus could underlie the FH phenotype. Families from all over the world were analysed 
in this study, including three families initially characterised at the DNA level in South Africa. 
This analysis included extensive mutation and haplotype analysis at both the LDLR and apo B 
gene loci (Thiart et al. submitted). The genetic heterogeneity of ADH was confirmed by 
several other studies (Haddad et al. 1999, Pajukanteet al. 1998, 1999), and evidence was also 
provided for tneexistence of autosomal recessive hypercholesterolaemia (ARH) (V arret et al. 
1999, Zuliani et al. 1999). These proposed novel genes probably underlie only a small 
proportion of primary hypercholesterolaemia in Afrikaners without the documented founder-
type mutations, since LDLR gene mutations were detected in ~80% index cases subjected to 
extensive mutation analysis. 
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Conclusion 
The systematic mutation screening strategy conducted in South Africa during recent years 
resulted in the identification of 65 different LDLR gene mutations in -50% of patients. The 
65 LDLR gene mutations detected in the South African patients reflect -10% of the total 
number of currently documented FR mutations. This emphasise the significance of these 
fmdings and provide a solid platform for subsequent mutation analysis. The relative low 
mutation detection' efficiency, and non-segregation with markers at the LDLR and apo B 
genes in selected families, highlighted the value of DNA-based diagnostic methods in the 
complete genetic description of ADH. The information gained through the effort of defming 
the mutational spectrum in South Africa was applied to develop a cost-effective population-
directed screening approach for accurate diagnosis of FR, a prerequisite for preventive 
treatment of this common lipid disorder. Evaluation of the types and frequencies of mutations 
identified have also broadened our understanding of disease patterns in the diverse South 
African population. 
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Number Exon/ Molecular Event Designation CpG No. Origin/ References 
Fig.1 Intron Found in 
," 
,:r:~ .. :4,FRIKANER ;POPJILATlON'", . :tti ~n\i tl ~·w 
7 Exon3 T~Gat259 W66G - 1 Fr-Canadian Leitersdorf et a1. 1990 
11 Exon4 G~Aat523 -D154N - 31 UK Kotze et a1. 1989b 
13 Exon4 A~Gat662 ,.])200'0 ,~ ':'''l~l(!'jCilii - 5 UK Hobbs et a1. 1992 
59 Exon4 Ins 18-bp after 681 681ins18 - 1 Germany Kotze et a1. 1996b 
15 Exon4 C~Gat681 D206E rf o' ,; ON + 144 UK Kotze et a1. 1990 
21 Exon6 C~Tat 917 . S285L ,iii! . ' ~,.[ ~ 
.--
- 3 France Hobbs et a1. 1992 
45 Exon 7 C~T at 1048 R329X + 1 Norway Solberg et a1. 1994 
65 Intron 7 T~C at 1061-8 IVS7-8T~C - 1 Dutch Jensen et a1. 1996 
22 Exon8 G~A at 1130 C356Y .,. - 4 South Africa This study 
24 Exon8 G~Tat 1145 ' G36:lV -, , - 2 South Africa This study 
32 Exon9 G~A at 1285 ' V4Q8M '~i ~ , + 57 Netherland Kotze et a1. 1989b 
39 Exon 15 C~Tat2177 T7051 - 1 Fr-American Hobbs et a1.1992 
41 Exon 16 G~Aat2389 V776M + 1 Cuba Pereira et a1. 1995 
II! 
"MIXED ANCESTRY;(COLQURED' FOPULATIONi . ~ .. ~ 
1 Promoter C~T at-59 -59c~t - 1 South Africa Scholtz 1999 
3 Exon 1 T~C at 28 W-12R - 1 Italian Marx et al. 1997 
4 Exon2 G~A at 148 A29T + 1 South Africa Loubser et a1. 1999 
5 Exon3 C~Tat232 R57C + 1 English Day et al. 1997b 
6 Exon3 C~T at 241 R60C + 1 Danish Nissen et a1. 1998 
52 Exon4 del TC at 369 369deiTC - 1 South Africa Loubser et al. 1999 
11 Exon4 G~A at 523 "D154N "f 2 UK Kotze et a1. 1989b >"?: -
54 Exon4 del GGT at 652 652delGGT - 4 Lithuania Meiner et al. 1991 
.... 
o 
o 
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13 Exon4 A~Gat 662 
14 Exon4 A~G at 680 
15 Exon4 C~ Gat681 
16 Exon4 G~Aat682 
17 Exon4 T~Gat691 
19 Exon5 G~Aat772 
64 Intron 6 G~A at 941-4 
55 Intron 6-8 de12.5-kb 
25 Exon8 T~G at 1154 
32 Exon9 G~A at 1285 
37 Exon 14 C~Tat2054 
='i" IU ,ril'l 
''" oil 
49 Promoter del CTC at -92 
50 Exon2 del6-bp at 137 
51 Exon2 del Gat 172 
61 Intron 3 G~A at 313+1 
10 Exon4 G~C at 514 
18 Exon 5 C~Tat 756 
28 Exon9 G~A at 1217 
29 Exon9 G~A at 1222 
38 Exon 14 C~Tat2096 
42 Exon 17 G~A at 2441 
'. ;;'!i 
-"" 
2 Exon 1 A~Tat 1 
5 Exon3 C~Tat232 
8 Exon3 G~Tat268 
9 Exon4 G~A at418 
D200G - 1 
D203A - 1 
"D206E '· .. ':: ,::,> + 19 
" .,'. .,.,t."" ~ "mL 
E207K + 1 
C210G - 1 
E237K - 1 
IVS6-4G~A - 1 
de12.5~kh ',' 10 -
, . 
L364R - 1 
V408M ," a + 13 
J>§64L ,.:~ *' + 3 
BLACK POPULATION 
-92delCTC - 1 
l37deW ~'" Iii - 4 
172delG - 1 
IVS3+1G~A + 1 
D151H + 1 
R232W + 1 
R385Q - 1 
E387K + 1 
P678L + 1 
R793Q + 1 
, 
I'NDIAN POPULATION 
M-21L - 1 
R57C + 1 
D69Y + 1 
E119K + 1 
UK 
South Africa 
UK 
Fr-Canadian 
Norwegian 
South Africa 
South Africa 
South Africa 
South Africa 
Netherland 
India 
".;,," .. 
l1:li 
" 
'~ 
South Africa 
South Africa 
South Africa 
South Africa 
South Africa 
South Africa 
South Africa 
Algerian 
German 
South Africa 
'i 
South Africa 
South Africa 
South Africa 
USA 
Hobbs et al. 1992 
Loubser et al. 1999 
Kotze et al. 1990 
Leitersdorf et al. 1990 
Sundvold et al. 1996 
Loubser et al. 1999 
Loubser et al. 1999 
Henderson et al. 1988 
Loubser et al. 1999 
Kotze et al. 1989b 
Hobbs et al. 1992 
"-
" 
Peeters et al. 1998 
Leitersdorf et al. 1988 
Hobbs et al. 1992 
Thiart et al. submitted 
Thiart et al. submitted 
Thiart et al. submitted 
Thiart et al. submitted 
Hobbs et al. 1992 
Schuster et al. 1995 
Thiart et al. submitted 
Langenhoven et al. 1996 
Kotze et al. 1997 
Rubinsztein et al. 1993a 
Rubinsztein et al. 1993a 
, 
.-. 
o 
.-. 
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12 Exon4 
16 Exon4 
47 Exon8 
27 Exon9 
37 Exon 14 
40 Exon 16 
~; . :,:, ' ;(':' 
'" 
43 Exon3 
44 Exon4 
54 Exon4 
15 Exon4 
62 Intron 9 
31 Exon9 
32 Exon9 
63 Intron 14 
~ 
5 Exon3 
58 Exon4 
53 Exon4 
15 Exon4 
20 Exon6 
23 Exon8 
46 Exon8 
26 Exon8 
30 Exon9 
33 Exon9 
60 Exon 10 
G~Tat661 D200Y + 1 Finland 
G~Aat682 E207K + 2 Fr-Canadian 
C~A at 1175 C371X - 1 South Africa 
C~Gat 1215 N384K - 1 South Africa 
C~Tat 2054 E664L ,qt,;;'~, iiFWJil' .3\ 
.. ~ I~.;. , + 10 India 
A~Tat2356 S765C - 1 South Africa 
~ fi 
"""{/: lEWISH'POPULATI6N ' . -'C Ii.' ~~ $:', ,j i. . - ''''',; ~ . . . . ~ ' : . 1 
~ 
C~Tat253 Q64X - 2 Germany 
C~Tat 373 QI04X - 1 South Africa 
del GGT at 652 652delGGT :fo'" , - 5 Lithuania 
C~ Gat681 D206E + 1 UK 
G~A at 1358+1 IVS9+1 G~A - 1 South Africa 
C~Gat 1284 N407K + 1 South Africa 
G~A at 1285 V408M + 1 Netherland 
G~A at 2140+5 IVSI4+5G~A - 1 South Africa 
.. 
"'" -EuRoPEAN ANCESl'RY, ~0' 
- , 
C~Tat232 R57C + 1 St H, Ind, Fr 
ins G after 558 558insG - 1 German 
del G at 617 617deiG - 1 French 
C~Gat681 D206E + 1 UK 
G~A at 910 D283N - 1 Irish 
A~C at 1133 Q357P - 1 UK 
C~T at 1150 Q363X - 1 Cypriot 
C~G at 1156 D365E - 1 Cypriot 
G~A at 1247 R395Q + 1 German 
G~C at 1329 W422C - 1 UK 
Complex deVins 13 79de116~ 5bp - 1 Wales 
Koivisto et al. 1995 
Leitersdorf et al. 1990 
Langenhoven et al. 1996 
Kotze et al. 1997 
Soutar et al. 1989 
Kotze et al. 1997 
iilt l!jffi':'!11 m , 
Schuster et al. 1995 
This study 
Meiner et al. 1991 
Kotze et al. 1990 
Callis (unpublished results) 
Callis (unpublished results) 
Kotze et al. 1989b 
Heath et al. 1999 
Callis et al. 1998 
Thiart et al. 1998 
Callis et al. 1998 
Kotze et al. 1990 
Bilheimer et al. 1985 
Callis et al. 1998 
Kotze et al. 1997 
Kotze et al. 1997 
Thiart et al. 1998 
Hobbs et al. 1992 
This study 
...... 
o 
tv 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
34 Exon 10 T~C at 1447 W462R - 1 
35 Exon 11 G~A at 1646 G528D - 1 
36 Exon 11 A~C at 1690 N543H - 1 
48 Exon 14 C~A at 2043 C660X - 2 
56 Exon 14 del T at 2092 2092deiT - 1 
63 Intron 14 G~A at 2140+5 IVSI4+5G~A - 1 
57 Exon 17 del9-bp after 2393 2393de19-bp - 1 
-------
Number refers to location of mutation, as illustrated in figure 1 
Events occuring at a CpG dinucleotide: "+" indicates yes and "_" indicates no 
Highlighted mutations indicate founder-related/common LDLR gene mutations 
Scotland Ward et al. 1995 
Greek Hobbs et al. 1992 
Netherlands Tricot-Guerber et al. 1995 
Lebanese Lehrman et al. 1987 
USA Hobbs et al. 1992 
Ireland Heath et al. 1999 
Netherlands Lombardi et al. 1996 
The majority of mutations summarised in this table were included in a recent mutation update (Varret et al. 1998) 
The possibility that some of the mutations listed here are not disease-causing, could not be excluded 
Both mutations T7051 (pH-Paris 9) and IVS7-8T~C are probably non-pathogenic (Jensen et al. 1996, Lombardi et al. 1997, Nissen et al. 1998). 
"Afrikaner" refers to an individual of European descent, mainly Dutch, French, German and British stock; "Coloured" refers to an individual of 
mixed ancestry, including San, Khoi, African Negro, Madagascar, Javanese and European origin; "Black" refers to South Africans of central 
African descent. 
Mutation names are given according to Beaudet et al. 1996 and Antonarakis et al. 1998. 
..... 
o 
Vol 
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Figure 1 Schematic representation of the genomic organisation of the LDLR gene in relation 
to five distinct functional domains of the LDLR gene. The sites of 65 different LDLR gene 
mutations identified in the South African population are shown. Further details of each 
mutation are provided in Table 1. 
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Promoter 
Missence 
Nonsense 
Deletions 
Insertions 
Del/Ins 
Signal 
Sequence 
~ 
1 
Ugand EGF Precursor O-linked 
Binding Homology Sugars 
I I I 
II III 
2 3 4 5 6 7 8 9 10 1112 1314 15 
Splice donor - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Splice acceptor - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Spanning 
~~asm~ 
16 17 18 Exon 
1---3' Gene 
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Chapter 6 
Conclusions 
Inherited lipid disorders represent the most common form of genetic disease world-wide. 
Defects in the low density lipoprotein receptor (LDLR) and other lipid-related genes 
underlying atherosclerotic cardiovascular diseases, account for the majority of deaths in 
Western societies, with men usually affected 10 years earlier than women (Henderson 1996). 
Factors underlying popUlation differences in coronary heart disease (CHD) mortality and 
morbidity have been under study for decades (Tunstall-Pedoe et al. 1994). 
The treatable disorder, familial hypercholesterolemia (FH), has been well 
characterised in the South African Afrikaner population. Direct mutation screening for three 
founder-related LDLR gene mutations, D154N, D206E and V408M, causing FH in the 
majority of affected Afrikaners (Kotze et al. 1991), confirmed the high prevalence of 
heterozygous FH (-1170) in this population (Steyn et al. 1997). Mutation analysis has now 
been extended to the remaining -10% of Afrikaner FH patients who screened negative for the 
previously-described founder mutations, as well as several other homogeneous and 
heterogeneous populations. The purpose of this study was to defme the mutational spectra in 
-different populations, with the ultimate aim to compare the types and frequencies of mutations 
in an attempt to broaden our knowledge on disease patterns in these groups. In addition to 
providing the potential of accurate FH diagnosis in families, mutation screening revealed 
important information on the origin and distribution ofLDLR gene mutations and contributed 
largely to our knowledge of the biological history of the South African population. 
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South African Population 
Delineation of the mutational spectrum in the diverse South African population has provided 
some explanations for the observed ethnic differences in CHD risk, ranging from high to low 
in the Caucasian and Black populations, respectively, and intermediate in the Coloured 
population of mixed ancestry (Steyn et a1. 1985). The exceedingly high death rate from 
premature CHD in Afrikaners is undoubtedly a consequence of multiple founder-related 
LDLR gene mutations underlying FH in this population of European descent. These include 
the well-characterised gene defects D154N, D206E and V408M accounting for FH in ~90% 
of affected Afrikaners (Kotze et a1. 1991), and four apparently minor founder mutations 
D200G, S285L, C356Y and G361V. Haplotype analysis using intragenic LDLR gene 
polymorphisms and two highly informative microsatellite markers flanking the LDLR gene, 
were consistent with common origins for these mutations. 
The founder-related basis for the high prevalence of FH in South Africa provided the 
opportunity to use direct mutation screening to test whether the increasing manifestation of 
CHD in the Coloured population (San, Khoi, African Negro, Madagascar, Javanese and 
European origin) can be explained by Caucasoid admixture. This appeared to be the case, 
since six founder-type "South African mutations" were responsible for FH in ~20% of the 
study cohort including 236 patients with primary hypercholesterolaemia (Loubser et a1. 1999). 
Only one of these probands of mixed ancestry was heterozygous for mutation R3500Q 
4 _ _ ~ 
causing familial defective apolipoprotein B-IOO (FDB). Apart from the Afrikaner founder 
mutations, P664L and de1197 known to be common in South Africa due to multiple entries of 
these mutant alleles into the Indian and Jewish communities, respectively, were also prevalent 
in the Coloured population. These [mdings indicated that Caucasoid admixture contribute 
significantly to the apparently high prevalence ofFH in South Africans of mixed ancestry. 
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None of the LDLR gene defects identified in Black FH patients have been detected in 
any other South African population group. This finding is in accordance with data from 
Loubser et al. (1999), suggesting minimal, if any, admixture of the Black population with 
other populations. The unique mutational profile defmed in the Black population of South 
Africa included mutations in the promoter and coding region of the LDLR gene, as well as a 
mutation in one of the splice junctions. Predominance of a 6-bp deletion in exon 2 of the 
LDLR gene (28%) in this population where FH is rare was an unexpected fmding, that can 
probably be explained by earlier propagation of the mutant allele within a small group of 
people who later evolved separately into different African tribes. An interesting observation 
was the relatively mild expression of the 6-bp deletion in the homozygous state, confirming 
the initial hypothesis that the low prevalence and/or under diagnosis of FH in this population 
may be a consequence of altered expression of disease-related LDLR gene mutations due to 
interaction with other (protective) factors. Genetic variation was frequently detected in the 
LDLR promoter region in FH patients with an African genetic element, whilst apparently 
absent in South African Caucasians. This fmding raises the possibility that sequence changes 
upstream of the gene may influence the phenotypic expression of the disease in popUlations 
where these mutations prevail (Scholtz et al. 1999). 
Non-South African Populations 
Knowledge on the- molecular basis of FH in Costa Rica/South America and New Zealand is 
limited. FH patients from these populations included in this study were first screened for the 
founder-type mutation R3500Q (Soria et al. 1989) in the apo B gene, causing FDB in the 
majority of patients with this lipid disorder. This mutation was absent in the Costa Rican 
study cohort, but was identified in three of four New Zealand probands who demonstrated 
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normal receptor function using an in vitro lymphocyte receptor assay. The molecularly-
uncharacterised hypercholesterolaemics were subsequently examined for LDLR mutations in 
the promoter and coding region by HEX-SSCP analysis, using three different gel systems. 
Four novel mutations (Q665X, I140T, 8-bp ins at 681 and 2389+6C~T) were identified in 
the Costa Rican study population (Kotze et a1. 1996, Thiart et a1. 1997, Varret et a1. 
1998/Appendix 2, Peeters et a1. 1999). LDLR gene mutation screening in New Zealand 
patients led to the identification of a novel 2-bp deletion and several previously-described 
mutations including the Afrikaner-founder mutation, D206E (The art et a1. 1995, Thiart et a1. 
submitted). 
A comparison between the ratio of nonsense versus missense mutations detected in 
different populations (South Africans, New Zealanders and Costa Ricans), including those 
locally identified in Belgian FH patients (Varret et a1. 1998/ Appendix 2) indicated a ratio of 
1110 in South Africa to 115 in non-South African populations. The latter is in agreement with 
the fmdings of Day et a1. (1997), who observed a fourfold overrepresentation of substitutional 
stop codons to amino acid changes; 115, compared to the expected value of 1120 (Day et a1. 
1997, Hobbs et a1. 1992). We therefore postulate that South Africa might be an especially 
good environment for unmasking "milder" LDLR mutations. 
DNA diagnosis ofFH: implications and new perspectives 
Data generated during this study demonstrated that the array of mutations varies considerably 
in different populations. Increased knowledge of the mutational profile underlying FH in 
different countries/populations facilitated disease diagnosis, genetic counselling and 
preventive treatment in affected families. Failure to identify the disease-causing mutation in 
all the patients clinically diagnosed with FH, was initially ascribed to limitations imposed by 
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the mutation detection methods used. However, the low detection rate (~50%) and subsequent 
haplotype analysis performed at the LDLR and apo B gene loci, suggested the existence of 
additional genes underlying the FH phenotype. This hypothesis was recently confirmed by 
Varret et al. 1999/Appendix 3), implicating a third major locus for autosomal dominant 
hypercholesterolaemia (ADH) on chromosome 1 p. 
Future studies will be focussed on the elucidation of the molecular basis of ADH in 
mutation-negative subjects identified during this study. Both the homogeneous Afrikaner 
population and the heterogeneous Coloured population may serve as valuable candidate 
_populations for future mapping studies. The latter could be applied in admixture linkage 
disequilibrium (ALD) approaches to map genes, while the Afrikaner population is useful 
because of the likely restricted number of founder mutations. In conclusion, this study has 
opened new avenues in the search for gene mutations underlying ADH. 
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APPENDIXl 
Detailed Experimental Procedures 
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Protocol 1: Genomic DNA Extraction 
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res 16: 1215. 
Lysis of tissues to cells 
Collect 5-10 ml blood in EDTA-tubes 
Mix blood with 40 ml cold lysis buffer 
Place on ice for 15 min. 
Centrifuge for 10 min. at 1500 rpm 
-I, 
Lysis of cells and isolation ofnuc1ei 
Remove the supernatant 
Wash cell pellet with 10 m1 PBS buffer 
Remove the supernatant 
Lysis ofnuc1ei 
Re-suspend pellet in: 
3 mr nuclear lysis buffer 
50 !l110 mg/ml proteinase K 
300 !l110% SDS 
-1,' 
Vortex for 5 seconds 
Incubate overnight at 55°C 
-I, 
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Purification of DNA 
Add 1 ml6 M NaCI solution to each sample 
Shake vigorously for 1 min 
Centrifuge for 15 min at 2500 rpm 
Transfer the supernatant containing the DNA solution to a clean Falcon tube 
Precipitation of DNA 
Add 2X volume of cold absolute ethanol 
Leave at room temperature 
Transfer the precipitated DNA strands to a eppendorftube 
Wash DNA with 70% ethanol (to remove excess salt) 
Centrifuge briefly 
Remove excess ethanol 
Air-dry the DNA at room temperature 
Dissolve the DNA pellet in 300-500 f..LI SABAX-dH20 
Protocol 2: Polymerase Chain Reaction (PCR) 
128 
Saiki RK, ScharfS, Faloona F, Mullis KB, Hom GT, Erlich HA, Amheim N (1985) Enzymatic 
amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of 
sickle cell anemia. Science 230: 1350-1354 
Cocktail Mix 
20-50 ng genomic DNA 
20 pmol each of forward and reverse primer 
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1 00 ~M of each dNTP 
lOX Buffer with 1.5 mM MgChl or without MgCh + 
appropriate amount of 25 mM MgCh 
0.5 U Taq DNA polymerase (Boehringer Mannheim) 
200 ~M Cresol Red Loading Buffer 
Nuclease-free water to a [mal volume of251lV501l1 
~ 
PCR amplification 
~ 
PERKIN ELMER GeneAmp 2400/9600 PCR SYstem Thermal Cycler 
Appropriate thermal cycling conditions 
~ 
Analysis PCR products 
~ 
Load 5 ilion a 2% Agarose gel 
Electrophorese at 100 Volt for 20 min 
Stain for 5 min in 1 X TBE containing EtBr 
Examine gel with ultraviolet light illumination 
Primers used for amplification 
Primers for the promoter and coding region of the LDLR gene (Table 1) 
Jensen, H. K., Jensen, L. G., Hansen, P. S., Faergeman, O. & Gregersen, N (1996) High 
sensitivity of the single-strand conformation polymorphism method for detecting sequence 
variations in the low-density lipoprotein receptor gene validated by DNA sequencing. Clinical 
Chemistry 42: 1140-1146 
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Promotor Region 
95°C 
95°C 
60 °C 
72°C 
5' 
30" 
45" 
45" 
30" 
45' 
45' 
35°C 5' 
} x 10 cycles 
} x30cycles 
Coding Region 
95 °C 
94°C 
60/66°C 
5' 
l' 
2' 
72°C 10' 
5' 
} x35 cycles 
DGGE primers for the promoter and coding region of the LDLR gene (Table 2) 
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Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M (1996) Clinically applicable mutation 
screening in familial hypercholesterolemia. Hum Mutat 8: 168-177 
95°C 5' 
94°C 1 ' } 66 °C 5' x 40 cycles 
72°C 10' 
99.9°C 7' 
65°C 50' Ramp 10' 
37 °C 50' Ramp 10' 
25°C 10" 
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*Top B, Uitterlinden AG, Van der Zee A, Kastelein JJP, Gevers Leuven JA, Havekes LM, Frants 
RR (1992) Absence of mutations in the promoter region of the low density lipoprotein receptor 
gene in a large number of familial hyper cholesterolaemia patients as revealed by denaturing 
gradient gel electrophoresis. Hum Genet 89:561-565 
Primers for the Multiplex PCR assay (Table 3) 
Kotze MJ, Theart L, Callis M, Peeters AV, Thiart R, Langenhoven E (1995) Nonradioactive-
multiplex PCR screening strategy for the simultaneous detection of multiple low-density 
lipoprotein receptor gene mutation. PCR Methods and Applications 4: 352-356 
l' 
2' 
94°C l' 
l' 
2'-
35 °C 10" 
} x 15 cycles 
} x 20 cycles 
Primers for Microsatellite Analysis (Table 4) 
Traeger-Synodinos J, Mavroidis N, Kanavakis E, Drogari E, Humphries SE, Day IN, Kattamis C, 
Matsaniotis N (1998) Analysis of low density lipoprotein receptor gene mutations and 
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microsatellite hap10types in Greek FH heterozygous children: six independent ancestors account 
for 60% of pro bands. Hum Genet 102:343-347 
Marker D 19S221 
95 DC 5' 
IS" 
IS" 
30" 
10' 
5' 
} x 30 cycles 
Marker D19S394 
94 DC 2' 
94 DC 
55 DC 
72 DC 
l' 
l' 
2' 
l' 
l' 
2' 
33 DC 10" 
} x 5 cycles 
} x 30 cycles 
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Table 1. Primers used to am the and f"'nrllnn 
Oligonucleotide sequence (5' to 3') 
1 F CACATTGAAATGCTGTAAATGACG 
R CTATTCTGGCGCCTGGAGCAAGCC 215 
2 F TTGAGAGACCCTTTCTCCTTTTCC 
R GCATATCATGCCCAAAGGGG 183 
5 F 
R GGAAAACCAGATGGCCAGCG 180 
6 F TCCTCCTTCCTCTCTCTGGC 
R TCTGCAAGCCGCCTGCACCG 179 
10 F ATGCCCTTCTCTCCTCCTGC 
R AGCCCTCAGCGTCGTGGATA 278 
12 
R CGTGTGTCTATCCGGCCACC 236 
15 F 
R GTGTGGTGGCGGGCCCAGTCTTT 217 
16 F CCTTCCTTT AGACCTGGGCC 
R CATAGCGGGAGGCTGTGACC 173 
F 
R GATAGGCTCAATAGCAAAGGCAGG 196 
4A F 
R AGCCATCTTCGCAGTCGGGG 242 
4B F CCCCCAGCTGTGGGCCTGCG 
R CGCCCCCACCCTGCCCCGCC 237 
F G 
R GTTGCCATGTCAGGAAGCGC 236 
8 F CA 
R GCCTGCAAGGGGTGAGGCCG 220 
9 F CCCCTGACCTCGCTCCCCGG 
R GCTGCAGGCAGG C 224 
11 F TCCTCCCCCGCCCTCCAGCC 
R GCTGGGACGGCTGTCCTGCG 194 
13 
--
_.-
- RTTCCACAAGGAGGTrrCAAGGTTGGGGGGG 329 
14 F AAA 
R GCAGAGAGAGGCTCAGGAGG 268 
17 F GGGTCTCTGGTCTCGGGGGC 
RGGCTCTGGCTTTCTAGAGAGGG 242 
18 F GCCTGTTTCCTGAGTGCTGG 
R TCTCAGGAAGGGTTCTGGGC 135 
F = Forward primer, R = Reverse primer 
Stellenbosch University  https://scholar.sun.ac.za
282 
6 
262 
10 
349 
11 
239 
12 
336 
13 
264 
17 . 
GCTTTCTAGAGAGG 279 
Ap08** F 40-bp GC-clamp-GGAGCAGTTGACCACAAGCTTAGC 
R GGTGGCTTTGCTTGTATGTTCTCC 382 
256 
4A 
R G 297 
48*** F ACCTGTGGTCCCGCCAGC 
R CAGGGACAGGTGATAGGACG 345 
7 F 40-bp GC-clamp-AGAGTGACCAGTCTGCATCCCTGG 
R TTGGTTGCCATGTCAGGAAGC 253 
8 F 40-bp amp- <.J~<.J<.J,",~~,""n.~~~ 
R CCACCCGCCGCCTTCC 222 
9 F 46-bp GC-/1 O-bp AT -ciamp-CTGACCTCGCTCCCCGGACC 
R GGCTGCAGGCAGGGGCGACG 278 
14 F 50-bp GC-ciamp-TCTCGTTCCTGCCCTGACTCC 
R GACACAGGACGCAGAAACAAGG 274 
15*** F 3-bp GC-clamp-GGCACGTGGCACTCAGAAGACG 
R GC-cla GTGGCGGGCCCAGTCTTT 288 
16 F 50-bp GC-ciamp-CTCCATTTCTTGGTGGCCTTCC 
R CATAGCGGGAGGCTGTGACCTGG 239 
18 F 50-bp GC-ciamp-CCTGAGTGCTGGACTGATAGTTTCC 
R AAGGCCGGCGAGGTCTCAGG 190 
F = Forward primer, R = Reverse primer 
* see also promoter primers that span the -175 region: Top et al. (1992) 
**Apolipoproteien 8-100 (ap08) gene 
***Require 25 mM MgCI2 in PCR mixture 
3-bp GC-clamp: CGG 
40-bp GC-clamp: CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCG 
46-bp GC-/10-bp AT-clamp: CGCCCGCGCCCGCCGCGCCCCGCGCCCGTCCCG-
CCGCCCCCGCCCGAAATAATAAA 
50-bp GC-clamp: CGCCCGCCGCCGCCCGCCGCGCCCCGCGCCCGTCCCGCC 
GCCCCCGCCCG 
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Table 3. Multiplex amplification refractory mutation system (ARMS) primers used for 
IT f fth LDLR amp I Ica Ion 0 e gene 
Exon Oligonucleotide sequence (5' to 3') 
4 F (4.2.1) CGAGGCCTCCTGCCCGGTGCTCACC 
R (4.5.3) GGGCCTGCGACAACGACCCCGACTGCGAAA 
4 F (U) GGGACCCAGGGACAGGTGATAGGAC 
R (4.7) CCCGCCCATACCGCAGTTTTCCTCC 
9 F (9.5) GCTCACCTGCAGATCATTCTCTGGG 
R (9.7) AGCCTCATCCCCAACCTGAGGACCA 
Ap08* F GGAGCAGTTGACCACAAGCTTAGCTTGGAA 
R TGGAAGTGCCCTGCAGCTTCACTGAAGAAT 
F = Forward pnmer, R = Reverse pnmer 
*Mutation R3500Q in the Apoliprotein 8-100 (Ap08) gene 
PCR reaction requires 2mM tetramethylammonium chloride (Me4NCI) 
and 15% glycerol 
T bl 4 M' t II"t f hit 'r a e Icrosa e I e pnmers or aplotype assocla Ions 
Marker Oligonucleotide sequence (5' to 3') 
D19S221 F FAM-GCAAGACTCTGACTCAACAAAA 
R PIG-tail-CATAGAGATCAATGGCA 
D19S394 F* AGACTACAGTGAGCTGTGG 
R GTGTTCCTAACTACCAGGC 
F - Forward pnmer, R - Reverse pnmer 
*Can add FAM-Iabelling to 5'-primer 
PIG-tail: GTTTCTT 
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Protocol 3: Heteroduplex-Single-Strand Conformation Polymorphism 
(HEX-SSCPl Analysis 
Kotze MJ, Theart L, Callis M, Peeters AV, Thiart R, Langenhoven E (1995) Nonradioactive 
multiplex PCR screening strategy for the simultaneous detection of multiple low-density 
lipoprotein receptor gene mutation. PCR Methods and Applications 4:352-356 
Gel Preparation 
.J, 
Clamp the two glass plates (8 x 20 cm) together with binder clips 
Pour an agarose plug 
Pour polyacrylamide gel between the two glass plates (1 mm) 
Gel polymerise for -10-15 minutes 
.J, 
Electrophoresis 
.J, 
Load 10-15 III PCR product (PCR was performed with cresol-red loading buffer) 
or 
10 III PCR product mixed with 5111 bromophenol-blue loading buffer + 5111 TBE 
Denature for 5 min. at 90-95°C 
Place on ice 
Load samples in a 10% polyacrylamide gel supplemented with Urea or Gliserol 
and on a 20%_polya~ryla~de g~l (Mighty_Small) 
Electrophorese at room temperature overnight at 250 Volt 
.J, 
Staining of polyacrylamide gel 
.J, 
Stain gel in 1 X TBE containing IOOIlg/ml EtBr for 10 min 
Destain gel in dH20 or 1 X TBE 
Examine with ultraviolet light illumination 
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Protocol 4: Denaturing Gradient Gel Electrophoresis (DGGE) 
Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M (1996) Clinically applicable mutation 
screening in familial hypercholesterolemia. Hum Mutat 8:168-177 
Gel Preparation: 
Denaturant concentrations: 30-70% and 40-80% 
-J,. 
Clamp two glass plates (8 X 20 crn), with 1 mm spacers~ together with binder clips 
. (A "homemade" gel apparatus are currently in use in our laboratory) 
-J,. 
Place the gradient mixer above the DGGE frame 
Pour 14 ml of the solution with the Lower denaturant concentration (eg. 30%) in the Left 
and 14 ml of the higher concentration (eg. 70%) in the right chamber of the gradient mixer . 
.J, 
Open the connection between the two chambers and let the gel-solution pass through the plastic 
tubing between the two glass plates (Avoid air bubbles). 
Leave gel to polymerise for 60 min . 
.J, 
Electrophoresis 
- --------{-
Place the gel apparatus into the bath containing 1 X TAE buffer heated to 60°C. 
Load 7.5-10 III PCR product on the gel 
(PCRwas performed in cresol-red loading buffer) 
Electrophorese for 5 hours at 150 Volt or overnight at 60 Volt 
.J, 
Staining 
Stain gel in 1 X T AE containing EtBr 
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Examine gel with ultraviolet light illumination 
Protocol 5: DNA Sequencing 
Direct DNA Sequencing 
T7 Sequenase Version 2.0 Kit (USB) 
I· .. Enzymatic Pre.;.treatment of PCR product 
'" 
, 5-7 f.11 PCR amplification mixture (purified product) 
1 f.11 Exonuclease 1(1 OU/f.1l) 
(removes residual single stranded primers and extraneous DNA products) 
1 f.11 Shrimp Alkaline Phosphatase (2U/f.1l) 
(removes remaining dNTP's) 
Incubate at 37D C for 15 minutes 
Incubate at 80 DC for 15 minutes (inactivates Exonuclease I and SAP) 
I. Annealing DNA and primer 
'" 5 f.11 enzyme-treated PCR product 
Primer (5-10 pmollf.11) 
dH20 to 10 f.11 
'" Denature at 1 OODC for 3 min 
Place on ice for 5 min 
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Labelling Reaction 
10 Jll cold annealed DNA mixture 
2 III reaction buffer 
1 III O.IM DTT 
2 III diluted labelling mix (1 :5) 
0.5 III 35S dA TP 
2 III Sequenase enzyme 
'" Place on ice for 1 0 min . 
Termination Reaction 
Add 2.5 III of each (G, A, T, C) termination mix in four separate eppendorftubes 
Incubate at 37°C for 5 min 
Add 3.5 III labelling reaction to each termination tube 
Incubate at 37°C for 10 min 
Add 4 III stop solution to terminate the extention reaction 
Prepare samples for loading 
Heat the samples at 75-80 °C for 2 minutes 
Put on ice immediately 
Set up the sequencing run 
6% polyacrylamide sequencing gel polymerise for 2-24 hours 
Wash gel slots well to remove excess urea, etc 
Preheat gel for at least 30 min to 47-50 °C 
Load 2 ilion the gel. 
Electrophorese at 47-50 °C at constant voltage (2500 Volt) for 1-3 hours 
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Gel drying and exposure 
-l.. 
Fix gel in Acetic acid:Methanol (1:3) for 10-15 min 
Transfer gel to filter paper and cover with cling wrap 
Dry gel for 30 min on gel drying apparatus 
Autoradiograph overnight at room termperature 
Automated Fluorescent DNA Sequencing 
ABI 373A Stretch automated sequencer 
Enzymatic Pre-treatment ofPCR product 
3 ~l PCR amplification mixture (purified product) 
0.5 ~l Exonuclease I (1 OU/~l) 
(removes residual single stranded primers and extraneous DNA products) 
0.5 ~l Shrimp Alkaline Phosphatase (2U/~l) 
(removes remaining dNTP's) 
-l.. 
Incubate at 37 DC for 15 minutes 
----Incubate ar80 DC fof 15 minutes (inactivate ExonUclease I arid SAP) 
-l.. 
Cycle Sequencing 
4 III enzyme-treated PCR product 
4 ~l Terminator Ready Reaction Mix (available from kit) 
Primer (5-12 pmol!lll) 
dH20 to 20 ~l 
-l.. 
140 
Stellenbosch University  https://scholar.sun.ac.za
2400 PE cycle program 
II) 94°C 20" 
59 °C 20" (primer Tm) 
60°C 30" 
(X 30) 
-I, 
Precipitation 
ill) 72 °C 5' 
25°C 10' 
Transfer the 20 III PCR sequencing reaction to a 1.5 ml micro centrifuge tube 
Add 20 III 2mM MgCl 
And 50 III 95% EtOH 
-I, 
Mix and leave 10-15 minutes at room temperature 
Centrifuge for 15-20 minutes 
Dry pellet 
-I, 
Prepare samples for loading 
Add 4 J..Ll of the loading buffer to the pellet 
Vortex! spin 
Heat the samples at 90°C for 2-5 minutes 
Immediately put them on ice 
~ 
Set up the sequencing run 
.. 
CLEAN the glass plates with Alconox (3-4 times) 
leave to air-dry 
Leave gel to polymerise for 2-24 hours (Preferable for 2 hours) 
Place the gel in the 373A machine and fill buffer chambers with 1 X TBE buffer 
Load 2 III (Sample pellet + 4 III loading buffer) on the gel. 
Electrophorese overnight for 14 hours (only for ABI 373) 
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Analyse on the 373A system 
Protocol 6: Restriction Enzyme Digestion (RED) 
Sambrook J, Fritsch EF and Maniatis T (1989) in Molecular Cloning: A Laboratory Manual. 
Cold Spring Harbor Laboratory Press NY Vol 1, 2 and 3. 
RED preparation 
10 III PCRproduct (~40 ng) 
2 III 10 X Enzyme-specific buffer (1110 of total volume) 
3-10 Units restriction enzyme 
dH20 to 20 III 
~ 
Incubation 
Incubate at appropriate temperature for 3 hours or overnight 
Add 5-10 III Bromophenol blue- or Ficoll-Orange G loading buffer 
~ 
Analyse RED products 
Load on an Agarose or Polyacrylamide gel 
(depending on fragment size) 
Stain for 5-10 min in 1 X TBE containing EtBr 
Examine gel with ultraviolet light illumination 
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Protocol 7: Haplotype Association/Analysis 
Direct Microsatellite Analysis 
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd ed. Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY. 
End-labelling of Primer 
10 pmol primer 
5 Jll y32p dA TP (100 JlCi) 
16 U T4-polynucleotide-kinase (PNK) 
PNK-Buffer 
dH20 to 20 Jll 
,l, 
Incubate at 37°C for 45 min 
Inactivate at 70°C for 10 min 
Preparation for loading 
peR with I-pmol End-labelled primer per PCR 
,l, 
4 Jll PCR product (y32p dATP end-labelled primer) 
Add 4 Jli of the Bromophenol Blue loading buffer 
Heat the samples at 95°C for 5-10 minutes 
Put on ice immediately 
Set up the sequencing run 
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6% denaturing polyacrylamide gel, left to polymerise for 2-24 hours 
Load 2.5 ~l on the gel 
Load a a 35S-labelled M13-DNA marker 
Electrophorese at 47-50 °C and constant voltage for 2200 Volt for 3 h 
-L. 
Gel drying and exposure 
-L. 
Fix in Acetic acid:Methanol (1 :3) for 10-15 min 
Transfer gel to filter paper and cover with cling wrap 
Dry gel for 30 min on gel drying apparatus 
Autoradiograph overnight at room temperature 
Automated Fluorescence Genescan Analysis 
ABI A373 Stretch automated sequencer from Perkin Elmer 
GENESCAN 672 
Fluorescence PCR product preparation 
for loading 
0.5 ~l PCR product (FAM-labelled primer) 
Add 4 ~l ofthe Blue Dextran loading buffer 
Add 0.5 ~l internal size standard Genescan ROX 500 marker 
V ortexl spin 
Heat the samples at 95 °Cfor 5-10 minutes 
Put on ice immediately 
-L. 
Set up the polyacrylamide run 
CLEAN the glass plates with Alconox (3-4 times) 
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leave to air-dry 
Leave gel to polymerise for 2-24 hours (preferable for 2 hours) 
Plac gel in the 373A machine and fill buffer chambers with I X TBE buffer 
Load 2111 on the gel. 
Electrophorese overnight for 9 hours (only for ABI 373) 
Analyse on the 373A system: GENESCAN 672 
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Solutions 
40% Acrylamide (5%C) stock 
30 g BIORAD Bis-acrylamide:Acrylamide [19:1] 
dH20 to 75 m1 
40% Acrylamide (5%C) stock 
76 g Acrylamide 
4 g Bis-acrylamide 
dH20 to 200 ml 
40% Acrylamide (1 %C) stock 
39.6 g Acrylamide 
0.4 g Bis-acrylamide 
dH20 to 100 ml 
30% Acrylamide (3.4%C) stock 
58.8 g Acrylamide 
1.2 g Bis-acrylamide 
dH20 to 200 ml 
2% Agarose gel 
2 g Seakem LE Agarose 
20 ml5 XTBE 
dH20 to 100 ml 
10% Ammonium persulfate (APS) 
--- . ···1 g AIi1fif6hium persulfate 
dH20to 10 ml 
Blue Dextran Loading buffer (for automated sequencing/genescan) 
5 mt-50 mM EDTA (PH 8.0) 
150 mg Blue Dextran (30 mg/ml) 
25 ml deionised formamide 
Bromophenol Blue loading buffer 
0.0125 g 0.05% Xylene cyanol FF 
0.0125 g 0.05% Bromophenol blue 
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0.168 g 20 mM EDTA (disodiumsalt) 
22.7 ml deionised formamide 
dH20 to 25 ml 
Cresol Red loading buffer 
100 ml Cresol Red (1 mmolll) 
60 g Sucrose 
0% Denaturant stock solution, (6% Acrylamide) 
75 ml 40% Acrylamide 
10 m150 X TAE 
dH20 to 500 ml 
-80% Denaturant stock solution,~(6% Acrylamide) 
75 ml 40% Acrylamide 
10m150XTAE 
169 g Urea 
160 ml Formamide 
dH20 to 500 ml 
30% Denaturant gradient 70% Denaturant gradient 
8.75 ml 0% denaturant 
5.25 ml 80% denaturant 
14.0 ml 
Add in both: 7.2 III TEMED 
125 III APS 
40% Denaturant-gradient- .. -·-- ------- n 
7 ml 0% denaturant 
ml 80% denaturant 
14 ml 
Add in both: 7.2 III TEMED 
125 III APS 
0.5 M EDTA, pH 8.0 
146.1 gEDTA 
dH20 to 1 liter 
1. 7 5 ml 0% denaturant 
12.25 ml 80% denaturant 
14.0 ml 
80% Denaturant gradient . n 
14 ml 80% denaturant 
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Adjust pH 8.0 with NaOH 
10 mg/ml Ethidium Bromide 
1 g EtBr (10 mg/ml) in 100 ml H20 
Ficoll-Orange G loading buffer 
0.1 g (m/v) Orange G (fmal 0.1%) 
20 g (m/v) Ficoll (fmal 20%) 
0.29 g EDTA (PH 7.0) (fmall0mM) 
dH20 to 100 ml 
Lysis buffer 
8.3 g NlltCI (fmal 155 mM) 
1.1 g KHC03 (fmall0 mM) 
0.03 g EDTA (PH 7.4) (fmal 0.1 mM) 
dH20 to 1 liter 
Nuclei lysis buffer 
1.21 g Tris-CI (fmall0 mM) 
23.4 g NaCI (fma1400 mM) 
0'.6 g EDTA (PH 8.2) (fmal2 mM) 
dH20 to 1 liter 
PBS buffer 
Dissolve 10 tablets in 1 liter ddH20 
6% Polyacrylamide (for automated sequencing) 
25 g Urea 
1 g Amberlite 
7.5 m140% Acrylamide 
18 ml dH20 
Mix well, filter and degas for 10 minutes 
Add 5 ml lOX TBE 
dH20 to 50 ml 
Add 300 III 10% APS 
16 III TEMED 
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6% Polyacrylamide sequencing gel 
37.S m140% (S%C) acrylamide 
120 g Urea 
SOmIS XTBE 
dH20 to 2S0 ml 
6% Polyacrylamide (Sequencing gel) 
37.S m140% (S%C) acrylamide 
120 g Urea 
SOmlSXTBE 
dH20 to 2S0 ml 
10% Polyacrylamide gel (RED) 
2.S m1 40% (3.4%C) acrylamide 
2mlS XTBE 
S.39 dH20 
80 III 10% APS 
30 III TEMED 
10% Polyacrylamide gel supplemented with S% Glycerol CHEX-SSCP) 
3 m1 Glycerol 
IS m140% acrylamide (1 %C) stock 
6 ml S X TBE (0.5 X) 
36m1ddH20 
800 III 10% APS 
- 80 III TEMED -- ----- ---
10% Polyacrylamide gel supplemented with 7.S% Urea (HEX-SSCP) 
4.S gUrea 
IS m140%acrylamide (1%C) stock 
18 mlS X TBE (1.S X) 
26 m1 ddH20 
800 III 10% APS 
80 III TEMED 
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20% Polyacrylamide gel on Mighty Small (SSCP) 
5 ml 40% acrylamide (1 %C) stock 
1 ml 5 X TBE (0.5 X) 
4 ml ddH20 
8011110% APS 
40 III TEMED 
10 mg/ml Proteinase K 
10mg Proteinase K 
SABAX H20 to 1 ml 
50 X TAB electrophoresis buffer 5 
242 g Tris base 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA, pH 8.0 
dH20 to 1 liter 
lOX TBE electrophoresis buffer (for automated sequencing) 
108 g Tris base 
55 g Boric acid 
8.3 g Na2 EDTA 
dH20 to 1 liter 
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APPENDIX 2 
LDLR Database (second edition): new additions to the database and 
the software, and results of the first molecular analysis 
Varret M, Rabes JP, Thiart R, Kotze MJ, Baron H, Cenarro A, Descamps 0, Ebhardr 
M, Hondelijn JC, Kostner GM, Miyake Y, Pocovi M, Schmidt H, Schmidt H, 
Schuster H, Stuhnnann M, Yamamura. T, Junien C, Beroud C, Boileau C 
Nucleic Acids Research (1998) 26:248-252 
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ABSTRACT 
Mutations in the LDL receptor gene (LOLR) cause 
familial hypercholesterolemia (FH), a common auto-
somal dominant disorder. The LOLR database is a 
computerized tool that has been developed to provide 
tools to analyse the numerous mutations that have 
been identified in the LOLR gene. The second version 
of the LOLR database contains 140 new entries and the 
software has been modified to accommodate four new 
routines. The analysis of the updated data (350 
mutations) gives the following informations: (i) 63% of 
the mutations are missense, and only 20% occur in 
CpG dinucleotides; (ii) although the mutations are 
widely distributed throughout the gene, there is an 
excess of mutations in exons 4 and 9, and a deficit in 
exons 13 and 15; (iii) the analysis of the distribution of 
mutations located within the ligand-binding domain 
shows that 74% of the mutations in this domain affect 
a conserved amino-acid, and that they are mostly 
confined in the C-terminal region of the repeats. 
Conversely, the same analysis in the EGF-like domain 
shows that 64% of the mutations in this domain affect 
a non-conserved amino-acid, and, that they are mostly 
confined in the N-terminal half of the repeats. The 
database is now accessible on the World Wide Web at 
http://www.umd.necker.fr 
THE LOL RECEPTOR AND 
HYPERCHOLESTEROLEMIA 
The LDL receptor is a 160 kDa transmembrane glycoprotein 
ubiquitously distributed, playing a major role in cholesterol 
homeostasis (1). Impairement ofLDL receptor activity results in 
the accumulation of LDL cholesterol in the circulation leading to 
familial hypercholesterolemia (FH). Affected individuals display 
arcus comeae, tendon xanthomas and premature symptomatic 
coronary heart disease (2). FH is an autosomal dominant disease, 
homo zygotes being more severely affected than heterozygotes. 
FH is also one of the most common inherited disorders with 
frequencies of heterozygotes and homozygotes estimated to be 
11500 and 11106, respectively. In certain communities FH 
frequency is higher due to founder effects (3). The LDL receptor 
gene (LDLR) lies on the short arm of chromosome 19 
(19p13.1-13.3) (4,5). It contains 18 exons encoding the six 
functional domains of the mature protein: Signal peptide, 
ligand-binding domain, epidermal growth factor (BOF) precursor 
like, O-linked sugar, transmenbrane and cytoplasmic (6). To date, 
*To whom correspondence should be addressed at: INSERM U383, Clinique Maurice Lamy, Hopital Necker-Enflllts Malades. 149-161 rue de Sevres, 
75743 Paris Cedex 15. France. Tel: +33 144 49 44 85; Fax: +33 I 47 83 3206; Email: boileau@ceylan.necker.fr 
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444 mutations in the LDLR gene have been identified that are 
distributed as follows: 350 point mutations (77%), 68 major 
rearrangements (15%), 20 splice mutations (4%), 6 mutations in 
the promoter sequence (1%) (3,7). 
THE LDLR DATABASE 
This second version of the LDLR database contains 350 entries. 
Table 1 shows the 140 new entries of the database corresponding 
to mutations either recently published or contributed by the 
co-authors of this paper (8-31). It is not intended to replace 
primary publications, although it does contain unpublished data. 
As in the previous edition, mutation names are given according 
to Beaudet et ai. (32) and are often followed by the name of the 
city or country from which the proband's family originated. For 
each mutation, information is provided at several levels: gene 
(exon and codon number, wild type and mutant codon, mutational 
event, mutation name), protein (wild type and mutant amino acid, 
affected domain, activity, mutation class), personal (ethnic 
background, age, sex, body mass index, familial history of 
coronary heart disease), clinical (values of plasma total choles-
terol, LDL-cholesterol, HDL-cholesterol and triglycerids, 
presence or absence of xanthomas, arcus corneae and sympto-
matic coronary heart disease) and impact (private, recurrent, 
founder). We have included possible recurrent mutations (when 
no comparable haplotypes of the LDLR gene where available) in 
two instances: (i) when carriers of the same mutation were from 
distant ethnic or geographic background, and if not (ii) when 
clinical data were provided for the mutations to allow analysis of 
phenotypic variability. This last point concerns mutations W23X 
identified in probands of German-Canadian and German origin, 
533ins8 and R395Q identified in probands from Germany, 
D200G identified in probands of Afrikaner and British origin, 
S285L identified in probands of Afrikaner and Dutch origin and 
P664L identified in probands of Belgian, Flemish-Walloon and 
Dutch origin. The ambiguity between recurrent and founder 
mutations will only be solved when a consensus will be reached 
on the polymorphic sites of the LDLR gene that should be 
systematically typed. Finally, since many teams now systematic-
ally screen the whole gene, two-mutations alleles are now being 
reported. Eleven of these appear in Table 2 (18,33-37). They are 
not included in the mutations file of the database since it cannot, 
at present, accomodate two mutations on a single allele. 
NEWLY DEVELOPED SOFTWARE ROUTINES 
The software package contains routines for the analysis of the 
LDLR database that were developed with the 4th dimensionR 
(4D) package from ABI. The purpose of the software is to 
facilitate the mutational analysis of the LDLR gene at the 
molecular level and to provide the tools to promote the analysis 
of relationships between phenotype and genotype. Initially, six 
specific routines were developed (3). Four new routines have 
been added to the software: (i) «Restriction enzyme» appears on 
the first page of the mutation record. If the mutation modifies a 
restriction site, the program shows a restriction map displaying 
the new or abolished site and the enzymes of interest (Table 1, 
Column I). (ii) «Amino acid type search» studies the mutations 
with respect to phylogenic conservation. In effect, the LDLR gene 
has been identified, sequenced and converted to protein sequence 
in four mammalian species [complete coding sequence of the 
Nucleic Acids Research, }YW), Vol. 26, No.1 24<) 
chinese hamster (SWISS-PROT accession number: p35950), the 
rabbit (p20063), the rat (p35952) and the mouse (p35951) LDL 
receptor] and in the xenope (38). The identity at the amino acid 
level between the human and chinese hamster, rabbit, rat, mouse 
and xenopus sequences are 81 %, 79%, 77%, 76% and 70%, 
respectively. Therefore, the routine lists the mutations affecting 
conserved or non-conserved amino acids in the four mammals, in -
the xenope, or in all these sequences. (iii) «Phylogeny» studies the 
distibution of mutations (missense, stop and frameshift) in 
conserved amino acids between humans and mammals or 
vetebrates and in amino acids specifically found in the human 
protein. (iv) «Binary comparison» compares two mutation 
groups, each group being defined by distinct research criteria 
chosen from the database records (molecular, clinical, personal, 
etc.). The result can be displayed as either of several graphic 
representations (by amino acids, by exon, or by protein domain) 
of the distribution of the sorted mutations. Furthermore, the sorted 
mutations can also appear in a cumulated or detailed format 
(insertion, deletion, missense, nonsense). 
RESULTS OF THE FIRST MOLECULAR ANALYSIS 
The results of the first molecular analysis of the 350 point 
mutations of the database shows that 63% of the mutations are 
missense, and only 20% occur in CpG dinucleotides in opposition 
to the 32% observed in other human disease genes (39). The 
origin of this deficit is unknown. Although the mutations are 
widely distributed throughout the gene, there is an excess of 
mutations in exon 4 (P = 0.001) coding for the three central 
repeats of the ligand binding domain, and in exon 9 (P = 0.01) 
coding for the NH2 end of the central region of the EGF precursor 
like domain, between repeats Band C. Conversely, there is a 
deficit of mutations in exon 13 (P = 0.001) coding for the COOH 
end of the central region of the EGF precursor like domain, 
between repeats Band C, and in exon 15 (P = 0.001) coding for 
the O-linked sugar domain. These mutation hot- or cold-spots 
cannot be attributed to a technological bias since most teams 
screened the 18 exons of the LDLR gene. The analysis of the 
distribution of mutations in the ligand-binding domain, after 
alignment of the seven repeats, shows that 74% of the mutations 
in this domain affect a conserved amino acid, and that they are 
mostly located in the C-terminal region of the repeats. 
Conversely, the same analysis in the EGF-like domain, after 
alignment of the three repeats, shows that 64% of the mutations 
in this domain affect a non-conserved amino acid, and that they 
are mostly clustered in the N-terminal half of the repeats. Finally, 
the investigation of genotype/phenotype correlations remains 
difficult since clinical data are usually incomplete in many 
published mutation reports. Furthermore, many mutations were 
identified in compound heterozygotes and the clinical data 
provided results from the combined effect of the two mutations. 
To overcome this shortage, we are currently developing an entry 
in the Web site that will facilitate the input of high quality clinical 
information for each mutation. 
DATABASE ON THE WEB 
The LDLR database is now accessible through the World Wide 
Web at http://www.umd.necker.fr . Users of the database must cite 
this article. Finally, notification of omissions and errors in the 
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Table 1. The 140 new mutation reports of the LDLR database 
A B C D E F Q H I J K L N N 0 P Q R S T 
213 I I ·21 ATG TIG A·,.T No N1a 111· M·2IL Mel Leu S' 1 Htz Wa P S. AIr. Ircian 26 
356 2 91 10 Go'G TAG O->T No Amal. EIOX Gu SIOO LBI 1 HI. W. ? Aemlsh .. Walloon 29 
2'9 2 91 10 Go'G TAG (l->T No Soe I + EIOX a:u Slo. LBI 1 Htz W. ? F 6I:lO Soarish 13 
335 2 91 10 Go'G TAG G->T No SOl I + EIOX·MOAOCCO au SroD LBI I W. ? Jewish AsI"J(anazi 23 
215 2 13' 23 1m TAG G->A No BsoYI· W23X Tr. SlOP LBI , HIZ W. ?·F Darish 21 
211 2 13' 23 1m TAG G-,.A No DSlYI· W23X Trp~ Sioo LBI , HIZ WI ?-F Gelman 
'. 300 2 '3' 23 TOG TAG G->,4 No BsiYII· W23X Tr. Sio LB, 1 HIZ WI ? BelCrlan "2 
316 2 139 26 GAT AAT G->" Yoa 026N·HVOGO As M" LBI HIZ W. P Japanese '3 
261 2 ... 29 ccr N::r G->" Y .. Dr.1IlII+ "'29T AI. Thr LBI Hrz W. ? Aus',... .. n '2 
2.3 2 14. 29 ccr N::r G->" Yes 0nI1II+ "29T AI. Thr LB' Hrz W. ? S. Afr. Coleured '" 
32' 2 166 35 TCT CCT T-,.C No HcJe III + S3SP S .. Pm LB' WI F 217"2 Norw~an 21 
222 3 232 57 = TOT C->T Yes Haem· Rs7C Ar. 0.. LB2 P Bri1:s."I 8 242 3 232 57 = TGT C->T V .. Haelll .. Rs7C Ar LB2 P S.Afr.I(\(f1an 12 2.2 3 253 6. CAD TAG C->T No O"X an 510 LB2 1 Hrz W. ? S. Air. Jewi$h "3 
216 3 259 66 1m <In T->G No 8s''YI+ W66G TrD G LB2 Hrz W. F Oal"isrl 27 
211 3 259 66 1m <In T-,.G No BgYI+ W66G Trp_ G LB2 :1 or 5 Htz W. ? Gem-an '. 2B6 3 259 66 1m <In T·,.G No BsiYl. W66G Trp ru, LB2 Hm, ab ? ? Afdkarer I
223 3 260 66 1m TAG G->A No Xbal. W66X Tr. SloO LB2 P Brifis!'l 8 
224 3 26B 6. m:: TAC G->" No .... 1. eS8Y C T r LB2 P Britis!"l • 22' 3 26B .9 GAT AAT G->A Yes 069N "0 
"'" 
LB2 P Brilis~ • 2.3 3 293 74 m:: 00: T->O No C74G C'" Gly LB2 HIZ WI P Soar.:is!'l 19 
227 3 30' .0 Go'G della Stop at 204 301deiG G1u Fr. LB2 F 3/791 Br.tis~ 8 
262 3 311 .3 TGT TIT G·>T No CB2F c,.. 1'1"4 La2 HIZ W. P Brit:s!'l 'I 
2'0 3·4 3' 3 •• ea: 10: C·>T No PB4S Pm S ... La3 HIZ W. P F""'-'sn 11 211 • 335 91 Q;lC del10b StOD at 201 335daltO A, Fr. LB3 HIZ W. P [)ar;s., 9 
355 • 337 92 (l.'G TAG G·>T No Amal. E92X G1u SI.QQ La3 
, HIZ Wa ? FlemiSh 29 
317 4 344 .. ea: DC G·>A Yes A!)4H • FUKUOKA Ar ... L03 HIZ W. P Jap<lt"CS1) '3 
30. • 347 95 m:; TIC G->T No Fnu4H I· C95F C'" I'I"s LB3 Hrz W. P Belciarl "2 
252 • '29 122 m:: TOA C·>" No .1. C122X 5'0 LB3 1 Hrz W. F 13(70 •• 3180 FI. Flemish· Wa.1oon 15 
269 • '60 133 CAD TAG C·>T No Amal+ 0133X an SlOP LB4 Htz W. P Soarish ,. 
325 • 465 '34 m:: TGA C->A No C134X 0.. 5100 LB4 W. F 12n042 Norwec:lan 21 
228 • .79 139 m:: TAC G·>" No C139Y 0.. Tvr lB4 P Brit:s' 9 299 • 'B2 "0 ATC ACe T·>C No 1140T U. Thr LB4 Hrz Wa P Costa Pean 'I 
27. .. 500 14. m:: TAC G·>" No C146Y 0.. Tyr LB. Htz W. P Gerrr.an '. 229 • 502 147 Q;lC MC G·>" Yes D147N A, M" LB. P Br.r1$!'1 a 
2 •• • 5' 9 '52 m:: del1b 5100 at 204 Ti!~lt 518delG <:;ys Fr. LB4 1 Htz W. F 4J3O 50a,.i:s.' 13 
272 4 5' • 152 m:: TAC G·>" No Cl.52Y 0.. Tyr LB. H" W. P Gem-.an '. 3" • 519 '52 m:: TOG C->G No BsaYI+ C152W 0.. Tro LB4 Htz W. P Ge""", 5 326 • 523 154 GAT TAT G·>T No 0154Y As Tyr LB4 W. P N::u ...... ~:al'l 21 302 • 527 155 00: GTe G->T No BsoWI· G155V GIY V.I LB4 HIZ W. P BelQian "2 264 • 530 156 TCG TIG C·>T Yes S156L So< Leu LB4 H1z WI R Soar;s.' 18 345 • 533 157 GAT InsBb 5100 at 118 533insS As Fr. LB4 H.z W. ?·F German '. 3'3 • 554 164 AGO inslb Stop at 118 5~jnsG ArQ Fr. HIZ W. P GCrr.1Zn '5 33. • 558 165 GGT della 5100 al 204 S56delG • ISRAEL GIY Fr. ob 65 P Arabt.\:slem 23 290 • 558 '65 GGT Inslc SlOP at 118 5SBInsG Gly Fr. HIZ W. P German , 9 295 • 617 lOS AGT del1b Slqp.al 204 617delO Sor Fr. LB5 Hlz W. P F"""" "3 230 • 848 195 TGT della Stop al 204 646delT 0.. Fr. LB5 P Bri~sh 8 
3'2 • 661 200 Q;lC AAC G·>A Yes 0200N As 
"'" 
LBS Hlz W. P Gerrn.an '5 
266 • 662 200 Q;lC 00: A·>G No Mso 1 + 02000 A, G~ LB5 2B H1z W. ? _Sparish 19 
273 4 .62 200 Q;lC 00: A->G No Msol+ 02000 A, G" LBS 2B H1z W. ? Ge~n '. 2.0 • 862 200 Q;lC 00: ... ·>G No Msp I + 02000 As G LBS HIZ W. ?·F "'fr:b,"\er I
2'3 • .. , 200 Q;lC TAC G·,T . No 0200Y As Tyr LBS Hlz W. ? S.Alr. Irod"l3n '2 
A B C D E F Q H I J K L 
" 
N 0 P 0 R 5 T 
265 4 6.' 200 GIC TAC G-,T No 0200Y As TV' LB. HI, W. ? ,. 
28. 4 67' 203 Q;lC co:: A·>C No Haelll + 020JA ASO Ala LBS HI, W. P S. Air. CcOcured "I 
250 4 6., 206 Q;lC ins7c 5100 at 216 6a1ins7 Aso Fr. LBS , Hlz W. P French-Ca:-.ac~n 
" 239 4 6. , 206 GIC insSc In, 681ins8 As Ft. LB5 Hlz W. P Costa fI.ic.l." 10 
245 4 6.2 207 Go'G MG G->A Yes E207t( GIu LV' LB5 2B Hlz Wa ?·F2f7 S. Afr. Irdan 12 
336 4 6.2 207 Go'G CAD G·>C No EooA II + E2070·IAAQ Gu Gn LB5 2B W. ? Jewish Ashkenui 23 
354 5 731 223 TCT TAT C_>" No S223Y Ser Tyr LB8 HI, W. P Ae!"!is."\ 28 
23, 5 736 225 GOA del1a SIQQ..a, 263 736de:G GIY Fr. LB6 P Br:Cs.."\ 8 
255 • 757 232 m:; 1m C·>T Vas IAsol· R232W Arg Trp LB6 HIZ .b 2'-41).5: G> .... P 
Ai,:$~r'.a:'l '2 
358 5 767 235 Q;lC C>'Il ... ·,G No 023SE As au LB6 HI. W. ? F" ...... .is.., 2. 
256 8 829 255 m:: TOA C_,,, No C255X 5100 LB7 H1z W. F 21508 Aur.tr'.al1 '2 
353 6 829 256 Go'G MG G->A Vas E256K au Lv. LB7 H1z W. ? Wal\o..."'O 29 
303 • 855 284 ex: CAA c->,!, No H2 .. 0 .... Gn LB1 HI. W. P Beic:ian "2 341 6 .62 267 OM AAA G·,..\. V"" E267K Gu LV' LB1 Hrz Wa P GerT.a:'l '5 
2'3 8 902 2.0 Q;lC 00: A-,.G No 02BOO Asc Gly LB7 HI, F 5/115 Gr~ '6 
29. 6 9'0 2.3 Q;lC MC G·,.A No BsIKI· D2S3N A 
"'" 
LB7 2B W. ? Ir'..sf' "3 
21. 6 917 2.5 TCA TTA C·>T No S2B5L S" L", LB7 2B Hm, .. ? Germ" 29 
279 8 9'7 2.5 TCA TTA C·>T No S2BSL 5 .. L", LB7 2B Hrz W. ?-F Alrill;;arer " 
232 6 93' 290 AM del2a SlOp II 298 93Ide!"A L Fr~ LB1 P B~:..s" • 
233 6 93. 292 m:; TAC G·>" No AMI. C292Y 0.. Tyr LB7 F ~n91 Br.:;s." • 
23' 7 979 306 ex: TAC C·>T No H306Y His Tvr EG'A p B:~::!!\ • 
33' 1 9 •• 308 = 00: T·>G No C308G - POLA.'lD C EG'A W. P 
Jey,ri$h4 .. .itenazJ 23 
3' • 1 1012 317 m:: 00:: T·>C No Hae II + c:J17R· GIFU ::ys A", BrA Hrz W. P J.!I~.""'de '3 
235 7 1024 321 Q;lC AAC G·:::.A Vos D321N ASD 
"'" 
EG'A P Br'~~ 8 
304 1 1027 322 00: Ny:; G-,.A. V .. Alul- G322S GIy So< EG'A 290,5 HIZ W. ? Be>;:= "2 
337 7 1027 322 00: PCC G·>" Yes Alu I· G322S·SYRtA GIY So< EG'A 2Bo,S We ? Jewish A..s.~enazi 23 
236 7 1033 32' CAG TAG C·>T No Pwll- 0324X GIn SIOO EG"A P O(\t!5!'\ • 
333 7 104G 32B CAD dellb SlOP at 368 t646deIA - RUSSlA,'kUNGARY an Ft. I33'A W. P Jewish A.s. ...... enazi 23 
25. 7 1048 329 CGA TOA C·:::.T Vas AJ29X Ar. SIOO EG"A ? - F anB 8ti::.s~ 11 
292 7 1048 329 CGA TOA C·>T Yes R329X Aro 5100 I33'A Hu w. ?·F Gern"~ 19 
305 7 1056 33' m:: 1m C·>G No C331W C~ Tro I33'A HIZ W. P Bek:;:.a., "2 
319 • 1066 335 OAT CAT (he No Tao I· 0335H • KANAGAWA Aso lis Em! Hrz W. P Jaoa ....... '3 306 • 1066 33. OAT TAT G->T No Taq r· 0335Y Asp Ty. Em! HI, W. ? B&iI:;-an "2 321 .. 1066 335 GAT TAT G->T No T.!Io r· D335Y Aoo TV' Em! .b ? 1 ~ F 81742 No~:.an 2' 
251 8 1124 354 TAC m:; A·>G No Fnu.fHI+ V354C Tvr 0.. Em! W. F ~2188 Ftef\Ctlo.Ca."I,.l(j"~n 14 
296 8 1 133 3'7 CAD = A·>C No Bspt2B61 03S7P an Pm Em! Htz Wa P Be"," 
"3 
2.' 8 1154 364 CTG em T·>G No Alu I· L36-4R Leu Am Em! H1z W. P 5. Afr. C,Scured 
.. , 
21. • 1176 311 m:: TOA C·,.'!' No C371X c.,. Sioo Em! 1 HI, W. P 
S. Al,. k'c.i.an 25 
32. 9 1201 380 CTC GTe C·>G No Maell. L380V Leu V.I ElF W. F sn'2 NO"""l!I;ian 21 
320 9 1207 392 TIC CTC T·>C No F3.2L·WAKAYA. ... A Pho Leu ElF HI, W. P Japaneso '3 
218 9 1210 393 ACe ea: A·>C No T353P Thr Pm ElF H1z W. .p [)uois.' 27 
2.6 9 1215 3 •• MC MG C->G No IAsol· N384K A", Lv. ElF H1z W. P S. ~.lrOan 12 
314 9 1217 3.5 em CAll G-:>A Yes lAoo I· R3BSO Ara Gn ElF H1z W. P S. AIr. S!ae\. Sotho "2 
332 9 1216 3.5 em TGG C·>T Yes IA",-" AJa5W· RUMA.."'IIA Ar. Tro ElF W. P Jewish A.s. . ..II.enaz! 23 
307 9 12.3 39. G.'{; DC G->C N. Fnu4H I + 039.cH ASD lis ElF H1z W. P A.""" "2 
291 9 1247 395 em CAD G·:>" Yo. IASCI. A39SO A Gh ElF H1z W. ? ~ 19 
339 9 1247 395 em CAD G->" V.., M50I· A3'SO Ar. Gh ElF H1z W. ? G== '6 
237 9 1246 395 em TOG C-,T Yes ... ",1. R3.5W Ar Tro ElF ? - F4I1" err...sh • 
329 • 1248 395 em 1m C->T V .. 1A501· R3.SW Ar. T", ElF W. ? - F an42 No~n 
21 
309 9 1257 399 TAC TAG C->G No Rso I· Y398X ,yr 5'00 ElF H1z W. P Beban "2 
299 9 12B4 '01 AAC AAG C·>G No MaoH· N407)( A", Lvs EF Hmz .. e p s.Afr. Jeow1sh "3 
212 • 1285 .09 Gm ATG G->A Yes Masn· V.c08M Val .... 1 EF 5 Hmz .. F a- 30 
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Table 1. continued 
A B C D E F G H I J K L 
'" 
N 0 P 0 R S T 
321 • 1285 408 GIG .. m G->A Y .. Maell· v .. oaM • OSAKA Val .... , SF 5 Htz W. 
, Ja~nese °3 
347 9 1294 411 em GIG c;..G No LAtlV lou V', ID' Htz W. P Go"""" oS 
287 9 1301 413 KG AAll C·>A No T413K Thr l" ID' 5 Htz W. , Soat<sh 19 
309 9 1301 "3 K:JJ N:J3 C->G No T413R Thr Aro ID' Htz W. 'oF Bek;;ian 0°2 
352 9 0101 413 K:JJ Jro C..a N. HI3R Thr Am SF Htz W. '·F Flemish· Walloon 29 
330 9 1307 "5 GTI) ((Xl T·>c N. ,",sci· V·USA Val ALa ID' W. P Du"", 22 
299 9 1329 422 100 = G->C N. W422C Tm 
I"", SF 2Bor5 Htz w. , S. Afr. Ef\Cnsh • British 0°3 
258 10 1372 437 AGA cfel2s 5too at 438 1372deIAG "ro Fr. ID' Nt. W. P Austrian °2 
323 10 U69 469 100 TAG G·,.A N. Flmal+ W469X Tm St. ID' 1 Hrnz ... P German 2. 
257 to 1047. 47t G'C Me G·>" Yes Xeml+ D411N Aso A!n ID' Htz W. F 2/494 Austrian °2 
334 to '567 502 GIG dal9a d.1 Bam HI- 1 567de19· IRAQ V.I Fr. ID' W. P J8'WiSh Ashkenazj 23 
28. ft U4S 528 CGT GAT G .... No G5280 GIf A,o ID' 2 .. Nt. W. , G,..k 0°3 
219 ft 1650 52. GIG delle StOD at 546 1650deiG Val Fr. SF Htz W. P Danish 27 
220 12 1730 556· 100 1tXl Q.>C N. W556S Tm Set ID' 1 HI. W. F 8I6t Osnish 9 
351 12 1775 57t 003 GIG G-:>A N. G571E G" GlJ ID' 5 Htz W. , Aemish • Wal100n 28 
322 12 1784 57. aD coa G·>" V .. "'",1· R574Q Aro Gn SF Htz W. P Ja..".,. °3 
310 12 1823 587 = etC C·>T No P597l Pro leu SF Htz W. P BekJian 0°2 
311 12 1840 593 TIT del2a Stop at 600 1840derTT Pho Fr. ID' Htz W. P ~ian 0°2 
350 13 1864 601 GAT TAT G->T N. EeoRV· 060tY A •• Tvr ID' HI> W. P Aem$h 28 
349 13 '978 639 coa TAG C·>T N. Rmal. C6:J9X an St. ID' Htz W. p. Flemish 26 
259 14 199B 845 TOO TGA Q.;o.A. N. W04SX Tro 510 BR: HI. W. P Austrian ·2 
268 14 2000 646 TGT TAT G->,a. No C646Y C .. Tvr BR: 2'" HlZ W. R 18 
348 14 200t 848 TG7 TGA T·>A N. C646X 
"'" 
$100 BR: Wa P Swedish 31 
357 14 205.4 864 0:0 em C->T Yes Pst I + P664L Pm leu BFC 1 . F 71915 DulCh 24 
3 t2 14 2054 66. 0:0 em C->T Yes Pst I. Pi364L Pro leu BR: 2B Htz W. , ·F Be' . n 0·2 
348 I. 2054 684 0:0 em C->T Ves Pstl. P664L p", leu BR: 28 Htz W. '·F Aemish - WaUoon 28 
315 I. 2056 665 CAli TAG C->T N. Acll- Q6G5X an SIan EGC Htz w. P Costa Rican 20 
270 14 2085 674 NX; dol1ge StOD at 701 2085del19 Thr Fr. BFC Htz Wa P Soarish 18 
2.3 14 2092 677 TGC della Sloo at 707 2092deiT Cvs Fr. BFC Htz W. , Gteel(.·Ftench 0·3 
260 14 2093 677 TGC TAC G->A No C6nV rr.,;;- T r BFC HI. W. F3I03O Austrian °2 
3t3 14 2096 678 0:0 em C->T Y .. Msol- P678L Pro lou BFC Htz W. '·F e~ian ·°2 
221 15 2177 70S NX; ATC C·>T No T7051 Thr he as HlZ W. , Oal"ish 27 
244 16 2358 785 /C£ = A->T No S765C S'" Cvs as Hmz 
.. P S. AIr. Indlan 12 
281 .a-17 2389 778 GIll ATG G->A V .. Nia III + V776,.. Val .... t 1M HlZ Wa , Afrikaner °1 
340 17 2392 777 CIC del9a d.' 2392del9 l.u Fr. 1M Htz .b 186 P Gem-en °6 
267 17 2441 7.3 aD CAG G->'" Ves Alul+ R7930 Aro Gn CP HI. W. P S. Alt_ Stacie· Xhosa 0°2 
Each line represents a single LDLR mutation report. The columns contain the following informations and abbreviations: 
A: Report number. 
B: Exon number in which the mutation occured. Exons are numbered according to SUdhof et al. (6) with respect to the translational initiation site given by Yamamoto et al. 
(5). 
C: Nucleot(de position in which the mutation occured. 
D: Codon number in which the mutation occured. Codons are numbered according to Yamamoto el al. (5). Therefore. the 21 amino acids of the signal peptide (exon I) are 
numbered in negative (from -21 to -I). Codon number I is the last codon of exon I and encodes the first amino acid (Ala) of the mature LDL receptor. If the mutation spans 
more than one codon. e.g .• there is a deletion of several bases. only the first (5') deleted codon is entered. 
E: Nonnal base sequence of the codon in which the mutation occured. 
F: Mutated base sequence of the codon in which the mutation occured. If the mutation is a base pair deletion or insertion. this is indicated by «del» or «ins» followed by the 
number of bases deleted or inserted and the position of this deletion or insertion in the codon (a. b or c). The nucleotide position is the first that is deleted or the one preceding 
the insertion. For example. «deI19c» is a deletion of 19 bases including the third base of the codon. «ins8b» is an insertion of 8 bases occuring between the second and the 
third base of the codon. 
G: Concerns base substitutions. It gives the base change. by convention. read from the coding strand. If the mutation predicts a premature protein-termination. the novel stop 
codon position is given. e.g .. «stop at 204». 
H: Concerns events occuring at a CpG dinucleotide (only C--7T or G--7A). 
I: Concerns the restriction site that is lost. e.g .. «Msp I -». or created. e.g .• «Taq I +». by the mutation. 
J: ~Iutation name according to Beaudet et al. (32). Missense mutations are designated by the codon number flanked by the single letter code of the normal amino acid prior 
and of the mutant amino acid after (e.g.o Val to Met at codon 408 is designated «V 408M,,). Nonsense mutations are designated similarly exept that X is used to indicate any 
tennination codon (e.g .. Cys to stop at codon 134 is designated «CI34X»). Frameshift. insertion and deletion mutations are designated by the nucleotide number followed 
by «ins" for insertion or «del» for deletion. The nucleotide position is the first that is deleted or the one preceding it in the case of insertions. Exact nucleotides are indicated 
for two or less bases (e.g .• 617deIG). For three or more bases. the insertion or deletion is specified by the size of the change (e.g. 681ins8 indicates a 8 bp insertion starting 
after nucleotide 681). For many of the mutations that have been reported this nomenclature has not been used. Therefore. the original name also appears in this column. These 
names were given according to the popUlation or the city in which the mutation was reported first (e.g. TOKYO). 
K: Wild type amino acid. 
L: Mutant amino acid. Deletion and insertion mutations which result in a frameshift are designated by «Fr. ,,; Nonsense mutations are designated by «Stop». 
1\1: Protein domain in which the mutation occurs. «SP» for the signal peptide. «LB" for the ligand binding domain. "EGF,. for the Epidermal Growth Factor precursor like 
domain. «OLS" for the O-linked sugar chains domain. «TM" for the transmembrane domain. and "CP" for the cytoplasmic domain. In the ligand-binding domain (LB). each 
of the seven repeats are numbered separately and according to their position with respect to the N-tenninal end of the protein. 
N: Functional class as defined by Hobbs et al. (40). 
0: Clinical status according to Goldstein et al. (2): «Hmz" indicates homozygotes and «Htz" indicates heterozygotes. 
P: Genotype: «aa" indicates homozygoteso «ab" indicates compound heterozygotes. and «Wa., indicates heterozygotes. Empty cases appear when no infonnation is available. 
Q: Number of the report in which the second mutation identified in a compound heterozygote is described. When the second mutation is one of those omitted in the database. 
this mutation is briefly described with respect to the coding sequence. Finally. «?" indicates that the second mutation has not been identified. 
R: Recurence of the mutation. «F» indicates a founder effect. «F 2/140» indicates that the mutation was found in two unrelated probands in a sample 1-10 FH patients. "R" 
indicates recurrent mutations. «7» indicates mutations that have been identified in at least two unrelated probands of different ethnic backgrounds but for which LDLR gene 
haplotypes are not described. «7-F" indicates mutations for which LDLR gene haplotypes are not described (or incomplete) and that either are associated with a founder effect 
in the proband's ethnic or geographic origin. or have been identified in at least two unrelated probands of the same ethnic or geographic background. and "p» indicates muta· 
tions identified. to date. in a single proband. 
S: Ethnic or geographic background of the proband. 
T: Reference number indicating the publication in which the mutation is described. Full citations (authors. year. title. journal. volume, pages) are provided with the database. 
If the same mutation has been reported for the same patient in different papers. only one entry is made. 
"Indicates the co-authors who provided the infonnation: "I (Rochelle Thiart and Maritha J. Kotze)o "2 (Helena Schmidt and Gert M. Kostner). *3 (Yasuko Miyake and Taku 
Yamamura). *4 (Heike Baron and Herbert Schuster). *5 (Margit Ebhardt and Manfred Stuhrmann) and *6 (Hartmut Schmidt). 
**Indicates submitted papers: ** J (O.Loubser et al.). **2 (A.Peeters et al.) and *"3 (M.Callis et al.). 
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Table 2. Each line represents a single LDLR mutation report 
FIrst mulaUon Second mutation 0 R S T 
J B C D I! F 0' K L M P .J B C D I! F G K L II P 
W·18X • '2 -.8 100 TelA Q->A Try SlOp SO Wa E256K 8 829 256 <Wl MO G-,A GU Lv< L.97 Wa Hlz P Scanlsh 18 071E 3 274 7. CM OM C->G GtI GIu LB2 Wa 313.1I0·.C 3 313+1 
- -
G->C LS3 Wa Hlz P Sca_ 18 
C9SR 4 346 95 1GC ax: T·>C c... ArQ lB3 Wa D679E 14 2100 679 G.'C <Wl C->G ASD Gb = Wa Hlz P Soan!sh 18 8541"56 4 654 197 GGT Ins6 Ins GN Fr LBS 657del5 4 857 198 co:: dalSc del Glu Fr 1SS P Garrran 37 
C281Y 6 905 281 1GC TAC Q->A c... Tvr LB7 Wa 1708-10 G->A 
" 
1706-10 G·)oA 
-
ED' Wa Hlz P SOanlsh 18 
D333A 8 1061 333 GAT GTt: A·>C Aso Ala e:;m ea 2140+5 G·>A 14 2140+5 
111Sdel9 8 1115 35. <Wl delg del GIu Fr e:;m Wa 1151ns8 8 
03B3X 8 1150 383 GAG TAG C->T ~ 5100 e:;m Wa D365E 8 
N543H 11 1690 543 MT CAT A->C Asn HIs B::F Wa 2393del9 17 
N543H 11 1890 543 MT CAT A->C Asn HIs B::F Wa 2393del9 17 
A585T 12 1818 585 Gee ACe G·>A Ala Thr B::F Wa G654S 14 
Footnotes as for Table I. 
current version as well as specific phenotypic data would be 
gratefully received by the corresponding authors. 
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Summary 
Autosomal dominant hypercholesterolemia (ADH), one 
of the most frequent hereditary disorders, is character-
ized by an isolated elevation of LDL particles that leads 
to premature mortality from cardiovascular complica-
tions. It is generally assumed that mutations in the LDLR 
and APOB genes account for ADH. We identified one 
large French pedigree (HC2) and 12 additional white 
families with ADH in which we excluded linkage to the 
LDLR and APOB, implicating a new locus we named 
"FH3." A LOD score of 3.13 at a recombination fraction 
of 0 was obtained at markers D1S2892 and D1S2722. 
We localized the FH3 locus to a 9-cM interval at 
1p34.1-p32. We tested four regional markers in another 
set of 12 ADH families. Positive LOD scores were ob~ 
tained in three pedigrees, whereas linkage was excluded 
in the others. Heterogeneity tests indicated linkage to 
FH3 in -27% of these non-LDLRlnon-APOB ADH 
families and implied a fourth locus. Radiation hybrid 
mapping located four candidate genes at 1p34.1-p32, 
outside the critical region, showing no identity with 
FH3. Our results show that ADH is genetically more 
heterogeneous than conventionally accepted. 
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Introduction 
Autosomal dominant hypercholesterolemia (ADH) is an 
inherited disorder of lipid metabolism, characterized by 
a selective increase of LDL particles in plasma (type IIa 
hyperlipoproteinemia) giving rise to tendon and skin 
xanthomas, arcus corneae, and premature mortality 
from cardiovascular complications (Goldstein and 
Brown 1989). Twenty-five years ago, Goldstein and 
Brown (1974) showed that ADH results from defects in 
the cell-surface receptor that removes LDL particles from 
plasma. They coined the disorder "familial hypercho-
lesterolemia" (FH; MIM 143890). The LDL-particle re-
ceptor is a ubiquitous transmembrane glycoprotein of 
839 amino acids that mediates the transport of LDL 
particles into cells via endocytosis (Goldstein and Brown 
1974). The LDL-particle receptor gene (LDLR) was 
cloned by Yamamoto et a1. (1984) and mapped to 
19p13.1-13.3 by Lindgren (1985), and >600 mutations 
scattered throughout the 45-kb gene have now been re-
ported (Varret et a1. 1997a, 1997b, 1998; LDLR Mu-
tation Database). Innerarity et a1. (1987) demonstrated 
the genetic heterogeneity of ADH by reporting hyper-
cholesterolemic patients with normal LDL-particle re-
ceptor activity and defective apolipoprotein B-100 that 
displayed low affinity for its receptor. This new molec-
ular disorder was called "familial ligand-defective apo-
lipoprotein B-100" (FDB; MIM 144010). The APOB 
gene spans 43 kb, is divided into 29 exons, and maps 
to chromosome 2p23-p24 (Law et a1. 1985). To date, 
three mutations in the APOB gene associated with ADH 
have been reported: the R3500Q mutation is the most 
frequent, whereas the R3531C and the R3500W are 
relatively rare (Rabes et a1. 1997). Thus, it convention-
Stellenbosch University  https://scholar.sun.ac.za
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ally is assumed that only two distinct genetic disorders 
account for the AOH phenotype. 
The existence of a greater level of genetic heteroge-
neity has never been formulated clearly. However, care-
ful examination of the literature shows that, by different 
approaches, a few families have been identified in which 
the AOH phenotype was not associated with defects in 
the LDLR and APOB genes. Lestavel-Oelattre et al. 
(1994) studied 41 patients with the ADH phenotype 
(plasma LOL-cholesterollevel >95th percentile, xantho-
mas, and/or personal or family history of coronary artery 
disease) and found normal LO L-particle receptor activity 
and normal LOL-particle binding in nine patients who 
did not carry the R3500Q mutation in the APOB gene. 
Further studies showed that six of these patients carried 
a mutation in the LDLR gene, but for the three other 
AOH subjects the genetic origin of the disease is pres-
ently unknown (Nissen et al. 1998). These results could 
be explained by a defect in the regulation of the ex-
pression of the LDLR gene or by the involvement of 
another locus. This latter hypothesis was indirectly con-
firmed by other teams (Miserez and Keller 1995; Sun et 
al. 1997) who reported AOH families in which they 
found normal LOL-particle receptor activity and a ge-
netic exclusion of the LDLR and APOB genes. Fur-
thermore, several cases of pseudohomozygous type lIa 
hypercholesterolemia have been reported by Masana et 
al. (1990), who showed that pro bands of this rare au-
tosomal recessive hypercholesterolemia (ARH) have nor-
mal levels of LOL particles and normal LOL-particle 
receptor activity. In the present study we found 13 fam-
ilies that not only support these observations but also 
give evidence for the existence of a third gene involved 
in AOH, which we named "FH3." To identify FH3, we 
performed linkage analyses and exclusion mapping in a 
large French AOH family in which defects in LDLR or 
APOB have been conclusively ruled out. After positive 
LOO scores were obtained, confirmation of linkage in 
this first stage was sought in a second sample of 12 AOH 
families originating from France, Austria, Spain, Bel-
gium, and New Zealand and presenting the typical AOH 
phenotype. Two Sardinian ARH families were also 
tested. 
Families and Methods 
Families and Clinical Evaluation 
Family HC2 is a large AOH pedigree comprising three 
generations (fig. 1). All affected members were charac-
terized by levels of total cholesterol above the 97.5th 
percentile when compared with other French indivud-
uals matched by age and sex (Steinmetz 1990). The pro-
band (II-9) is a 36-year-old woman, ascertained at age 
17 years with 3.32 gil total cholesterol, 2.36 gil LOL 
1379 
cholesterol, 0.48 gil HOL cholesterol, 0.61 gil triglyc-
erides, and arcus corneae. Her sister (11-7) is a 40-year-
old woman ascertained at age 20 years with 4.10 gil 
total cholesterol, 3.12 gil LOL cholesterol, 0.52 gil HOL 
cholesterol, 0.75 gil triglycerides, and arcus corneae, ten-
don xanthomas, and xanthelasmas. Distribution of total 
and LOL cholesterol values in all tested HC2 members 
is bimodal, indicating the autosomal dominant trans-
mission of the disease (data not shown). All lipid values 
were confirmed with at least a second lipid measurement. 
Among the 39 family members, seven (11-3, III-3, III-4, 
III-5, III-6, 11-13, and III-15) were scored as "unknown" 
in linkage analyses because they presented with border-
line lipid values or because only one lipid determination 
was available. In the second set of families, all affected 
subjects were scored according to their level of total or 
LOL cholesterol above the 95th percentile when com-
pared with other individuals from their origin popula-
tion matched by age and sex (Civeira et al. 1990; Mo-
reda et al. 1990; Williams et al. 1993). Affected subjects 
(n = 46) had mean lipid values as follows: 3.02 ± 0.81 
gil total cholesterol, 2.25 ± 0.76 gil LOL cholesterol, 
0.52 ± 0.19 gil HOL cholesterol, and 1.23 ± 0.51 gil 
triglycerides. Unaffected subjects (n = 54) had mean 
lipid values as follows: 2.04 ± 0.27 gil total cholesterol, 
1.32 ± 0.27 gil LOL cholesterol, 0.52 ± 0.12 gil HDL 
cholesterol, and 0.88 ± 0.36 gil triglycerides. Subjects 
with an unknown phenotypic status (n = 6) had the fol-
lowing mean lipid values: 2.86 ± 0.33 gil total choles-
terol, 1.94 ± 0.27 gil LOL cholesterol, 0.52 ± 0.10 g/ 
I HOL cholesterol, and 1.46 ± 0.83 gil triglycerides. All 
these values were confirmed with at least a second lipid 
measurement. Finally, in the Sardinian ARH families, 
the four affected subjects presented an elevated level of 
total (>4 gil) and LOL (>3.5 gil) cholesterol, and normal 
triglyceride (<1.5 gil) and HOL «0.5 gil) levels. All sub-
jects gave informed consent. 
DNA Analysis and peR Amplifications 
DNA was isolated from whole blood samples with 
use of a method described by Collod et al. (1994). PCR 
amplifications and electrophoresis were performed un-
der conditions reported by Collod et al. (1994) or 
adapted from Reed et al. (1994) by use of f1uorescent-
labeled primers. Alleles observed in the pedigrees were 
numbered arbitrarily for each marker. All marker-typing 
data were collected blindly and independently by two 
investigators (M.V. andJ.P.R.), and all linked Ip markers 
were typed twice. Nonpaternity/nonmaternity was ruled 
out indirectly because no incompatible phase was found 
with the numerous highly polymorphic markers tested. 
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Figure 1 Segregation of chromosome Ip34.1-p32 markers in the French family HCl, Lipid values given under each family-member symbol 
are (top to bottom): age at lipid measurement; levels of total, LDL, and HDL cholesterol (in grams per liter); levels of triglycerides (in grams 
per liter); and apoE genotype (INNO-LiPA ApoE, Innogenetics, Murex, Chatillon) (Harrington et al. 1994). Haplotypes (top to bottom) at tel-
D lS255 -D 1S472-D lS2892-D 1S2 722-D 1S211-D 1S197 -cen markers are shown for each family member tested. Half-blackened symbols indicate 
affected members, unblackened symbols indicate unaffected members, and hatched symbols indicate members with an unknown phenotypic 
status. The haplotype in brackets of subject 1-1 was unequivocally deduced. The common region segregating with the disease phenotype in the 
family is boxed. 
Parametric Linkage Analysis 
Pairwise and multipoint linkage analyses were per-
formed with SLINK,. MLINK, and LINK MAP· ·of the 
LINKAGE package (Ott 1991) and the VITESSE algo-
rithm (O'Connell and Weeks 1995), with the assumption 
that ADH is an autosomal dominant disease with a gene 
frequency of .002. Marker-allele frequencies were cal-
culated with the data from the unrelated family mem-
bers. Linkage wa·s investigated with the assumption of 
equal female-to-male recombination rates. The distances 
between markers used in the LINK MAP analyses were 
estimated from family data. We assumed the penetrance 
for disease carriers to be .9, knowing that complete pen-
etrance can lead to false exclusion and that reduced pen-
etrance has been reported in FH and FDB. Penetrance 
for noncarriers was assumed to be zero. EXCLUDE (Ed-
wards 1987) was used to produce the exclusion map. 
This program estimates the positional likelihood of the 
disease locus on each chromosome and the percentage 
of probability of the disease locus to be on any of the 
22 autosomes. Heterogeneity tests were performed with 
HOMOG (Ott 1983), which computes likelihoods of 
linkage under genetic heterogeneity by estimating re-
combination fractions (0) and the proportion of families 
showing linkage to the markers under study (a). 
Nonparametric Linkage AnalysiS 
GENEHUNTER (Kruglyak et al. 1996) performs 
complete multipoint analysis to infer the degree of iden-
tity-by-descent sharing among all affected family mem-
bers at each map point. We used the modified version 
of this program, GENEHUNTER-PLUS (Kong and Cox 
1997), which has been shown to be less conservative, 
particularly when data are less than perfectly informa-
tive. GENEHUNTER-PLUS calculates a serniparametric 
LOD score (ghpLS) by using a single parameter that is 
a measure of the inheritance vector in the pedigree and 
allele sharing. 
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Table 1 
Description of the FH3 Families Studied 
LOD ScORE MlTrATION 
No. OF SUBJECTS WITH STATUS AT SCREENING IN 
LDL REFERENCE 
FAMILY ORIGIN Affected Unaffected Unknown RECEPTOR ACTIVITY' LDLR APOB' LDLR' APOBb POPULATION 
HCl France 6 25 7 Normal 
HC67 France 4 2 0 nd 
Al Austria 3 5 3 nd 
S150 Spain 3 3 0 nd 
S108 Spain 3 4 0 nd 
SIB Spain 4 4 0 nd 
S517 Spain 4 1 0 nd 
S509 Spain 4 2 0 nd 
S601 Spain 5 4 0 nd 
S129 Spain 4 0 0 nd 
S206 Spain 4 9 nd 
Bl Belgium 6 7 0 nd 
NZ1 N. Zealand 2 3 2 Normal 
13 Sardinia 2 5 1 nd 
14 Sardinia 2 10 4 nd 
• nd = not determined. 
b R3500Q and R3531C. 
, Promoter sequence not investigated. 
Candidate Gene Mapping 
We used the Radiation Hybrid Mapping Panel GENE-
BRIDGE 4 and performed PCR according to the pro-
tocol described by the supplier (Whitehead InstitutelMIT 
Center for Genome Research [WIIMIT]). The primers 
used to test the candidate genes were reported for SCP2 
(He et al. 1991), EPS15 (Genome Database; STS SHGC-
14865), and FABP3 (Phelan et al. 1996). Original prim-
ers designed in the 3' region of the APOER2 gene were 
forward, 5'-TTCTTGGCTTTGGCGAAGGTC-3' and 
reverse, 5'-TTGGGCTGATCTGGAAACGTC-3'. 
Results 
We have identified a large French family (HC2) in 
which linkage to either LDLR or APOB was conclu-
sively excluded. In this family, 22 meioses are investi-
gated. Linkage analysis with LDLR gene markers iden-
tified two recombinants (one affected subject and one 
unaffected subject). Linkage to APOB was excluded be-
cause seven recombinants were identified (two affected 
subjects and five unaffected subjects). This result was 
confirmed by a functional test that showed normal bind-
ing, internalization, and degradation of control LDL 
-6.38 - 4.47 nd Negative Steinmetz et al. 1990 
-2.75 .56 nd Negative Steinmetz et al. 1990 
-1.88 .19 Negative' Negative Williams et al. 1993 
-1.18 -3.79 nd Negative Moreda et al. 1990; 
Civeira et al. 1990 
-3.53 .82 nd Negative Moreda et al. 1990; 
Ci veira et al. 1990 
-1.98 -3.26 nd Negative Moreda et al. 1990; 
Civeira et al. 1990 
-.19 ' -1.73 Negative Negative Moreda et al. 1990; 
Civeira et al. 1990 
-1.72 -1.72 nd Negative Moreda et al. 1990; 
Civeira et al. 1990 
-2.41 .30 nd Negative Moreda et al. 1990; 
Civeira et al. 1990 
-1.50 -1.61 nd Negative Moreda et al. 1990; 
Civeira et al. 1990. 
-4.53 -2.74 nd Negative Moreda et al. 1990; 
Civeira et a!. 1990 
-4.67 -.88 nd Negative Williams et al. 1993 
-.25 -.66 Negative Negative Williams et a!. 1993 
-:x: nd nd Negative Williams et a!. 1993 
-:x: nd nd Negative Williams et a!. 1993 , , 
particles in fibroblasts from the proband (data not 
shown). Furthermore, no family member carried either 
of the two most frequent hypercholesterolemic APOB 
gene mutations (R3500Q, R3531C; table 1). Finally, to 
exclude the possibility of type lIb, III, or N hyperlipo-
proteinemia in this family, lipid measurements were re-
peated and apolipoprotein E variants were determined 
(fig. 1). 
We estimated the power of the family for linkage using 
SLINK (Ott 1991) assuming an autosomal dominant 
trait. We found a maximum LOD score (z",aJ of 4.13 
(expected average Zma" in 500 replicates was 2.16, with 
34% > 3.00) in family HC2, showing that this family 
was sufficiently informative for linkage. Two hundred 
four genetic markers from 22 autosomes were tested for 
linkage to the FH3 locus. These (CA)n microsatellite 
markers spanning the human genome were chosen on 
the basis of two criteria: heterozygosity and spacing of 
-15 cM between adjacent markers (Dib et al. 1996). 
Each locus was tested for linkage to the AD H phenotype 
by use of MLINK (Ott 1991) and VITESSE (O'Connell 
and Weeks 1995). The combined genotype data were 
also analyzed with EXCLUDE (Edwards 1987): a non-
overlapping exclusion zone of ~2,955 cM, correspond-
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ing to 80% of the genome, was established from the 
cumulative exclusion intervals for each marker. The EX-
CLUDE analysis also indicated that the most probable 
position for the FH3 locus in family HC2 was on chro-
mosome 1, with a probability of 96%. In this region, a 
LOD score of 2.13 at () = 0 had been obtained at 
D1S255 (table 2). Other microsatellites were tested 
around D1S255, and a Zmax of 3.13 (() = 0) was obtained 
at D1S2892 and D1S2722 in the HC2 family (table 1). 
Multipoint linkage analyses did not provide higher LOD 
scores (data not shown). As shown in figure 1, we found 
a common region (D1S2892-D1S2722) that segregated 
with the ADH phenotype, localizing FH3 to a 9-cM 
interval at 1 p34.1-p32 (GENATLAS). 
To investigate the reproducibility of linkage, other 
families from different countries-with 12 presenting 
ADH and 2 presenting ARH-were collected through an 
international collaborative effort (table 1). Markers 
D1S472, D1S2892, D1S2722, and D1S211 were tested 
in these families. In three families (SI13, S150, and 
S517) originating from northeast Spain, LOD-score val-
ues near their Zmax were obtained for these markers. 
Thus, these families present a very high probability of 
linkage between the disease and the FH3 locus on chro-
mosome 1 (fig. 2, table 3). In the two Sardinian ARH 
families, linkage with all the markers tested was ex-
cluded (fig. 3). To investigate whether exclusion of link-
age of ADH to Ip could be a result of wrong model 
specification, we performed model-free linkage analyses 
by using GENE HUNTER-PLUS (Kong and Cox 1997). 
Positive ghpLS scores were obtained for families HC2, 
S150, SI13, and S601 (data not shown). This analysis 
confirmed that the FH3 nonlinked families outlined by 
our parametric linkage analyses were not excluded be-
cause of misspecification of ADH inheritance mode. Fi-
nally, to estimate the proportion of families linked to 
the PH3 locus on Ip, we performed an admixture test 
using HOMOG (Ott 1983), in the whole sample (family 
HC2 and the 12 ADH families). As shown in table 3, 
the test was statistically significant with markers 
Table 2 
Am. J. Hum. Genet. 64:1378-1387, 1999 
D1S472, D1S2892, and D1S2722. Furthermore, the es-
timated proportion of families with linkage to the FH3 
locus was ex = 27% (P = .005) at D1S2892 and ex = 
25% (P = .005) at D1S2722. Multipoint HOMOG 
analysis gave a .2.nax of 2.97 (ex = 25%, P = .0025) be-
tween D1S2892 and D1S2722 at () = .01 from 
D1S2892. 
The PH3 gene maps to Ip34.1-p32, which also har-
bors numerous genes including those that encode a sterol 
carrier protein (SCP2; Ohba et al. 1994), a fatty 
acid-binding protein (FABP3; Phelan et al. 1996), an 
apolipoprotein E receptor (APOER2; Kim et al. 1997), 
and an epidermal growth factor receptor-pathway sub-
strate (EPSI5; Wong et al. 1994). To determine whether 
these positional and functional candidate genes mapped 
within the critical interval defined by D1S472 and 
D1S211 should be further investigated, we used the 
GENEBRIDGE 4 radiation hybrid panel. The results 
showed that all these genes did not map within the in-
terval, excluding the possibility of identity between the 
FH3 gene and one of these regional candidates (data not 
shown) and suggesting a novel gene for ADH on Ip34.1-
p32. 
Discussion 
We located a third gene involved in ADH on chro-
mosome 1 p34.2-p32 and identified a large French family 
in which the involvement of either LDLR or APOB was 
excluded conclusively. This result was confirmed by a 
functional test that showed that fibroblasts from the pro-
band showed normal binding, internalization, and deg-
radation of control LDL particles. Furthermore, no fam-
ily member carried either of the two most frequent 
hypercholesterolemic APOR gene mutations (R3500Q, 
R3531C). To exclude the possibility of type lIb, III, or 
IV hyperlipoproteinemia in this family, lipid measure-
ments were repeated and apolipoprotein E variants were 
determined. Furthermore, linkage was also clearly ex-
cluded between the disease gene and the LPL locus on 
Pairwise LOD Scores for Chromosome 1 Markers and ADH in HC2 
LOD 5CORE AT 8 = 
Locus DISTANCE' .00 .001 .01 .05 .10 .20 .30 .40 Zm»< 8= • 
015234 -6.49 -4.95 -3.81 -2.60 -1.84 -.99 -.52 -.24 -.24 .40 
015513 .15 1.05 1.06 1.09 1.16 1.17 1.03 .73 .31 1.18 .08 
0152830 .01 -1.02 -1.01 -.94 -.70 -.49 -.22 -.08 -.01 -.01 .40 
015255 .11 2.13 2.13 2.15 2.16 2.09 1.75 1.24 .58 2.16 .05 
015472 .02 2.13 2.14 2.15 2.16 2.09 1.75 1.24 .58 2.17 .03 
0152892 .08 3.13 3.13 3.11 2.98 2.77 2.22 1.54 .73 3.13 .00 
0152722 .02 3.13 3.13 3.11 2.98 2.77 2.22 1.53 .72 3.13 .00 
015211 .04 -4.52 .13 1.11 1.70 1.81 1.62 1.17 .57 1.81 .10 
015197 .08 -2.97 -.86 .15 .88 1.13 1.15 .87 .43 1.19 .15 
• Distance between two adjacent markers in 8. 
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Figure 2 Segregation of chromosome Ip34.1-p32 markers in the Spanish families 5113, 5601, 5150, and 5517. Lipid values given under 
each family-member symbol are (top to bottom): age at lipid measurement levels of total, LDL, and HDL cholesterol (in grams per liter); and 
levels of triglycerides in (grams per liter). Haplotypes (top to bottom) at tel-DlS472-DlS2892-DlS2722-DlS211-cen markers are shown for 
each family member tested. Half-blackened symbols indicate affected members and unblackend symbols indicate unaffected members. The 
common region transmitted with the disease phenotype in each family is boxed. 
chromosome 8, as well as the APOAI-C3-A4 gene clus-
ter on chromosome 11 and the 1q21-q23 region, both 
of which are associated with familial combined hyper-
lipidemia (Wojciechowski et al. 1991; Pajukanta et al. 
1998). Because this family was clinically and biologically 
indistinguishable from FH or FOB families and the ex-
pected LOD score showed sufficient power in the ped-
igree, we used exclusion mapping to localize the disease 
gene. The phenotypic status of each family member was 
carefully and independently established by four research-
ers (M.D., M.K., J-P.R., and C.B.) and by other recog-
nized French experts. To avoid spurious results from 
misclassification, members with borderline lipid values 
were scored as "unknown" in the genetic analyses (seven 
" 
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Table 3 
Pairwise LOO-Score Analyses for AOH and 1 p Regional Markers 
Z""" (8) AT MARKER 
FAMILY D1S472 D1S2892 D1S2722 D1S211 Z"",,' 
HC2 2.16 (.05) 3.13 (0) 3.13 (0) 1.81 (.1) 4.13 
HC67 -.01 (.4) 0(.4) 0(.4) o (.4) .86 
Al .15 (0) -.09 (.4) -.02 (.4) -.09 (.4) 1.01 
5150 .56 (0) .82 (0) .82 (0) .82 (0) .82 
5108 nd -.02 (.4) -.02 (.4) nd .84 
5113 .07 (0) 1.34 (0) .21 (0) .2 (0) 1.35 
5517 -.03 (.4) 0(.4) .64 (0) .01 (.3) .79 
5509 nd 0(.4) -.01 (.4) nd .79 
5601 .09 (0) .50 (.05) .07 (0) .41 (.05) 1 .61 
5129 nd -.02 (.4) -.02 (.4) nd .75 
5206 -.05 (.4) .. 19 (.3) -.01 (.4) .15 (.3) 2.46 
Bl -.43 (.4) -.20 (.4) -.2 (.4) -.18 (.4) 1.94 
NZI nd -.01 (.4) 0(.4) nd .50 
Total Z""" (8) .17 (.3) 1.59 (.2) 1.04 (.2) 1.13 (.2) 
HOMOGENEITY ADMIXTURE TEXT AT MARKER 
Total Zmax (8 [a]) 1.43 (.1 [32%]) 2.88 (0 [27%]) 2.43 (0 [25%)) 1.45 (.01 [46%]) 
P VALUE .01 .005 .005 .11 
POSTERIOR PROBABILITY OF LINKAGE AT MARKER 
HC2 .985 .998 
HC67 .155 .027 
Al .399 .004 
5150 .625 .700 
5108 .320 .014 
5113 .351 .883 
5517 .005 .096 
5509 .320 .025 
5601 .316 .533 
5129 .320 .023 
5206 .0004 .123 
Bl .001 .001 
NZI .320 .103 
NOTE.-nd = not determined . 
• Zmax encountered in the 500 SLINK replicates. 
subjects). We chose this conservative approach despite 
loss of power. In the absence of established genetic pa-
-rameters for this autosomal dominant disease, we as-
sumed it to be comparable to FH or FOB. Therefore, 
linkage analyses were performed with a gene frequency 
of .002 and penetrance of .9. At DlS2892 and 
DlS2722, the 2max exceeded the threshold of 3 in the 
family (2ma " = 3.13, () = 0; table 2), strongly supporting 
the hypothesis of an AOH locus at 1p. As shown in 
figure 1, family data also showed an affected subject (lI-
S) with a proximal recombination event, between 
DlS2722 and DlS211, and an unaffected subject (III-
1) with a distal recombination event between DlS472 
and DlS2892. Furthermore, all affected individuals 
shared the region flanked by markers DlS2892 and 
DlS2722. Together these data place PH3 in a region <9 
cM, flanked by markers DlS472 and DlS211. Inter-
estingly, the subjects with no definite diagnosis (11-3, Ill-
3, III-4, III-s, III-6, 11-13, and III-1s), did not carry the 
.998 .982 
.004 .319 
.155 .154 
.688 .792 
.001 .460 
.351 .540 
.593 .344 
.002 .460 
.281 .676 
.009 .460 
.035 .314 
.001 .032 
.155 .460 
disease-associated two-marke~ haplotype. This obser-
vation supported our conservative approach. However, 
an 8-year-old boy (III-3), with a total-cholesterol level 
of 1.46 gil and an LOL-cholesterollevel of 0.72 gil, also 
carried the disease-associated region. This observation 
explains why the 2 ma" was not reached at 1 p. 
In an attempt to replicate this positive linkage, we 
studied a second set of 12 AOH families from various 
countries (table 1). These families met the following clin-
ical and biological criteria: (1) AOH phenotype; (2) nor-
mal LOL-particle receptor activity, and/or absence of 
mutations in the whole LDLR gene, and/or genetic ex-
clusion of the LDLR gene; and (3) genetic exclusion of 
APOB and/or absence of mutations R3s00Q and 
R3s31C in APOB. Phenotypic status was established 
for each subject on the basis of the appropriate national 
reference population. Three families (S113, S150, and. 
Ss17) gave two-point LOO scores, with DlS2892 and 
D1S2722 very close to their possible 2max (table 3), sup-
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Figure 3 Segregation of chromosome Ip34.1-p32 markers in the Sardinian families It3 and It4. Lipid values given under each family-
member symbol are (top to bottom): age at lipid measurement; levels of total, LDL, and HDL cholesterol (in grams per liter); and levels of 
triglycerides (in grams per liter). Haplotypes (top to bottom) attel-D1S2892-D1S2722-D lS211-cen markers are shown for each family member 
tested. Blackened symbols indicate affected members, unblackened symbols indicate unaffected members, and hatched symbols indicate members 
with an unknown phenotypic status. 
porting the localization of the FH3 gene. In families S113 
and S150, a common four-marker haplotype was carried 
by all the affected members. Conversely, in family S517 
a positive LOD score was obtained only at D1S2722, 
but careful examination of family data did not show a 
conserved region shared by affected members. In family 
S601, LOD scores were of small value; however, all af-
fected members shared a common region. Furthermore, 
this region was also shared by an unaffected 24-year-
old woman (II-9; 1.94 gil total cholesterol and 1.29 gil 
LDL cholesterol). This observation could be compared 
with that of subject III-13 of the HC2 family. It is un-
likely that both these subjects are double recombinants. 
However, it is highly possible that, with the criteria used 
for the classification of family members, the penetrance 
of the disease gene is not complete in children and young 
adults. 
Admixture tests were performed on a sample com-
prising the HC2 family and the set of 12 ADH families. 
The hypothesis of genetic homogeneity was rejected 
against the hypothesis of heterogeneity at a significance 
level of 1 %. These results showed that the ADH phe-
notype is more heterogeneous than what we at first had 
assumed. For the remaining ADH non-lp families, an-
other locus, named "FH4," could be involved. We also 
studied two Sardinian families displaying ARH, the rare 
pseudohomozygous type lIa hypercholesterolemia dis-
ease with an autosomal recessive transmission. Despite 
the different transmission modes, we thought it was pos-
sible that some mutations in the FH3 gene could give 
rise to ADH and that some others could lead to ARH, 
as has been reported for other diseases, such as retinitis 
pigmentosa (MIM 268000). As shown in figure 3, no 
allele identity was apparent between the affected sibs (11-
2 and 11-3) of family 1t3, and identical alleles are shared 
by the affected sibs (11-1 and IT-4) of family 1t4 and their 
unaffected sib (IT-2). These results show that, in the two 
ARH families, the disease is not linked to the FH3 gene. 
In these families, the disease gene could be identical to 
either the FH4 gene or another as yet unidentified gene. 
Our data provide strong evidence for an additional 
locus contributing to ADH and its assignment to chro-
mosome Ip34.1-p32. Positioning the disease locus in 
relation to the genetic map indicates that the FH3 gene 
is located within a 9-cM interval flanked by D1S472 
and D1S211. These microsatellite markers map to a re-
gion that contains four candidate cloned genes, as fol-
lows: SCP2 (sterol carrier protein 2), which encodes a 
lipid transport basic protein believed to facilitate the 
movement of cholesterol and phospholipids within the 
cell (Ohba et al. 1994); MDGIIFABP3 (mammary-de-
rived growth inhibitor/fatty acid-binding protein 3-mus-
cle and heart), which encodes a protein that transports 
vehicles of hydrophobic fatty acids throughout the cy-
toplasm and is a candidate tumor-suppressor gene for 
human breast cancer, although no mutation in this gene 
has been reported in sporadic breast tumors (Phelan et 
al. 1996); APOER2 (apolipoprotein E receptor 2), 
which encodes a receptor that resembles LDL and very-
low-density lipoprotein receptors and is most highly ex-
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pressed in human brain and placenta (Kim et al. 1997); 
and EPS15 (epidermal growth factor receptor path-
way-substrate), which encodes a protein that is impli-
cated in the receptor-mediated endocytosis pathway 
(Wong et al. 1994). To clarify the positional relationship 
between these regional candidate genes and the markers 
linked to the PH3 gene, we mapped them relative to the 
WI/MIT radiation hybrid map. The results showed that 
all these candidate genes are not located within the 
D1S472-D1S211 interval, excluding possible identity 
between the PH3 gene and one of these candidates and 
suggesting a novel gene for ADH on Ip34.1-p32. 
To conclude, the 13 families we have identified give 
evidence for the existence of a greater level of genetic 
heterogeneity than conventionally has been assumed tor 
ADH. Our results indirectly show that PH3 encodes a 
protein, as yet unknown, whose function is important 
in the control of cholesterol homeostasis. Defects in this 
new pathway could explain the resistance to drug ther-
apy observed among some patients with hypercholes-
terolemia. The identification of the PH3 gene may help 
to develop new intervention strategies to limit elevation 
of LDL particles and prevent morbidity and mortality 
from premature atherosclerosis. 
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